UNITED STATES OF AMERICA

CENTERS FOR DISEASE CONTROL

+ + + + +

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

67th MEETING

+ + + + +

THURSDAY FEBRUARY 11, 2010

+ + + + +

The meeting convened at 9:00 a.m., Pacific Standard Time, in the Marriott Manhattan Beach, 1400 Parkview Avenue, Manhattan Beach, CA, James M. Melius, Chairman, presiding.

PRESENT:

JAMES M. MELIUS, Chairman
HENRY ANDERSON, Member
JOSIE BEACH, Member
BRADLEY P. CLAWSON, Member
R. WILLIAM FIELD, Member
MICHAEL H. GIBSON, Member*
MARK GRIFFON, Member
RICHARD LEMEN, Member
JAMES E. LOCKEY, Member
WANDA I. MUNN, Member
JOHN W. POSTON, SR., Member

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 PRESENT: (continued)

ROBERT W. PRESLEY, Member
DAVID B. RICHARDSON, Member*
GENEVIEVE S. ROESSLER, Member
PHILLIP SCHOFIELD, Member
PAUL L. ZIEMER, Member
TED KATZ, Designated Federal Official

REGISTERED AND/OR PUBLIC COMMENT PARTICIPANTS

ADAMS, NANCY, NIOSH Contractor

AL-NABULSI, ISAF, DOE

BRADFORD, SHANNON, OCAS

BURGOS, ZAIDA, NIOSH Contractor

CANO, REGINA, DOE

CRUZ, RUBEN, CDC

DARNELL, PETE, OCAS

GLOVER, SAM, OCAS

HOWELL, EMILY, HHS

HINNEFELD, STU, OCAS

FITZGERALD, JOE, SC&A

KOTSCH, JEFF, DOL

LAM, LIVIA, Senate Committee on Health, Education, Labor, and Pensions*

LIN, JENNY, HHS

MAKHIJANI, ARJUN, SC&A

MAURO, JOHN, SC&A

MCFEE, MATTHEW, ORAU Team

MILLER, RICHARD, House Committee on Education and Labor*

NETON, JIM, OCAS

PRESLEY, LOUISE

RAFKY, MICHAEL, HHS

ROBERTSON-DEMERS, KATHRYN, SC&A

RUTHERFORD, LaVON, OCAS

TURNER, LEROY, OCAS

VON ZEPPELIN, ROBERT, Westinghouse Electric Corp. Petitioner*

WADE, LEW, OCAS

ZEITOUN, ABE, SC&A

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

^{*}Participating via telephone

CONTENTS

Welcome, Chairman Melius4
Westinghouse Electric Corp SEC Petition 5 (Bloomfield, NJ (83.14) LaVon Rutherford, NIOSH
SEC Petition Status Update
Subcommittee and Work Group Reports 78 Subcommittee/Work Group Chairs
Board Working Time
Adjourn

1	P-R-O-C-E-E-D-I-N-G-S
2	(9:04 a.m.)
3	MR. KATZ: Good morning,
4	everybody, for the third day of the Board
5	meeting. Let me again this is the Advisory
6	Board on Radiation Worker Health, of course.
7	For folks on the phone, let me check first to
8	see if we have our two at-large Board Members
9	present already.
10	So, Dr. Richardson, are you with
11	us?
12	MEMBER RICHARDSON: Yes, I am.
13	MR. KATZ: Great. And Mr. Gibson.
14	There is a possibility he won't be here for
15	all of the meeting.
16	CHAIRMAN MELIUS: Actually, Mike
17	emailed. He thought he would be on later this
18	morning, our time.
19	MR. KATZ: That is right. Then
20	just let me remind everyone on the phone,
21	please, to mute your phones. Use *6, and if
22	you need to come off mute to address the

- 1 Board, you just press *6 again. Then it will
- 2 bring you back online.
- 3 CHAIRMAN MELIUS: We have a number
- 4 of things to cover today. I know Dr. Lockey
- 5 has to leave early. Does anybody else need to
- 6 leave early? Josie, I know about, yes. It
- 7 helps in terms of what actions we take later.
- 8 MEMBER MUNN: But our Chair will
- 9 remain with us, right?
- 10 CHAIRMAN MELIUS: The Chair will,
- 11 yes. You haven't heard about the ankle
- 12 bracelet?
- 13 MEMBER MUNN: That comes with the
- 14 job.
- 15 CHAIRMAN MELIUS: LaVon,
- 16 Westinghouse Electric.
- 17 MR. RUTHERFORD: LaVon Rutherford.
- 18 I am the Special Exposure Cohort Health
- 19 Physics Team Leader for the Office of
- 20 Compensation Analysis and Support, and I am
- 21 here to talk to you about the Westinghouse
- 22 Electric Company and the SEC Petition for

- 1 that.
- On December 10th, NIOSH informed a
- 3 Westinghouse Electric claimant that we were
- 4 unable to do his dose reconstruction, and we
- 5 sent that claimant a Form A Petition Form. On
- 6 December 18th of 2009, we received that Form A
- 7 back as an 83.14 SEC Petition.
- 8 On December 18th, again we
- 9 qualified that Petition for evaluation. On
- 10 January 15th of this year, we issued our
- 11 Evaluation Report.
- 12 A little background about
- 13 Westinghouse Electric. Westinghouse Electric
- is located in Bloomfield, New Jersey. It was
- 15 basically the home of the lamp division. It
- was an Atomic Weapons Employer from August 13,
- 17 1942, which is the beginning of the MED,
- 18 through December 31, 1949. They actually had
- 19 involvement prior to 1940, that August 13th
- 20 date, but that is the official beginning of
- 21 the MED.
- 22 They were involved in the

	thorium metal work.	thorium	and	uranıum	Οİ	production	1
--	---------------------	---------	-----	---------	----	------------	---

- 2 They were deeply involved in the process of
- 3 preparing the metal in support of the CP-1 and
- 4 the atomic bomb.
- 5 Sources of available information:
- 6 We looked at Site Profile Technical
- 7 Information Bulletins, and we have no Site
- 8 Profile associated with Westinghouse Electric
- 9 work. We also looked at the Site Research
- 10 Database, and we did data captures.
- I do want to point out that,
- 12 because I think there might have been some
- 13 confusion on others, there is a detailed data
- 14 capture synopsis. It is located at the back
- 15 of the Evaluation Report. It lays out the
- locations we searched, different parameters in
- 17 searching, and what we found at those places.
- 18 We put that at the back of all of our
- 19 Evaluation Reports.
- 20 One of our biggest sources of
- 21 documents that we got was actually from
- 22 Westinghouse Electric work from their History

1	Center.	t.he	Senator	John	Heinz	History	Center

- We also looked at the ADAMS
- 3 Database, DOE Legacy Management, all our
- 4 standard places. We typically will go to the
- 5 Department of Health for the state that the
- 6 facility is located. We did. We went to New
- 7 Jersey Department of Health, National Archives
- 8 Record Centers.
- 9 We did get some good documentation
- 10 from the National Archives as well, Washington
- 11 State University, DOE OpenNet, internet
- 12 searches, CEDR database, the Hanford DDRS or
- 13 Declassified Document Retrieval System,
- 14 National Academies Press, and that was it.
- 15 As of January 27th, you will
- 16 notice that we had one claim for this site.
- 17 The one claim does fit within the Class
- 18 Definition, and dose reconstruction -- we have
- 19 not completed any dose reconstruction on that
- 20 one claim, and we do not have any internal or
- 21 external monitoring data for that.
- 22 A little background about

1	Westinghouse.	In	August	1942,	Westinghouse

- 2 was contracted by the Manhattan Engineer
- 3 District to produce uranium metal at the
- 4 Bloomfield, New Jersey, plant. It actually,
- 5 back in the 1930s, had experimented with
- 6 uranium as using uranium as a filament to
- 7 replace tungsten. However, that process took
- 8 about -- it took them about four years to
- 9 refine the process to produce the uranium, and
- 10 in that process they determined that the
- 11 actual uranium would melt quicker than the
- 12 tungsten. So they did not use it.
- 13 So they continued to produce the
- 14 uranium, but only on small scales per
- 15 university applications. They were ultimately
- 16 contacted by MED to produce massive
- 17 quantities. It started out as a smaller
- quantity of roughly 500 pounds which, when you
- 19 are producing kilograms to 500 pounds, is a
- 20 big difference.
- 21 They beefed up their scale of
- 22 production. They ultimately went from 500

1 pounds to over one ton per month, and produce

- 2 150,000 pounds from the 1942 through 1943
- 3 period.
- 4 This was a unique process they
- 5 used. It was uranyl nitrate with a mixture of
- 6 potassium fluoride, hydrochloric acid, sucrose
- 7 and formic acid that was mixed on trays and
- 8 put on top of the building. They used the
- 9 ultraviolet light to cause a reaction to occur
- 10 to actually produce the potassium uranium
- 11 fluoride, which they actually called green
- 12 salt, which is not what we would call green
- 13 salt today.
- 14 This production was then -- these
- trays, or this green salt was then pumped down
- 16 to the basement of the facility. This was in
- 17 Plant 7 of the building. It was pumped down
- 18 to the basement, and in the basement they did
- 19 some filtration to remove the supernate, and
- 20 they actually took the green salt at that
- 21 point, and they mixed it with a sodium, or
- 22 actually a calcium fluoride sodium chloride

1	mixture,	and	they	used	by	electrol	ysis	process

- 2 and superheated that to separate the uranium
- 3 from it.
- 4 The uranium then was broken away
- 5 from the electrodes, and it was centered and
- 6 then pressed into buttons. After it was
- 7 pressed into buttons, the buttons were put in
- 8 and melted to form the uranium melt that was
- 9 ultimately shipped to the University of
- 10 Chicago for Enrico Fermi's Stagg Field
- 11 experiment.
- 12 In August of 1944 -- again, they
- 13 produced the uranium from 1942 through 1943.
- 14 In August of 1944, they were actually
- 15 contracted by the MED to produce thorium
- 16 metal. We have very little information on
- 17 this process.
- I want to bring up another thing.
- 19 The work that occurred for the uranium at the
- 20 Bloomfield Site recognized that there were no
- 21 production facilities built for this uranium
- 22 application. This was a lamp division that

1 was doing work for producing lam	1	lamps.
------------------------------------	---	--------

- 2 They, in a matter of months,
- 3 pulled together the equipment and the
- 4 necessary design application, and you can also
- 5 find in the reference documents the actual
- 6 procedures that were used for the production
- 7 of this metal. They used very crude stuff,
- 8 trash cans, wooden trays and so on, in the
- 9 production of this process.
- 10 It is assumed that they used the
- 11 same production process to produce the thorium
- 12 metal as well, but I have no information on
- 13 that and any details on that.
- 14 This is consistent with that it is
- 15 roughly the same time that the Ames Facility
- 16 was producing thorium for the MED. We had
- 17 indications they produced a total of 200
- 18 pounds of thorium metal in the form of bars,
- tubes, sheets and wires in 1945.
- 20 Again, no information could be
- 21 found describing the process, and it is not
- 22 clear when the thorium processing stopped. We

1 do have documentation that indicates th	documentation that	do have documentation) h	L do	1
---	--------------------	-----------------------	-----	------	---

- 2 there were thorium inventories on site in
- 3 1949.
- 4 The Westinghouse Site consisted of
- 5 11 principal buildings, several smaller
- 6 structures, and it was located on 14 acres of
- 7 property. It appears most of the work that
- 8 took place was on the rooftop and in the
- 9 basement of Building 7. There was indication
- 10 that there were some laboratory applications
- 11 that took off in other places, but no real
- 12 definition of that type of work.
- 13 There is no information concerning
- 14 the control of personnel movement or control
- of radiologic materials to identify nonexposed
- 16 workers. I do know that, based on the
- 17 documentation that we have, that the thorium
- 18 nitrate feed material was sent to the site.
- 19 We do not know who the supplier was of that
- 20 thorium nitrate, but it is indication because
- 21 when they received it from the vendor, there
- 22 are discussions of the testing to ensure that

1	it was the proper quality that they needed.
2	Internal exposure hazards,
3	inhalation and ingestion from operations
4	involving uranium, thorium, and their
5	respective progeny radionuclides. There is a
6	little discussion in the reference documents
7	about that most of the people are aware. Most
8	everyone is aware of the pyrophoric issues
9	associated with uranium. It talked about the
10	uranium fires that they incurred from the
11	incinerated material and trying to control
12	that.

and beta sources from operations involving 14 15 uranium, thorium and their respective progeny. internal 16 Available monitoring data: 17 We have no internal or external monitoring data available. We have no air 18 19 monitoring data. We have no surface contamination monitoring data available, and 20 there is no data available associated with 21 22 medical X-rays.

External exposure hazards: Photon

13

1	We do have some source-term
2	information, the total uranium metal produced
3	of 150,000 pounds. One thing I will say is
4	you could tell just by the documentation we
5	read that it was a ramp-up process where they
6	started, where they were producing a few
7	hundred pounds, and then they went to 1,000
8	pounds and more ultimately. So it was an
9	increase over the months to that 150,000 pound
10	total that they actually produced.
11	Then we know they had thorium
12	metal, and we know they produced at least 200
13	pounds in 1945. We do not know if that
14	operation continued in '46 and '47.
15	There is insufficient source-term
16	information and process information to develop
17	occupational exposure models for uranium and
18	thorium.
19	We do have a good description of
20	how the uranium process, the actual chemical
21	process, of how it worked, but we do not have
22	the description enough description to

1	actually	put	together	а	model	using	the
---	----------	-----	----------	---	-------	-------	-----

- 2 source-term information and the process
- 3 information that we could come up with a good
- 4 exposure model for these workers, nor do we
- 5 have a surrogate facility based on this
- 6 operation that we could use any of that data
- 7 to bound the workers.
- 8 There are also some pictures that
- 9 you can look at in the reference documents
- 10 that kind of show you that the workers did --
- 11 it was actually the scientists at the time
- 12 looking at the uranium metal and how they
- 13 handled it. It was not -- they were not
- 14 wearing gloves. There was no protective
- 15 equipment involved in that.
- 16 Our internal exposures: We found
- 17 that there is insufficient monitoring and
- 18 source-term data from which to draw
- 19 conclusions regarding potential magnitude of
- 20 internal dose from exposures to uranium or
- 21 thorium and their progeny.
- Our external exposures, we again

1 found that there is insufficient monitor	oring	ľ
--	-------	---

- 2 and source-term data for us to draw
- 3 conclusions regarding the potential magnitude
- 4 of the external exposures.
- 5 We do think we can reconstruct the
- 6 medical dose using our standard Technical
- 7 Basis Document for that, and we will use any
- 8 personal monitoring data that would become
- 9 available for completing partial dose
- 10 reconstructions in the future.
- 11 So our feasibility determination
- is that, from August 13, 1942 through December
- 13 31, 1949, which is the covered period for
- 14 Westinghouse, that the internal dose
- 15 reconstruction is not feasible, and external
- 16 dose reconstruction is not feasible with the
- 17 exception of medical X-rays.
- 18 So our evidence revealed that
- 19 workers in the Class may have been
- 20 accumulating chronic exposures through intakes
- 21 of radionuclides and direct exposures from
- 22 radioactive materials. So we find that health

1 may have been endangered for those worker	1	may	have	been	endangered	for	those	workers
---	---	-----	------	------	------------	-----	-------	---------

- 2 Our proposed Class is all AWE
- 3 employees who worked at Westinghouse Electric
- 4 Corporation, Bloomfield, from August 13, 1942,
- 5 through December 31, 1949. That is the
- 6 standard language following that.
- 7 Again, our recommendation is from
- 8 August 13, 1942, through December 31, 1949,
- 9 and dose reconstruction is not feasible, and
- 10 health endangerment is yes. Questions?
- 11 CHAIRMAN MELIUS: Questions for
- 12 LaVon? Paul?
- 13 MEMBER ZIEMER: Lavon, do we have
- 14 an idea of the potential size of this Class,
- if it is approved?
- 16 MR. RUTHERFORD: It is not as
- 17 large, if you actually look at -- I think in
- 18 there I talk about the site consisted of 11
- 19 principal buildings and several smaller
- 20 structures on a 14 acre property. I asked the
- one claimant that we have, who is actually a
- 22 survivor, who is the petitioner, and I

1	couldn't	qet	а	real	good	number.

- I think that you wonder. We only
- 3 have one claim for this site. That could be
- 4 due to lack of information to those people.
- 5 It is also 1942 through 1949. So you would
- 6 assume the workforce is probably most
- 7 deceased. Their survivors are, obviously,
- 8 probably in their sixties time frame, 50-60
- 9 time frame, but it may just be outreach, maybe
- 10 not enough outreach.
- 11 CHAIRMAN MELIUS: Henry?
- 12 MEMBER ANDERSON: When was the
- initial claim filed? Do you know?
- MR. RUTHERFORD: You know, you got
- 15 me on that one. When we received the initial
- 16 claim for Westinghouse? I can find that out.
- 17 MEMBER ANDERSON: No, I am just
- 18 curious as to was this one of those legacy
- 19 cases that have been around a long time?
- 20 MR. RUTHERFORD: Yes, it is. It
- 21 is a legacy case that has been around for a
- 22 long time. You could have many reasons why it

1	took	so	long,	but	we	only	had	the	one	claim

- 2 for the facility, and so on. Yes, it is one
- 3 of the legacy cases.
- 4 CHAIRMAN MELIUS: Other questions
- 5 from Board Members? David Richardson, do you
- 6 have any questions?
- 7 MEMBER RICHARDSON: One question
- 8 is: There's an unknown end date for the
- 9 contract. So how did you select 1949?
- 10 MR. RUTHERFORD: The 1949 date was
- 11 selected by the Department of Labor. That is
- the end of the covered period, and we did not
- 13 find any information that would support
- 14 extending that covered period that we would
- 15 have fed to the Department of Labor. So we
- 16 did not pursue an extension of that.
- 17 MEMBER RICHARDSON: Okay.
- 18 MR. VON ZEPPELIN: Hello. Can you
- 19 hear me?
- 20 CHAIRMAN MELIUS: Yes, just a
- 21 second. We now need to -- if there are no
- 22 more questions from the Board Members, we will

1	hear	from	the	petitioner	who,	I	believe,	just
---	------	------	-----	------------	------	---	----------	------

- 2 tried to speak.
- 3 MR. VON ZEPPELIN: Yes. Can you
- 4 hear me?
- 5 CHAIRMAN MELIUS: Yes, we can.
- 6 MR. VON ZEPPELIN: Okay. You have
- 7 the question here. I petitioned this back in
- 8 -- and my [identifying information redacted]
- 9 and I, I am 66; my [identifying information
- 10 redacted] is [identifying information
- 11 redacted]. I petitioned this back in July of
- 12 2001, and this is going on nine years, and I
- 13 have talked to many people in this program
- 14 over the years, and I said this case here can
- 15 be settled in 15 minutes. I was told in no
- 16 uncertain terms to basically stick it up my
- 17 rear end, we are not interested in you.
- I said, I am dealing with a case
- 19 that goes back to the 40s, and I was talking
- 20 to people that never heard of Manhattan
- 21 Project, and World War II was actually history
- to them, too, and I am thinking, what is going

-		7
1	α n	here.
_	OII	TICT C •

- I can tell you that the protection
- 3 that these people wore, from what I understand
- 4 from what my father said and my mother said,
- 5 was rubber gloves and an apron, and she said
- 6 they were up to their rear ends in the stuff.
- 7 Do I have to say anything more?
- 8 CHAIRMAN MELIUS: No, you don't.
- 9 Thank you for your comments.
- 10 MR. VON ZEPPELIN: No, I have some
- 11 more here to say. You know, my [identifying
- 12 information redacted] and I are not in the
- 13 best of health, and I was determined I am
- 14 going to outlive this, and I told many people
- over the years that I have been dealing with
- 16 this. I said, what if both of us pass on
- 17 before this case is settled? I said, where
- 18 are you going to send the information that
- 19 this case goes one way or the other? Who is
- 20 going to receive it, if we are both in the
- 21 grave?
- 22 CHAIRMAN MELIUS: Well, all I can

1	say	is	I	think	that	the	Board	will	be	taking
---	-----	----	---	-------	------	-----	-------	------	----	--------

- 2 action, and I think this issue will get
- 3 resolved pretty shortly.
- 4 MR. VON ZEPPELIN: The thing is, I
- 5 have heard this going on eight-and-a-half
- 6 years now. I have been handed the same thing.
- 7 I even had my Congressman get involved in
- 8 this, and what I got out of him was a form
- 9 letter, and that is all I have been getting
- 10 over the years.
- I have been battling this and
- 12 battling this and battling this, and I have
- 13 come to the point where I want to see action.
- I don't want to hear talk, and I don't want
- 15 to see letters. I got a stack of letters that
- 16 go from probably a foot high, and that is all
- 17 I have gotten over the years.
- 18 I told people years and years and
- 19 years ago, this case can be settled in 15
- 20 minutes. There is no problem here. Listen to
- 21 me. But I am the stupid person.
- 22 CHAIRMAN MELIUS: I believe we

1 will settle it in the next 15 min	nutes.
-------------------------------------	--------

- 2 MR. VON ZEPPELIN: I hope so.
- 3 CHAIRMAN MELIUS: This is the
- 4 first time the Board, the Advisory Board --
- 5 that this has been brought to our attention.
- 6 So we will be taking action, I believe, over
- 7 the next 15 minutes, as soon as we --
- 8 MR. VON ZEPPELIN: Well, it is
- 9 good news, you know. the thing is, this is
- 10 back in the infancy of, basically, dealing
- 11 with nuclear energy and nuclear power or
- 12 anything else like that, because as you all
- 13 know, the atom was only split in '38, and
- 14 these people were working with very dangerous
- material, no safeguards, no nothing.
- 16 My mother, after my father died
- 17 back in 1967, said he died basically because
- of his work during the war, and the doctor who
- 19 treated him lastly said -- when he heard his
- 20 case history, he said this is definitely a
- 21 case of his work during the war, and every
- 22 person that has ever heard of this said that.

1	So this is what I don't
2	understand, is why this bureaucracy has taken
3	this long to finalize this when it is so
4	simple. Even an idiot like me can understand
5	it.
6	CHAIRMAN MELIUS: Thank you. We
7	have one question from a Board Member. Wanda?
8	MEMBER MUNN: Not a question. I
9	just wanted to make a motion.
10	CHAIRMAN MELIUS: We have one
11	question for you. Do you have any estimate
12	about how many people worked at the facility?
13	MR. VON ZEPPELIN: From what my
14	mother and my father said, it was a very, very
15	small number, and the only thing is the
16	problem is the only reason I ever knew about
17	this is that in the spring of 2001, USA Today
18	had about three or four main articles on this
19	program, and they listed all the facilities
20	that would be included on this, and
21	Westinghouse Electric was listed.

That is the only reason I ever

22

	1	knew	about	the	program,	and	I	had	to	get	or.
--	---	------	-------	-----	----------	-----	---	-----	----	-----	-----

- 2 the computer and get all the applications and
- 3 everything else to fill them out and send it
- 4 in, and then I sent it in to Washington, D.C.
- 5 Fifteen months later I get a call from
- 6 somebody in Jacksonville, Florida, telling me
- 7 I sent it to the wrong place. I said, how did
- 8 it get to Jacksonville, Florida? She said,
- 9 you sent it there. I said, I didn't send it
- 10 there; I sent it to Washington, D.C., and this
- is when the parade started.
- 12 CHAIRMAN MELIUS: Well, we
- 13 apologize for that, though some of us recall
- 14 the USA Today article. I am glad that you
- 15 were seeing that.
- MR. VON ZEPPELIN: Well, that is
- 17 the only reason I know about. The thing is,
- if you can go back in and check the number of
- 19 employees that were there working there by
- 20 their Social Security numbers, which probably
- 21 you can, and find out. Also, you can find
- out, too, is when their death dates occurred,

1	and	I	bet	you	none	of	them	got		it	was
---	-----	---	-----	-----	------	----	------	-----	--	----	-----

- 2 probably in the late 50s or mid- to late-60s
- 3 when they all passed away. You can bet your
- 4 dollar on that.
- 5 CHAIRMAN MELIUS: Okay, thank you.
- 6 We have a motion coming from Wanda?
- 7 MEMBER MUNN: Yes, you do. I
- 8 would like to reassure the claimant that there
- 9 are people who are deeply appreciative and
- 10 understanding of the work that your father
- 11 did.
- 12 MR. VON ZEPPELIN: Well, I
- 13 appreciate that, and thank you very much,
- 14 because a lot of people don't understand, and
- 15 I have battled it, and I have battled it, and
- 16 I have battled it, and they just didn't
- 17 understand, and they were just saying that are
- 18 you sure of this, are you sure? And I have
- 19 been asked for dosimeter readings. I have
- 20 been asked for Geiger counter readings. I
- 21 have been asked for health reports on him, and
- 22 everything else. And I am thinking, dosimeter

1	readings,	Geiger	counter	readings,	and	I	am
---	-----------	--------	---------	-----------	-----	---	----

- 2 thinking what planet are these people on or
- 3 what have they been smoking.
- 4 MEMBER MUNN: Well, our program
- 5 makes an effort to obtain as much specific
- 6 information as they possibly can, but that
- 7 doesn't change the fact that most of us truly
- 8 understand the kinds of work that has had to
- 9 be done for the real pioneers of the nuclear
- 10 age, and your father was one of those. That
- 11 is appreciated. His work and the material
- 12 that came from that plant were crucial to the
- 13 future of our nation. It is very much
- 14 appreciated.
- I am very pleased to make a motion
- 16 that we accept the NIOSH recommendation to
- 17 recommend to the Secretary that all Atomic
- 18 Weapons Employees who worked at Westinghouse
- 19 Electric Company in Bloomfield from August 13,
- 20 1942, through December 31, 1949, be added to
- 21 the Special Exposure Cohort.
- 22 MEMBER CLAWSON: I second.

1	CHAIRMAN MELIUS: Second from
2	Brad. Any further discussion among the Board
3	Members? If not, Ted?
4	MEMBER GRIFFON: Well, I think I
5	am just a little uneasy still on the overall
6	number of employee issue. I think yesterday
7	we had a lengthy discussion about that with
8	the GE facility, and I appreciate the
9	statement by the petitioner that there are
10	probably only a few people involved in this
11	operation, but it was a 14-acre site with 11
12	facilities. I can't imagine there were 10
13	people in these 14 buildings.
14	MR. VON ZEPPELIN: No, no, wait.
15	Wait, wait, wait. You are talking about
16	one building here. Now that is all they
17	worked on, is one building. It was not a 14-
18	acre project. It was a very from what my
19	mother told me and my father told me, this was
20	Top Secret. Nobody knew about it. Nobody was
21	supposed to know about it, only people and

they probably didn't know the whole story of

22

1	it.	They	only	had	the	need	to	know.

- 2 It was not what you call a big
- 3 facility like you have at these other plants
- 4 today that were during the Cold War. This was
- 5 very small. It was making especially one
- 6 project for basically a small number of bombs.
- 7 Now you would have to go back into
- 8 World War II mindset and what the project was.
- 9 This was not a Cold War project. Do you
- 10 listen to me? Do you hear what I'm saying?
- 11 MEMBER MUNN: We certainly do.
- MR. VON ZEPPELIN: I'm glad now,
- 13 because I don't want to go into this again and
- 14 try to educate people on what this project
- 15 was. I've had it over the years.
- 16 CHAIRMAN MELIUS: LaVon?
- 17 MR. RUTHERFORD: I would like to
- 18 address Mark's comment. I think this is
- 19 totally different than GE Evandale. First of
- 20 all, this is 1942 through 1949. It is not
- 21 1961 to 1970.
- 22 MR. VON ZEPPELIN: That is

-		
1	correct.	
_		

- 2 MR. RUTHERFORD: It is a site that
- 3 is one-tenth, or less than that, the size of
- 4 GE Evandale. The magnitude of the workforce
- 5 is not even near, and the fact of the matter
- 6 is this is a consistent application for what
- 7 we have done at Westinghouse Atomic Power
- 8 Development this same time period, Standard
- 9 Oil at the same time period, Metallurgical Lab
- 10 the same time period.
- 11 These are all those early 1942
- 12 period. We do not have data. They were
- 13 making this stuff. They were mixing it on the
- 14 roof of the building. We have no application
- of any environmental approach that we could
- 16 possibly use for that.
- 17 So my point is it is definitely
- 18 not comparable from a GE perspective.
- 19 MR VON ZEPPELIN: Okay. We got
- that point across now, I hope. I don't want
- 21 to hear another question that is just so
- 22 stupid, it blows my mind.

1	CHAIRMAN MELIUS: Okay. Any
2	further questions from Board Members? If not,
3	Ted, could you do the vote?
4	MR. KATZ: Dr. Ziemer?
5	MEMBER ZIEMER: Yes.
6	MR. KATZ: Mr. Schofield?
7	MEMBER SCHOFIELD: Yes.
8	MR. KATZ: Dr. Roessler?
9	MEMBER ROESSLER: Yes.
10	MR. KATZ: Dr. Richardson?
11	MEMBER RICHARDSON: Yes.
12	MR. KATZ: Mr. Presley?
13	MEMBER PRESLEY: Yes.
14	MR. KATZ: Dr. Poston?
15	MEMBER POSTON: Yes.
16	MR. KATZ: Ms. Munn?
17	MEMBER MUNN: Yes.
18	MR. KATZ: Dr. Melius?
19	CHAIRMAN MELIUS: Yes.
20	MR. KATZ: Dr. Lockey?
21	MEMBER LOCKEY: Yes.
22	MR. KATZ: Dr. Lemen?

Τ	MEMBER LEMEN. Yes.
2	MR. KATZ: Mr. Griffon?
3	MEMBER GRIFFON: Yes.
4	MR. KATZ: Mr. Gibson? Oh, I am
5	sorry. He is absent, and we will have to, as
6	our procedures are, collect his vote either
7	when he joins us later this afternoon or
8	afterwards.
9	Dr. Field?
10	MEMBER FIELD: Yes.
11	MR. KATZ: Mr. Clawson?
12	MEMBER CLAWSON: Yes.
13	MR. KATZ: Ms. Beach?
14	MEMBER BEACH: Yes.
15	MR. KATZ: Dr. Anderson?
16	MEMBER ANDERSON: Yes.
17	MR. KATZ: Did I call everyone?
18	So then it is unanimous, with one absent
19	Member at this point, 15 in favor.
20	CHAIRMAN MELIUS: Okay. Very
21	good. The petition is approved. We will move
22	forward with that. Thank you for your

- 1 participation, sir.
- 2 The next item is SEC Petition
- 3 Status Update, LaVon.
- 4 MR. RUTHERFORD: The purpose of
- 5 this presentation -- we typically do this
- 6 presentation at every Board meeting to provide
- 7 the Board an update of existing petitions --
- 8 MR. KATZ: LaVon, could you raise
- 9 your lavaliere? Thanks.
- 10 MR. RUTHERFORD: It would help if
- 11 I turn it on.
- 12 MR. KATZ: Turn it on. That would
- 13 be good, too. Thanks.
- MR. RUTHERFORD: Okay, does that
- 15 help?
- 16 Again, we do this presentation at
- 17 every Board meeting to provide an update to
- 18 the Board, qualified SEC Petitions that we are
- 19 currently in the evaluation phase. We also
- 20 discuss potential 83.14s that we have.
- 21 We do this -- this gives the Board
- 22 enough information to support future Work

1	Group	efforts	as	well	as	Advisory	Board

- 2 meetings.
- 3 As of January 25th, we had
- 4 received 163 petitions. I can say, as of
- 5 February 10th, which was yesterday, we had 165
- 6 petitions. I didn't look at it this morning
- 7 to give you a true value today.
- 8 We have seven petitions as of
- 9 January 25th during the qualification phase,
- 10 92 petitions that have qualified. Of those 92
- 11 petitions, four are in the evaluation process,
- 12 and 88 had completed the evaluation. We had
- 13 64 petitions that did not qualify.
- 14 Currently, these petitions are in
- 15 the evaluation phase. We have Weldon Spring
- 16 Plant. We did have a little difficulty in the
- 17 qualification process of this petition. We
- 18 had hoped to actually have this Evaluation
- 19 Report completed late in January/early
- 20 February.
- 21 We had not anticipated that we
- 22 would present it, though. Although we did --

1	we	ended	up	pushing	back	the	completion	of	the
---	----	-------	----	---------	------	-----	------------	----	-----

- 2 evaluation to March of 2010, we are trying to
- 3 address a couple of the surrogate data issues
- 4 in the evaluation.
- 5 Hooker Electrochemical, we
- 6 anticipate completing this month. The St.
- 7 Louis Airport Storage Site. Again, we are on
- 8 schedule for completion in March 2010. All
- 9 three, Weldon Spring, Hooker, and the SLAPS
- 10 Site, we anticipate presenting at the May
- 11 Board meeting.
- 12 Linde Ceramics, those you may
- 13 remember. We actually received a petition.
- 14 We had actually received a petition prior to
- for this same time period, and were unable to
- 16 qualify that petition.
- We have recently received another
- 18 petition, and through some additional work, we
- 19 actually have qualified that petition, and
- 20 that petition for the Linde Ceramics Plant,
- 21 and we will evaluate the rest of the covered
- 22 period of 1947 through 1953. The prior years

1 $$ to that are already part of the SEC. We $$

- 2 afraid Dr. Roessler's group was going to run
- 3 out of work.
- 4 Petitions with the Advisory Board
- 5 at this time. Chapman Valve, we did discuss
- 6 yesterday. I believe that the Board is going
- 7 to allow the new Board Members additional time
- 8 to review the documentation in hopes that we
- 9 can resolve that by the May Board meeting.
- 10 Blockson Chemical is in the same
- 11 situation as well.
- 12 Feed Materials Production Center.
- 13 There continues to be some work NIOSH is
- 14 working on, and NIOSH, SC&A, and the Work
- 15 Group are working to resolve the final issues
- 16 associated with that site.
- 17 Bethlehem Steel. That is with the
- 18 Surrogate Data Work Group, and I believe Dr.
- 19 Melius will correct me if I am wrong, but I
- 20 think there is a Work Group coming up very
- 21 shortly prior to the May meeting.
- 22 Hanford. This petition is -- we

1 recently did an 83.14 to add an additic

- 2 Class to Hanford. Since we have done that,
- 3 the Work Group, SC&A, and NIOSH have been
- 4 working to identify the remaining issues and
- 5 work through those issues associated with the
- 6 Hanford Site.
- 7 The Nevada Test Site. We issued a
- 8 revised Evaluation Report. Dr. Neton
- 9 presented yesterday, and the Board concurred
- 10 with recommending a Class for the Nevada Test
- 11 Site. So we should be able to move that one
- 12 to closure.
- The Mound Plant. Ms. Beach's Work
- 14 Group has worked to resolve the issues
- 15 associated with that, and based on the
- 16 discussions I have had with Dr. Ulsh, I
- 17 believe we are hoping to have that one closed
- 18 out, or hoping to come to some resolution by
- 19 the May meeting, if possible. I have to put
- 20 those caveats on that.
- 21 Texas City Chemical. We have
- 22 revised the Evaluation Report. It is not

1	issued	vet.	There	are	some	internal

- 2 discussions that are still proceeding
- 3 associated with the surrogate data and radon
- 4 model.
- 5 Area IV Santa Susana. This Work
- 6 Group continues to evaluate the issues
- 7 associated with that petition. We did just
- 8 add additional years up through 1964. We
- 9 presented that evaluation at this Board
- 10 meeting, and the Board concurred with that
- 11 recommendation. However, continued work on
- 12 the petition through '65 as well as Site
- 13 Profile issues continue.
- 14 Dow Chemical. We recently had a
- 15 Work Group meeting, Dr. Melius' SEC Work
- 16 Group. We discussed the remaining findings
- 17 from SC&A on that, and SC&A has been tasked to
- 18 go back and summarize the surrogate data use
- 19 that was identified in our approach in the
- 20 Battelle 6000 Appendix that we have for this
- 21 site.
- 22 Pantex. Again, research and

1	discussion	continues	on	this	site	between
_	arbcabbron.	COLLCTITACD	\circ		$D \perp CC$	200000011

- 2 SC&A, the Work Group, and NIOSH. I believe
- 3 NIOSH provided a response to SC&A. They did
- 4 not? It has not been released yet. I
- 5 apologize. Brad is shaking his head, and I
- 6 corrected myself there. So, hopefully, we
- 7 will get that to the Work Group soon, so we
- 8 can start getting a Work Group set up for that
- 9 -- meeting set up for that.
- 10 Savannah River Site. There was a
- 11 recent Work Group meeting on the Savannah
- 12 River Site, discussed issues associated with
- 13 the Evaluation Report and petition, and NIOSH
- 14 continues to work through a couple of issues,
- and that Work Group will continue its research
- 16 and discussion.
- 17 General Steel Industries is with
- 18 the Battelle 6000 Work Group headed by Dr.
- 19 Ziemer. As Dr. Ziemer mentioned yesterday,
- 20 there are a number of sites that that group
- 21 has been tasked with. Research and discussion
- 22 continues on that.

1 LANL. Mark Griffon's Work Gr	oup
--------------------------------	-----

- 2 is continuing work on that one as well.
- 3 Linde Ceramics Plant. Dr.
- 4 Roessler's Work Group has recently met,
- 5 actually, I believe, once in person and once
- on the phone, and continues to work through a
- 7 couple of issues that were described by the
- 8 petitioner, and we hope to be able to bring
- 9 that one to resolution soon.
- 10 Bliss and Laughlin Steel is with
- 11 the Battelle 6000 Work Group as well.
- 12 Electro-Met, again with the
- 13 Battelle 6000 Work Group.
- 14 United Nuclear. I presented that
- 15 Evaluation Report yesterday. I believe Dr.
- 16 Melius is going to allow the petitioner a
- 17 little more time until the May Board meeting
- 18 to do their presentation on that.
- 19 University of Rochester. This one
- 20 is one we presented at the Port Jefferson
- 21 meeting. Dr. Melius and Dr. Lockey were
- 22 concerned that we had possibly not done

1	complete	due	diligence	on	this,	and	Dr.	Melius
---	----------	-----	-----------	----	-------	-----	-----	--------

- 2 went back to the State of New York and
- 3 questioned to see if they could come up with
- 4 documentation on this University of Rochester
- 5 Site or identify where it may have went.
- 6 Actually, the University -- or the
- 7 State of New York was -- Dr. Melius didn't
- 8 come up with anything, but Dr. Lockey did
- 9 identify a person that indicated that the
- 10 records may have been sent to the Oak Ridge
- 11 National Lab or the Hanford Site.
- 12 We had searched the Oak Ridge
- 13 National Lab already. However, we had not
- done a detailed search of the Hanford records.
- 15 We did. In December we sent a -- we asked
- 16 the Hanford Site to do a preliminary search,
- 17 and their preliminary search showed positive
- 18 hits. We sent a formal letter requesting them
- 19 to search their records, and they identified a
- 20 number of documents.
- 21 They sent to us a list of 150
- 22 documents, I believe. If I am correct, it is

1	around	150	documents.	They	sent	а	list	to	us
---	--------	-----	------------	------	------	---	------	----	----

- 2 just recently. We are going through that list
- 3 right now to determine what records we want,
- 4 and they are going to send those records to
- 5 us.
- In the meantime, we had actually -
- 7 Dr. Glover in some of his work had
- 8 identified a different -- a search technique
- 9 for the nearer College Park in Maryland for
- 10 records, and additional searches there have
- 11 identified that there may be additional
- 12 records as well. We have already gone to
- 13 capture those records because there's also a
- 14 number of other sites that records were
- 15 identified.
- We anticipate that we will be able
- 17 to get those records, review those records,
- 18 and have a determination of any change at all
- 19 to the feasibility for the May meeting.
- 20 Brookhaven National Lab. The Work
- 21 Group has been established for that. However,
- 22 it has not met yet. They are, I believe,

1	waiting	on	SC&A's	review	of	the	post-1980
---	---------	----	--------	--------	----	-----	-----------

- 2 period.
- 3 Canoga Avenue Facility. We did
- 4 present that evaluation at this Board meeting.
- 5 However, due to Class Definition issues, we
- 6 have been sent back to do a little additional
- 7 homework, and we are going to do that. We
- 8 plan to provide an update to the Board at the
- 9 Board conference call, based on what we found
- 10 and, hopefully, we can get that resolved
- 11 quickly.
- 12 Westinghouse Electric Corp., I
- just presented, and the Board concurred with
- 14 that recommendation to add a Class.
- 15 Lawrence Livermore National Lab we
- 16 presented yesterday, and the Board concurred
- 17 with the recommendation to add a Class from
- 18 January 1, 1950 through December 31, 1973,
- 19 which was basically a modification of the
- 20 existing Class.
- 21 Lawrence Berkeley National Lab.
- 22 We presented the -- it was yesterday, I

1	believe, and the Board concurred with our
2	recommendation to add the Class there as well.
3	General Electric Company. We did
4	present that Evaluation Report yesterday.
5	However, the Board has requested that we do
6	additional work. We are going to go back and
7	do some interviews and do some additional, if
8	possible, data capture searches and,
9	hopefully, come up with a better either a
10	different Class Definition or a complete
11	argument based on our current Class
12	Definition.
13	During the last Board meeting in
14	October, there were a couple of questions that
15	were brought up by the Advisory Board. One is
16	what is NIOSH's process for ensuring that all
17	claims have been appropriately included in SEC
18	Class, and has NIOSH changed the way it
19	defines classes over time?
20	I wanted to talk when we go
21	through the process for identifying potential
22	SEC claims. We will make an initial

1 determination of an SEC Class after	after w	Class	SEC	an	of	determination	1
---------------------------------------	---------	-------	-----	----	----	---------------	---

- 2 determine there is an infeasibility.
- When we do that, during an
- 4 evaluation process we determine there is an
- 5 infeasibility. We will draft a Class
- 6 Definition. We will send that Class
- 7 Definition to the Department of Labor, and we
- 8 will ask the Department of Labor to determine
- 9 if they can administer the Class.
- 10 Once the Department of Labor
- 11 responds, if they respond that they can
- 12 administer the Class as written, we proceed
- 13 with the final evaluation. Then we will
- 14 present that final evaluation to the Advisory
- 15 Board, and the Advisory Board may concur, may
- 16 request additional work.
- 17 Once the final designation occurs,
- 18 we identify those claims that are affected by
- 19 that Class and send those claims back to the
- 20 Department of Labor. The Department of Labor
- 21 then evaluates whether the Class -- or whether
- the claims fit within the Class or not. If

1	they	return	claims	to	us,	then	we	would	assume

- 2 -- we assume that they have evaluated them
- 3 against the Class.
- 4 Ultimately, during that process,
- 5 we revise our Site Profiles to indicate the
- 6 current final designation and feasibility
- 7 determinations that we had identified in the
- 8 Evaluation Report.
- 9 So we basically revise the Site
- 10 Profiles to ensure that they identify any
- 11 infeasibilities that we identified in our
- 12 Evaluation Report to ensure that dose
- 13 reconstruction does not attempt to do those
- 14 infeasibilities.
- So once we start redoing claims --
- 16 so we are doing the partial dose
- 17 reconstructions now on non-presumptive claims
- 18 -- those reconstructions will come through,
- 19 and the dose reconstructor will review -- the
- 20 NIOSH dose reconstructor, as well as our
- 21 contractor, will review those dose
- 22 reconstructions against that revised Site

-	Pro		•	_	
1	レヤヘ	+	٦.	10	
_	$_{\rm F}$ $_{\rm L}$ $_{\rm O}$	ㅗ	ㅗ	\perp	•

- 2 If during that review the dose
- 3 reconstructor identified the claims that they
- 4 feel should have been evaluated or possibly
- 5 have been in the SEC, they will review the
- 6 claim file to determine if an SEC
- 7 determination was made from the Department of
- 8 Labor. If they go through that and they see
- 9 that there is a SEC determination, they can
- 10 determine from that determination why they
- 11 have been excluded from the Class.
- 12 If they still -- or if that does
- 13 not exist within the claim, they will
- 14 correspond with the Department of Labor to
- 15 determine why a claim was denied.
- 16 If in the process we determine
- 17 that there may have been -- that claims were
- 18 denied that ultimately we can't do dose
- 19 reconstruction from for the same reasons that
- 20 we had originally identified a Class, we will
- 21 initiate an 83.14 to basically modify that
- 22 Class.

1	If you look at what we did with
2	Y-12, here is a prime example. Y-12 was
3	defined as a Class. It was individuals
4	involved with uranium enrichment and other
5	radioactive material or other radioactive
6	areas or something. I can't remember,
7	something like that.
8	We had defined it in a manner
9	because we had felt that the site there was
10	radioactive material all through the site,
11	which would have included everyone. So we
12	defined it that way. However, the actual
13	interpretation of that was different than what
14	we had intended.
15	So we started receiving claims for
16	individuals that we felt should have beer
17	included in a Class. Ultimately, we ended up,
18	instead of what we ended up doing an 83.14
19	to modify that Class to change it to all
20	employees, which is what it is now, from '42
21	to '47.

So

the process is in place to

22

1	ensure	that	claims	that	qo	through	the

- 2 process, if they come back to us and we feel
- 3 that they were missed, we have ways to contact
- 4 the Department of Labor to review why the
- 5 claim was denied; and if, in that process, we
- 6 determine that they have denied a claim that
- 7 we can't do dose reconstruction, we can
- 8 initiate an 83.14 to resolve that.
- 9 Now I want to also say, now we
- 10 identified that with Y-12. We have done that
- 11 with Y-12 earlier. We have also done it with
- 12 Lawrence Livermore as well. So it has not
- 13 happened a lot, but it has happened.
- 14 I also want to talk about defining
- 15 SEC Classes. There has been a lot of
- 16 discussion on that as well, and I think they
- 17 kind of go hand in hand somewhat.
- 18 After going back from the Board
- 19 meeting, we perform -- we had a health
- 20 physicist, who is not typically involved with
- 21 the SEC process, perform an internal
- 22 assessment. Basically, what he was doing was

1	he	went	back,	and	he	looked	at	how	we	defined
---	----	------	-------	-----	----	--------	----	-----	----	---------

- 2 Classes from the very first one at
- 3 Mallinckrodt in Iowa to how we are defining
- 4 Classes today, and what criteria were we using
- or what boundaries were we using to do that.
- 6 From that assessment, he did find
- 7 there had been changes, as every Board Member
- 8 knows. Some of the early Class Definitions
- 9 went from defining divisions to defining
- 10 buildings, specific buildings and specific
- 11 areas, should have been monitored, and to all
- 12 employees, which we use a lot today.
- 13 So he actually went back. He went
- 14 through all these, and he laid it out. The
- 15 findings are, yes, we have changed over time.
- 16 So our path forward for that is we want to go
- 17 now, and we are going to go through each one
- 18 of the Classes we have added since the
- 19 beginning.
- 20 We are going to look at the
- 21 technical reasons that were used for defining
- that Class, from access control, environmental

1	controls,	all	the	different	things	that	we	use
---	-----------	-----	-----	-----------	--------	------	----	-----

- 2 in defining that Class, and we want to look at
- 3 the language that we used and determine if the
- 4 Class should be modified to be consistent with
- 5 how we would define a Class today.
- If that occurs -- when we do that
- 7 process, if that occurs, we would do an 83.14
- 8 to modify the Class. The difficulty with that
- 9 will be there has to be claims that are
- 10 actually being missed in order for that to
- 11 happen, meaning that we would have to have
- 12 claims that Department of Labor is denying
- 13 that we would feel would fit into that
- 14 modified Class.
- That's it.
- 16 CHAIRMAN MELIUS: That's it?
- 17 Okay. Do we have questions for LaVon? Dr.
- 18 Lockey and then Dr. Lemen.
- 19 MEMBER LOCKEY: Well, thanks for
- 20 the presentation. I have two points, because
- 21 I do have to leave in order to get a flight
- 22 out.

1	One is it is concerning about the
2	due diligence in relationship to looking for
3	records. Do you have is there a systematic
4	approach you take in that, and do you
5	reevaluate that approach on an ongoing basis?
6	MR. RUTHERFORD: Yes.
7	MEMBER LOCKEY: Why would these
8	records for Rochester be at Hanford and not at
9	Oak Ridge, and why would you have searched
10	Hanford?
11	MR. RUTHERFORD: Well, you know,
12	and we do do a general search of Hanford, the
13	DDR System, but a detailed search of every
14	record of all the records, electronic
15	databases and records, we don't do at every
16	site.
17	Now the lessons learned from that
18	and you know, it is like anything, any
19	process. If you look at what we searched at
20	the beginning of this program to what we
21	search now, it is huge, completely different,
22	because we have learned a lot of things, that

1	Hanford	is	а	great	repository	for	а	lot	of	the
---	---------	----	---	-------	------------	-----	---	-----	----	-----

- 2 records of all the sites.
- 3 So what I would say is that the
- 4 University of Rochester issue is kind of a
- lesson learned, that, okay, we need to do more
- of a formal search at Hanford for records
- 7 associated with these other sites.
- DR. GLOVER: LaVon, I just want to
- 9 make -- this is a special circumstance in that
- 10 it was Newell Stannard's collection.
- 11 MR. RUTHERFORD: I'm sorry?
- DR. GLOVER: Newell Stannard wrote
- on radioactivity and health, and he went from
- 14 Rochester to Hanford. So it is a special
- 15 collection of about 150 boxes of information
- 16 related to everything he gathered from the
- 17 beginning of time, but since he was at
- 18 Rochester, he also took the original reports
- 19 with him.
- 20 So it is a very unique
- 21 circumstance why this record collection
- 22 exists.

1 MEMBER I	LOCKEY: Some	day I would
------------	--------------	-------------

- 2 like to see maybe just a short presentation
- 3 about how you go about the process of
- 4 searching, retrieving records.
- 5 MR. RUTHERFORD: Should I add that
- 6 onto my SEC presentation next meeting?
- 7 MEMBER LOCKEY: Well, no, I don't
- 8 think we need to see it every week, but I
- 9 would like to --
- 10 MR. RUTHERFORD: No. I mean just
- 11 as a one-time.
- 12 CHAIRMAN MELIUS: As a one-time,
- 13 it is something we should consider for an
- 14 agenda item.
- I am just a little confused on
- 16 Rochester still. I thought you mentioned or
- implied that there was another set of records
- 18 someplace.
- MR. RUTHERFORD: Yes.
- 20 CHAIRMAN MELIUS: That one, I am
- 21 also --
- 22 MR. RUTHERFORD: Sam could

1	actually	talk	about	the	search	tool	that	was

- 2 identified, but it is National Archives
- 3 records at College Park, I believe, and they
- 4 had identified -- it was another search tool
- 5 that was used that actually identified records
- 6 that had been missed in the first search.
- 7 CHAIRMAN MELIUS: Maybe then as
- 8 part of the presentation -- Sam, do you want
- 9 to add anything to that?
- 10 DR. GLOVER: It was a -- DOE
- 11 captured certain historical records that they
- 12 had essentially -- we thought they were in one
- 13 location, and they had been subsequently
- 14 moved. So you had to pull a different thread,
- and it happened that I came across a different
- 16 finding, a large collection of these early AWE
- 17 facility records, but they had been moved. So
- 18 it was --
- 19 CHAIRMAN MELIUS: I think we
- 20 understand the difficulty, but as we are
- 21 talking about SEC Class Definitions, I think
- 22 we know that there will always be this stuff

1	out	there	that	is	going	to	be	found	10	years

- 2 later, but I think at least my concern is that
- 3 someday we are going to come across -- we will
- 4 have granted an SEC, and then we are going to
- 5 find all of the records for that SEC.
- I don't know if we have a
- 7 procedure for rescinding an SEC, but it is
- 8 just a difficult circumstance. Hopefully, we
- 9 don't have to confront it, but I think it is
- 10 as thorough as it can be, but we understand
- 11 that takes time and money to do. So there has
- to be some level of reasonableness on it.
- I think it would be helpful for
- 14 the Board maybe at one of the next few
- 15 meetings. Maybe we can even do it on our next
- 16 conference call, the kind of thing that we
- 17 could do for that. Dr. Lemen?
- 18 MEMBER LEMEN: Did you have
- 19 something else, Jim? You had you had two
- 20 points.
- 21 MEMBER LOCKEY: I have one other,
- 22 and this goes around the General Electric

1	issue	in	regard	to	how	а	Class	is	defined	in	а

- 2 large industrial complex where part of the
- 3 process at the complex is devoted to these
- 4 types of production issues, but the rest of it
- 5 is not.
- 6 It would be labor intensive, but
- 7 some type of archeological reconstruction of
- 8 the site would at least give us some
- 9 information as to what kind of issues we are
- 10 dealing with, with a large workforce where
- 11 perhaps only a small percentage of the
- 12 workforce is involved with this type of
- 13 nuclear production issue. General Electric
- 14 would be a good example of that.
- 15 How do we define what this plant
- 16 looks like? What were they making over what
- 17 time frame, and how many buildings? Just an
- 18 education so at least we have something we can
- 19 rely on to say we can't determine it or
- 20 perhaps we can determine boundaries in
- 21 relationship to Class limitation.
- 22 MR. RUTHERFORD: I have no problem

1 with that and agree with that. I think the	1	with	that	and	agree	with	that.	I	think	t.
--	---	------	------	-----	-------	------	-------	---	-------	----

- 2 biggest thing, from my perspective, is
- 3 understanding where that boundary -- where, at
- 4 what level of information or what definition
- is the Board going to be acceptable of? I
- 6 believe that, in order to reduce -- to define
- 7 any of these Classes in a more smaller
- 8 geographical area, in some cases it is going
- 9 to be a subjective determination based on
- 10 information that you hear from interviews and
- 11 such.
- 12 MEMBER LOCKEY: I think the Board
- is capable of making those decisions, but we
- 14 have to make them with at least some
- 15 foundation, and right now we don't have
- 16 foundations for certain of these sites.
- 17 CHAIRMAN MELIUS: Dr. Lemen?
- 18 MEMBER LEMEN: I would like to ask
- 19 if NIOSH in their future presentations on
- 20 their tables, under the SEC Evaluation
- 21 Reports, if it would be possible to add two
- 22 things.

1	First, under the ER completed,
2	could you add when the petition was initiated?
3	MR. RUTHERFORD: I certainly can.
4	MEMBER LEMEN: And secondly, under
5	the facility and Class evaluation, could you
6	give us an estimate, if you have it, of the
7	number of persons that would be covered under
8	those classifications? Is that possible? Do
9	you have estimates like we
10	MR. RUTHERFORD: Yes.
11	MEMBER LEMEN: I am going to what
12	Jim Lockey said, and that is yesterday when we
13	talked about General Electric and others, I
14	don't think that NIOSH understood the size of
15	the population that they were looking at, and
16	to include all 10,000 or 12,000 people you
17	know, the Board could pass that, but not
18	realize the size of it. Is there some way you
19	can estimate size and put that in your report
20	next time?
21	MR. RUTHERFORD: Yes, we can
22	estimate the workforce the size of the

1	workforce.	I	mean,	part	of	our	evaluation
---	------------	---	-------	------	----	-----	------------

- 2 process is to try to do that.
- I will say, though, that NIOSH was
- 4 very familiar with the size of GE Evandale,
- 5 considering the fact that most of us drive by
- 6 it or have been by it a number of times. So I
- 7 don't think that was not recognized, and we
- 8 have discussed that.
- 9 MEMBER LEMEN: Thank you.
- 10 CHAIRMAN MELIUS: Dr. Ziemer?
- 11 MEMBER ZIEMER: I have almost
- 12 forgotten what I was going to ask, but I do
- 13 have a follow-up.
- 14 I like the concept that Dr. Lockey
- 15 has suggested where, on a large site like GE,
- it may be possible for us; and this wouldn't
- 17 be completely subjective, but it would require
- 18 judgments, to think about the likelihood that
- 19 a person on another part of the site could
- 20 have roamed into the area unchallenged, and
- 21 maybe narrow down such a site.
- 22 Then the burden would be on

1 someone	outside	some	parameter	to	make	а	case
-----------	---------	------	-----------	----	------	---	------

- that, yes, I went there for lunch every day,
- 3 because my good buddy worked there, or
- 4 something like that. But it seems to me, we
- 5 can make some judgments, if necessary, that
- 6 would put some level of restriction on some of
- 7 these.
- 8 The original thing I was going to
- 9 talk about now -- I figured if I talked long
- 10 enough, it would come back to me. I do
- 11 commend what you are proposing, to go back and
- 12 look at how the language has evolved over
- 13 time, but can you give us some idea of when
- 14 that process will be ready? This isn't going
- 15 to take a whole lot of time. It sounds like
- 16 you are underway already.
- 17 MR. RUTHERFORD: Yes.
- 18 MEMBER ZIEMER: So are you going
- 19 to be reporting back fairly soon on that?
- 20 MR. RUTHERFORD: Yes. I can
- 21 probably give a better estimate of completion
- 22 at the Board conference call, and with any --

1	in	mу	mind,	I	can	sit	here	and	think,	oh,	we

- 2 can do that and be ready by May, but then I
- 3 start to actually look at resources and
- 4 everything else, and recognizing all the other
- 5 things everybody will remind me that they have
- 6 to do. But I think I could definitely give
- 7 you a good finish date at the Board conference
- 8 call.
- 9 CHAIRMAN MELIUS: We will hold you
- 10 to that, by May, but -- Henry?
- 11 MEMBER ANDERSON: I just wanted to
- 12 raise the issue. Is there any difference in
- the efforts to identify workers who were there
- 14 or I think, like at the GE Plant, there has
- 15 got to be, of all of those people, far more
- than you maybe talked to that could give us at
- 17 least a subjective feel for did people move
- around the site or what types of people did.
- 19 Certainly, if you were a
- 20 maintenance worker, you might have. So those
- 21 kind of things, and when you kind of make a
- 22 determination that you can't do dose

1	reconst	ruct	cion,	thin	ıgs	seem	to	move	e pr	retty
2	quickly	, ar	nd I d	don't	kno	w if	you	give	the	same
3	amount	of	emph	asis	to	goin	g aı	nd ti	rying	g to

- 4 track down and talk to people when you have
- 5 done a data search and it is not there, and
- 6 then it seems we may move ahead very quickly
- 7 when, in fact, describing how people
- 8 interacted on the site might be very helpful
- 9 in the Class Definition, once you have made
- 10 that --
- MR. RUTHERFORD: Dr. Melius has
- 12 actually made that point on a few occasions.
- 13 You know, again -- and we will definitely move
- in that direction in the future, and we will
- 15 work to make sure that we get additional
- 16 interviews.
- 17 Up to this point, we have kind of
- 18 looked at that the bar was up here and
- 19 reducing the Class, meaning that we needed to
- 20 have the data, the actual supporting
- 21 environmental monitoring data and other
- 22 information, that we could quantitatively

1	ensure	that	we	could	bound	exposures	for	those
---	--------	------	----	-------	-------	-----------	-----	-------

- 2 people outside.
- Now just in the Board's discussion
- 4 that there may be a little movement in that, I
- 5 think there is definitely some -- there would
- 6 be some added value in going back and doing a
- 7 lot more work with our worker interviews.
- 8 CHAIRMAN MELIUS: Can I just
- 9 follow up a little bit on that, on some
- 10 questions to what Dr. Ziemer is saying. I
- 11 think it was the point Brad made yesterday
- 12 also when we were talking about General
- 13 Electric, is that I think one of the concerns
- of the Board is that, okay, you are sort of
- 15 broadening your definitions for the major
- 16 sites where there is a lot of activity going
- on and a lot of workers who routinely would
- 18 have exposures of some sort.
- 19 Now that may be balanced by
- 20 controls on access and sort of also the nature
- of the facility and what it is doing. Then on
- the other hand, we have these AWE sites, these

1	older	sites	where	there	is	very	little

- 2 information, which is the problem, but at the
- 3 same time, I think there is a feeling at these
- 4 larger manufacturing facilities that there is
- 5 relatively less probability that a person on
- 6 that site would have significant exposures,
- 7 loosely defined.
- I think that is what we are sort
- 9 of wrestling with and trying to come up with a
- 10 right balance so that we are being equitable
- in terms of how we are treating people at
- 12 these different sites.
- 13 Back to the SEC Class Definition
- issues, my recollection is that way back when
- we started the program, originally -- we had
- 16 discussions on this and disagreements, I think
- 17 -- we had to redo a Class or so. I can't
- 18 remember what the circumstances were, but
- 19 originally it was that the Department of Labor
- 20 would show up at the meetings, and that would
- 21 be the first time they would see the report,
- 22 basically when it was presented for the Class

_						
1	Def	ı n	¬ +	٠,	α n	
工	DCI		エし		O_{11}	

- 2 So there was some -- we tried to
- 3 work out some problems there. So then you
- 4 started the process of sharing the information
- 5 with the Department of Labor. I think, from
- 6 Department of Labor's side, they are trying to
- 7 think how can they practically process that
- 8 Class Definition, make that operational, given
- 9 what information they have and the natures of
- 10 the claims coming in to them.
- 11 Then, clearly, they don't have the
- 12 same access or people with access to all the
- information that NIOSH may have, and they may
- 14 need other types of information that is
- 15 useful, clearly, evidence a person was
- 16 employed there. So personnel records or at
- 17 least records that people worked at these
- 18 sites are more critical to them.
- 19 I just would think that it would
- 20 help us if we also maybe had a better
- 21 understanding of how the Department of Labor
- 22 currently implements an SEC and how they get

1 instructions out.

We have done that occasionally

3 with other -- some of the Classes in terms of

4 their instructions on how to do that, but I

5 think some sort of overview from them and

6 update, because if we are going to change how

7 we do SEC Class Definitions, we should do it

8 with input from Department of Labor also on

9 that.

10 I think, clearly, something like

11 the GE -- the proposed GE Class Definition is

12 the most easy one to implement, just did you

13 work there and so forth. Then it should have

14 been monitored, clearly, is another high level

15 complication for them in terms of how they

16 make that work, or in a building and so forth.

17 So I think we need to find some

18 way that is appropriate in terms of who is

19 getting covered and, at the same time, is

20 practical to implement. So I would hope we

21 would be able to do that with input and

involvement from the Department of Labor also.

1	So, Jeff, if you could think about
2	that also.
3	David Richardson, do you have any
4	questions? Oh, sorry, Regina first.
5	MS. CANO: Dr. Melius, I just
6	wanted to add, I think it is also helpful if
7	this information is shared with the site as
8	well, because they can actually let you know
9	how difficult it may be to put somebody on
10	site or find records for those individuals.
11	So we have come into that problem
12	in the past. So I share that with NIOSH as
13	well as Department of Labor when they are
14	defining the Class.
15	CHAIRMAN MELIUS: I think that
16	would be appropriate also. I don't believe
17	that I think one of the difficulties we
18	have when we are defining a Class is the
19	nature most of the records at the site are
20	things that's being developed by NIOSH. You
21	are looking for exposure records, and you are

not looking at personnel records or what is

22

1 available at the site for conf	irming
----------------------------------	--------

- 2 employment at DOE, nor should you be.
- Most of the time, you don't need
- 4 it, but that is something that, I think,
- 5 Department of Labor needs to do. Clearly, it
- 6 puts a burden on the sites and on Department
- of Energy, and they may know other sources of
- 8 information that would make it facilitate that
- 9 process.
- 10 I know there are a lot of
- 11 difficulties with many of the -- confirming
- 12 subcontractors when people worked there and so
- 13 forth. So maybe we can work out a process
- 14 among the three agencies that would make this
- 15 all work better. That is a good suggestion.
- 16 Thanks. Sorry, David Richardson, do you have
- 17 any questions for LaVon?
- 18 MEMBER RICHARDSON: No, I don't
- 19 think so. I thought that the story of how
- 20 Rochester records ended up at Hanford was
- 21 really interesting, and it made me think about
- 22 whether there was -- you talked about one set

1	of	lessons	learned	about	looking	at	Hanford

- 2 but then it was pointed out that this was --
- 3 you know, it's got a particular narrative
- 4 thread to it, that somebody moved from one
- 5 institution to another one, and then those
- 6 records were archived there.
- 7 I know from my own experience that
- 8 that is often the case, that people will end
- 9 up leaving their records at an institution or
- 10 at a nearby library or archive where they
- 11 stop.
- 12 So I was trying to think if there
- 13 was a way to exploit that more, and have you
- 14 thought about that?
- MR. RUTHERFORD: No, I don't know.
- 16 We put together -- typically, when we go to
- 17 these sites like Hanford with large electronic
- databases, we put in a number of search terms.
- 19 We wouldn't just put in -- we may not just
- 20 put in University of Rochester. We may
- 21 actually put in other things, if we know there
- 22 were specific positions and such that worked

1	there.	We	may	put	their	name	in	as	well,	but

- 2 beyond doing that, I don't know what else we
- 3 can do.
- 4 It is something I can definitely
- 5 think about.
- 6 MEMBER RICHARDSON: Yes. I wasn't
- 7 thinking about search terms so much as there
- 8 are a few key personnel that -- people in
- 9 charge of health physics programs, for
- 10 example, if you could identify their
- 11 professional history when you are looking, do
- they end up moving to another DOE facility?
- We have had people that left their
- 14 records to the university in the city where
- 15 they were, for example. So I was trying to
- 16 think if that sparked an idea.
- 17 For example, could you identify
- 18 the key for a period, a covered a period, the
- 19 head of the health physics department, and
- 20 figure out where they ended up, and would that
- 21 give you another clue for another place to
- 22 look?

1	MR. RUTHERFORD: And that is a
2	good point. We do do that on a lot of
3	occasions. We will actually try to determine
4	who the RSO for some facilities or who the
5	head of the health physics department was
6	during those time periods. We have done that
7	in the past, but that is a good suggestion to
8	ensure that is part of our protocol.
9	CHAIRMAN MELIUS: David, in the
10	Rochester situation, NIOSH had talked to a lot
11	of people at the University who were
12	apparently trying to cooperate. It was just
13	identifying the person who had left with the
14	records was hard.
15	I was suspicious that they were
16	available, because I knew somebody that wanted
17	to do a study with them. So I thought they
18	might have been New York State might have -
19	- I knew they were available at least about 12
20	years ago. So where they were I didn't know,
21	but I knew somebody had access to them and
22	knew where they were.

1	So between Jim and I, with our
2	contacts at University of Rochester in New
3	York, we had a few more people that we could
4	talk to. But it wasn't that NIOSH didn't try,
5	and it is hard, but I think your points are
6	good, that especially in the universities and
7	settings, as people move around, yes, they do
8	tend to bring records with them, if they are
9	going to do some sort of follow-up with them.
LO	Hopefully, we can identify those
11	people.
L2	MEMBER RICHARDSON: Oh, yes. I am
13	not implying that you are not trying at all.
14	This is total detective work. I commend you
L5	for your efforts. I thought it was an
L6	interesting one and it made me think about
L7	other lessons learned. Thank you.
18	CHAIRMAN MELIUS: Thank you. Any
L9	other questions for LaVon? If not, you are
20	off the hook, LaVon, and we will take a break.
21	We will start at 10:45. I think we have
22	somehody calling in then as part of our

1	follow-up.	Ted	anv	announcements?
	TOTTOW up.	ieu,	ally	ammouncements:

- MR. KATZ: Yes. Just that we need
- 3 to try to start promptly at 10:45, for that
- 4 reason.
- 5 (Whereupon, the above-entitled
- 6 matter went off the record at 10:17 a.m. and
- 7 resumed at 10:47 a.m.)
- 8 CHAIRMAN MELIUS: If everyone can
- 9 get seated, we will get started here, please.
- 10 MR. KATZ: Thank you, everybody.
- 11 Before we proceed, let me check the phone
- 12 lines. First, our two Board Members, Dr.
- 13 Richardson and Mr. Gibson, are you with us
- 14 again?
- 15 MEMBER RICHARDSON: I am, David
- 16 Richardson.
- 17 MR. KATZ: Well, Mr. Gibson -- I
- 18 am not sure if he was going to be able to make
- 19 this session either.
- 20 Let me also check. We are
- 21 expecting a Congressional staffer to join us,
- 22 Mr. Richard Miller with the House -- Education

- 1 and Labor Committee of the House. Richard,
- 2 are you with us? Richard Miller? We are just
- 3 going to hang in here for a couple of minutes
- 4 and give Richard a little bit of time to join
- 5 us.
- 6 MEMBER RICHARDSON: I believe
- 7 Richard is on the phone. Can you hear him?
- 8 MR. KATZ: We couldn't. We
- 9 cannot. Richard, we can't hear you.
- 10 (Off the record comments.)
- 11 MR. MILLER: Hi, there. Richard
- 12 Miller.
- 13 MR. KATZ: Okay, thank you,
- 14 Richard. Glad you could join us.
- MR. MILLER: Sorry for the delay.
- 16 I called a little earlier.
- 17 MR. KATZ: No, that is quite all
- 18 right, and we have not begun.
- 19 MR. MILLER: Terrific.
- 20 CHARIMAN MELIUS: We are just
- 21 coming back from a break, and I would like to
- 22 start. We have a number of administrative

1	issues,	other	issues,	to	deal	with	for	the

- 2 rest of the day, including a number of Work
- 3 Group reports, Subcommittee reports.
- 4 The first issue -- a couple we
- 5 want to try at the time. As I said earlier,
- one will be this discussion of surrogate data,
- 7 and we will hear from Richard Miller from the
- 8 House Education and Labor Committee in a
- 9 second, and then, as I said, the worker
- 10 outreach evaluation framework we will talk
- 11 about.
- We are hoping that Mike Gibson
- 13 will join us on the line. He had some
- 14 personal business to deal with today, but
- 15 should be back on later this morning or early
- 16 this afternoon.
- 17 So why don't we start with the
- 18 surrogate data discussion. There is a draft
- 19 of the criteria. The Surrogate Data Work
- 20 Group met a few weeks ago. There is an
- 21 updated draft that I have circulated to
- 22 everybody and, I believe, is on your

1 information, the memory sticks that we wer
--

- 2 all given here.
- Before we start that, I believe
- 4 Richard Miller had wanted to give us a little
- 5 bit of background. So, Richard?
- 6 MR. MILLER: Hi, there. Well,
- 7 thank you. I won't take much of your time. I
- 8 assume you have the whole Board there except
- 9 David Richardson. Is that right?
- 10 CHAIRMAN MELIUS: David is on the
- 11 line.
- 12 MR. MILLER: Terrific. Well, I
- 13 appreciate you all just giving me two minutes
- 14 here on this issue. We have had some
- 15 discussions, just by way of background, both
- with the GAO and between and amongst a variety
- 17 of Congressional -- individual Congressional
- 18 offices and the Senate Health Committee and
- 19 the House Ed and Labor Committee, regarding
- 20 NIOSH's interpretation of EEOICPA as it
- 21 pertains to the use of surrogate data and,
- 22 while your Board may not be necessarily poised

1	to	address	the	specific	legal	issues,	the

- 2 intersect between science and laws, where
- 3 policy gets formulated,
- 4 In this instance, the discussions
- 5 that we have had and particularly with Dr.
- 6 Howard when he came in, with Stu Hinnefeld and
- 7 others about a month or so ago was to ask
- 8 NIOSH to please present to us their view on
- 9 why it is even permissible for surrogate data,
- 10 with the definition of surrogate data being
- 11 data used from other sites for purposes of
- 12 either individual dose reconstruction or for
- 13 use in decision making on whether to approve
- or deny a Special Cohort -- and the Agency's
- 15 view expressed to us was that they believe
- 16 that the statute, although it does not
- 17 expressly authorize the use of surrogate data,
- 18 it also does not preclude the use of surrogate
- 19 data.
- 20 What I had sorted wanted to make
- 21 sure you all had as a data point coming out of
- 22 that discussion, because it included people

1	who	 Members	who	were	involved	in	the

- 2 original negotiations on EEOICPA back in 2000,
- 3 including Senator Bingaman and Senator Harkin,
- 4 and other --
- 5 CHAIRMAN MELIUS: Richard, we just
- 6 lost you.
- 7 MR. MILLER: Sorry, I interrupted
- 8 you. I apologize for the interruption.
- 9 What happened was that, out of the
- 10 course of that discussion, there was an issue
- 11 raised which was, has the Department exceeded
- 12 its legal authority by using data from other
- 13 facilities in reconstructing dose.
- 14 Then, of course, a number of cases
- 15 have come up over the years where this has
- 16 arisen. A White Paper was provided by NIOSH
- to the committees, and here, I guess, is sort
- of where we came down, and for the benefit of
- 19 your deliberations.
- 20 Our view, based on a textual
- 21 reading of the law and the intent as folks
- 22 recall and understand it, is as follows: That

1 t	o the	extent	that	radiation	dose		and	this
-----	-------	--------	------	-----------	------	--	-----	------

- is out of Section 7384n, if you have a copy of
- 3 EEOICPA handy, which deals with the section on
- 4 exposure in the performance of duty -- Dr.
- 5 Melius, do folks have access to a copy of the
- 6 statute?
- 7 CHAIRMAN MELIUS: Yes, they do. I
- 8 believe it has also been provided to everybody
- 9 on the memory stick.
- 10 MR. KATZ: Yes. It was circulated
- 11 to everybody, at least by a link. But, yes,
- 12 it was provided in advance.
- 13 MR. MILLER: Thanks so much. In
- 14 Section 7384n, it was sort of our view that
- the use of surrogate data, while not expressly
- 16 prohibited, there was a clear preference to be
- 17 using the data from, quote, such facility,
- 18 meaning the facility where employees were
- 19 employed.
- 20 In particular, what I would like
- 21 to do is to draw your attention under Section
- 7384n covering exposure in the performance of

1	duty	to	Subpart	С,	which	deals	with	the

- 2 guidelines for estimating radiation dose.
- 3 Under that, the guideline should
- 4 be based on radiation dose received by the
- 5 employee, paren, or a group of employees
- 6 performing similar work at such facility. It
- 7 doesn't speak there to using other facilities.
- It does contemplate the notion of
- 9 coworker models by using a group of employees
- 10 performing similar work, but it didn't speak
- 11 to a group of employees performing similar
- 12 work at any facility other than such facility,
- and in this case the term such facility refers
- 14 to a facility where they were working, not
- 15 some other facility.
- So when we thought about the
- 17 Blockson Chemical instance when, at one point,
- 18 NIOSH had proposed to contend that they could
- 19 reconstruct radon dose from the Blockson
- 20 facility in Illinois based on emissions
- 21 measured coming off of a stack of phosphate
- 22 waste in Florida from a fertilizer factory

1 there, that clearly, although you may ${ t h}$	⊥	there, tha	crearry,	arthough	you	may	Have
--	---	------------	----------	----------	-----	-----	------

- other ways to choose on whether you would use
- 3 or not use such data, the question was is it
- 4 even permissible.
- 5 So since we are dealing here with
- 6 the guidelines for the interpretation of the
- 7 statute, dealing with dose received by the
- 8 employee or group of employees performing
- 9 similar work at such facility -- we felt it
- 10 was exceeding the statutory authority to even
- 11 contemplate the use of surrogate data for
- 12 approving or denying claims or approving or
- 13 denying petitions. However, such quidelines
- 14 also are to incorporate methods established
- 15 under Subsection D below.
- 16 The Subsection D on the methods
- 17 for dose reconstructions deal with coming up
- 18 with regulations for reasonable estimates of
- 19 dose received by an individual specified in
- 20 The Act for each of the following employees.
- 21 And again, an employee was not monitored for
- 22 exposure at such facility. They were

1	inadequately	monitored	at	such	facility.	The
---	--------------	-----------	----	------	-----------	-----

- 2 exposure records at such facility are missing
- 3 or incomplete.
- 4 What we have is we have a constant
- 5 emphasis in four cases here toward Congress'
- 6 intent that one look to such facility where
- 7 the employee was employed for purposes of
- 8 establishing dose, and if you can't do it
- 9 using those guidelines, then you go to a
- 10 Special Cohort. That is why the cohort is
- 11 there.
- 12 So from our perspective, as a
- 13 matter of what the boundary conditions were
- 14 that were established and are reflected in the
- 15 plain language of The Act, it seemed to us a
- stretch for NIOSH to conclude legally, unless
- 17 there is some formal legal opinion that they
- 18 have provided to you all and not provided to
- 19 us -- it seemed to us a stretch to interpret
- 20 that such facility could be construed to
- 21 include facilities where people were not
- 22 working and for where such dose could be

-	7 '		
1	deriv	\sim	
1		-(1	-

- 2 So that was our conclusion in our
- 3 communications. I think it was sort of a
- 4 consensus view from the Senate Health
- 5 Committee, Senator Bingaman, our Committee
- 6 staff, that the Department had exceeded its
- 7 legal authority in moving forward with the use
- 8 of surrogate data.
- 9 I don't think any of us took any
- 10 issue if surrogate data were to be used for
- 11 validation purposes. In other words, if you
- 12 already have some data from such facility, and
- 13 you want to validate that that is reasonable
- 14 data, that didn't seem to us to be exceeding
- 15 the boundaries, but if you didn't have data
- 16 from such facility to start with, importing it
- 17 from elsewhere exceeded the statutory basis.
- 18 That was just our comment on that,
- 19 and we thought we would put that on the table.
- 20 If folks have questions, we would be delighted
- 21 to take them.
- 22 CHAIRMAN MELIUS: Thank you, Mr.

1	Miller.	Anybody	have	questions?	Wanda,	I
---	---------	---------	------	------------	--------	---

- 2 see.
- 3 MEMBER MUNN: Well, not so much
- 4 questions as a comment or two.
- 5 Richard, I think you have defined
- 6 very clearly one of the greater issues that
- 7 exist in our society today. Snow talked about
- 8 it in his Two Worlds. When you say policy is
- 9 where law and science have to meet, you are
- 10 talking about large segments of people, both
- 11 with certain kinds of powers, who do not
- 12 communicate well with one another, and each
- 13 group working under the assumption that the
- 14 other does not understand the real issue.
- 15 That is probably true, to a large
- 16 extent. I risk offending both groups, I
- 17 suppose, by saying it is probably true that
- 18 most technical people don't understand and
- 19 don't appreciate the law very well, and most
- 20 people who are involved in the law don't
- 21 appreciate and understand science and numerics
- 22 very well. But that doesn't change the fact

1	that	we	have	а	job	to	do.

- I have been told on more than one
- 3 occasion in this particular forum that it is
- 4 not my place to question the sense of Congress
- 5 or to attempt in any way to --
- 6 MR. MILLER: I'm sorry. Could you
- 7 speak up, Wanda, a little bit? I have a hard
- 8 time hearing you, trailing off.
- 9 MEMBER MUNN: I'm sorry. I
- 10 thought I was right on the microphone. Can
- 11 you hear me now?
- MR. MILLER: Go ahead.
- 13 MEMBER MUNN: So, obviously, if we
- 14 are to not question the position that our
- 15 Congressional leaders take with respect to the
- scientific work that is being done, it is very
- 17 difficult for us to respond to concerns of the
- 18 sort that you are bringing to us here.
- 19 If those positions are writ in
- 20 stone, as it were, and we are asked not to
- 21 question them, then all we can do is accept
- the position that you bring to us as being an

1	accurate	one,	even	though	that	may	run
---	----------	------	------	--------	------	-----	-----

- 2 contrary to everything that our other
- 3 scientific minds may tell us.
- 4 When you speak of the Blockson
- 5 issue as being improperly compared to a
- 6 fertilizer plant in Florida, you are speaking
- 7 of a situation which is worthy of a couple of
- 8 hours of vigorous debate face to face, and we
- 9 certainly can't argue that with you here now.
- 10 But I am trying to understand exactly the
- 11 bottom line of what you are saying here.
- 12 Are you saying that the Committee
- which you represent is giving instructions to
- 14 this group to disregard anything other than
- 15 the position that surrogate data must consist
- 16 only of data from plants -- from, not
- 17 necessarily plants, but facilities involved in
- 18 exactly the same work with exactly the same
- 19 materials? Is that the purpose of your
- 20 discussion with us today?
- 21 MR. MILLER: Is that a question?
- MEMBER MUNN: Yes, it is.

1	MR. MILLER: Okay. I think the
2	concept of instructing you is a bit extreme,
3	if that is the word you were using. I think
4	the point we are making is that the statute
5	has plain language. There was discussion at
6	some length when this thing was put together
7	back in 2000.
8	Those considerations ought to be
9	factored in as you look at whether or not the
10	policy you have there conforms to your reading
11	of the statute and/or your and to the
12	extent that there is value in identifying the
13	parameters that the statute contains from our
14	perspective, then you can weigh that
15	accordingly.
16	You're a body tasked with
17	providing advice both on matters of science
18	and policy. You are not there to provide
19	you are not tasked by statute with rendering
20	legal determinations.
21	Having said that, you can either
22	take or leave what it is we have to offer

1	here,	but	I	think	that	from	the	folks	who	have
---	-------	-----	---	-------	------	------	-----	-------	-----	------

- 2 been looking at the use of this surrogate
- 3 data, there have been a lot of questions
- 4 raised.
- 5 There was a consideration as to
- 6 whether or not to even seek a separate legal
- 7 opinion from the Government Accountability
- 8 Office on whether or not NIOSH was going to
- 9 exceed its legal authorities by using
- 10 surrogate data in a manner to dispose of cases
- or petitions, and we had told NIOSH that we
- 12 would probably hold off on such a request for
- a legal opinion until we saw what the Advisory
- 14 Board came back with through its Working Group
- 15 process, which had been advised of by Dr.
- 16 Howard, and we were going to wait until we saw
- 17 what your policy looked like and whether Dr.
- 18 Howard adopted it or not.
- 19 So the final shape of what our
- 20 reaction will be from a Congressional point of
- view will, in part, be shaped by what you all
- 22 and Dr. Howard and the Agency adopt. So at

1	this	point,	our	view	is	 this	is	the

- 2 perspective we have to offer in terms of the
- 3 legislative language and our appreciation of
- 4 what the history was.
- 5 There may be different legal views
- 6 and different legal opinions about what this
- 7 law means or how you should or shouldn't use
- 8 surrogate data, and I am sure that NIOSH has
- 9 their own views, but to the degree and extent
- 10 that you are going to be developing a policy
- and sending it up through as a recommendation
- 12 to the Secretary, at that point we will make
- our own judgments as to how we will choose to
- 14 react, whether it is to seek a legal opinion
- 15 to provide greater legal clarity in the
- 16 statute, if necessary. So that remains to be
- 17 seen.
- 18 MEMBER MUNN: Thank you.
- 19 CHAIRMAN MELIUS: Dr. Ziemer.
- 20 MEMBER ZIEMER: Good morning,
- 21 Richard. Paul Ziemer here. I just wanted to
- 22 seek some clarity when you spoke about our

- 1 view and how we felt, and so on.
- 2 Are you expressing the views of
- 3 the current Senate Committee with which you
- 4 are working versus the initial views when the
- 5 legislation was established? It wasn't clear
- 6 to me, or were you indicating that it reflects
- 7 both? Could you clarify that, and then I have
- 8 a follow-up.
- 9 MR. MILLER: Sure. Hi, Dr.
- 10 Ziemer. Thank you for the question.
- 11 What we are reflecting right now
- is sort of a product of our Committee's work.
- 13 I know the Senate Health Committee is also on
- 14 this call. So they can certainly speak for
- 15 themselves, because I am only on the House
- 16 side, and there is another body on the other
- 17 side of the Capitol.
- 18 MEMBER ZIEMER: I'm sorry. I
- 19 meant to say the House side. I didn't want --
- 20 MR. MILLER: I think the Senate
- 21 folks are on the call as well.
- 22 MEMBER ZIEMER: -- didn't want to

1	insult	you	with	Senate	staff,	sir.	Go	ahead.
---	--------	-----	------	--------	--------	------	----	--------

- MR. MILLER: In any event, what we
- 3 are offering you is -- this issue was brought
- 4 to a head since I have come to the Committee
- 5 as something that a bipartisan working group
- in the House and the Senate of various member
- 7 offices, many of whom were signatories on the
- 8 request to the GAO, wanted to get addressed.
- 9 They had two sets of legal issues
- in the implementation of the statute, one of
- 11 which is this, and there is another one
- 12 involving the Labor Department. They have
- 13 asked for our assistance in bringing clarity
- 14 to this issue, and try to identify whether it
- 15 can be resolved administratively or whether
- 16 this is something that needs to be addressed
- 17 legislatively.
- 18 So that is the capacity in which I
- 19 am bringing this forward.
- 20 MEMBER ZIEMER: Thank you. That
- 21 is helpful. The other comment that I would
- 22 add at this point, and I think we are aware

1 that	there	has	been	some	debate	over	the	years
--------	-------	-----	------	------	--------	------	-----	-------

- 2 as to, certainly, the proper use of surrogate
- data, and one of the focuses and objectives of
- 4 Dr. Melius' Work Group is to bring clarity to
- 5 that in terms of how we use that and to
- 6 develop criteria for the proper use.
- 7 I think many of us on the Board
- 8 feel that, from a scientific point of view,
- 9 the use of surrogate data -- not just in this
- 10 particular instance, but as a broad scientific
- 11 approach to many matters where there may be,
- 12 for example, missing information -- is a valid
- 13 scientific process.
- 14 The public policy part of that, of
- 15 course, is what is being dealt with here, that
- if the public policy is going to use that, we
- obviously have to use it in a proper way, and
- 18 so far we have been operating under the sort
- 19 of understanding that surrogate data was
- 20 allowed, provided it was properly used.
- 21 You mentioned the criteria which
- 22 you want to look at, and I think that is

- 2 using surrogate data improperly, in any event.
- 3 So our goal in that regard, I think, matches
- 4 yours. However, if the legislative bodies
- 5 believe that, even with that, it is not
- 6 appropriate for this program, I think that is
- 7 their prerogative to move in what direction
- 8 they believe to be appropriate, and we would
- 9 have to live with that. But I do want to at
- 10 least personally be on record as indicating
- 11 that the proper use of surrogate data
- 12 certainly is not scientifically wrong, and
- 13 that could, if properly used, help in the
- 14 decision making within the framework of the
- 15 existing law.
- So those are my comments, Richard.
- 17 Thank you.
- 18 MR. MILLER: Well, Dr. Ziemer, I
- 19 think, if the statute were clear that there
- 20 were express authorization to do so, I don't
- 21 think there would be any dispute in this phone
- 22 call today; but I think there is significant

1 question as to whether the Departme	ent has
---------------------------------------	---------

- 2 exceeded its legal authority up to this point
- 3 in using surrogate data, and your Working
- 4 Group or the Working Group that Dr. Melius has
- 5 been chairing, I guess, has been trying to
- 6 refine a policy so that it is validated and is
- 7 appropriately applicable.
- I am still looking for someone to
- 9 show me where there is clear and express
- 10 authorization for the Department to do it,
- 11 given that when you read the statute, it seems
- 12 pretty clear that the statute wants to focus
- on the facility where the incident -- the data
- 14 from the facility where the employee was
- 15 employed, and not elsewhere.
- So I think, you know, your -- I
- 17 think the area of consideration here really is
- do you have express authority to even be going
- 19 down this road, or not?
- 20 CHAIRMAN MELIUS: Thank you,
- 21 Richard. Emily Howell, who is representing
- 22 HHS counsel is at the microphone. So I

1	believe	she	wants	to	say	something.

- 2 MS. HOWELL: I wanted to thank
- 3 Richard Miller for his input here today, but I
- 4 did want to clarify to the members of the
- 5 public and the Board that it is the Department
- 6 who has the sole provenance in interpreting
- 7 the statutory language where the legislative
- 8 intent is unclear.
- 9 I think we have informed the Board
- in the past that we do interpret the language
- 11 that Richard has pointed out to allow for the
- 12 use of surrogate data as a legal matter. It
- 13 is up to the Board to determine what
- 14 recommendations it feels are appropriate about
- 15 the use of surrogate data from a scientific
- 16 perspective. It is not to the Board to opine
- 17 about the legal interpretation that the
- 18 Department has rendered on this matter.
- 19 CHAIRMAN MELIUS: Before you sit
- 20 down, Emily, I continue to -- I just don't
- 21 recall. Has this ever been provided to the
- 22 Board in writing?

1 MS. HOWELL: I believe t	that t	this
---------------------------	--------	------

- 2 has been provided in presentations. I am not
- 3 sure if it has been provided in writing. I
- 4 know Dr. Wade may --
- 5 DR. WADE: There was a closed
- 6 session of the Board where this issue was
- 7 presented.
- 8 MS. HOWELL: So it is not typical
- 9 HHS protocol to provide the Board with legal
- 10 opinions rendered for the Agency.
- 11 CHAIRMAN MELIUS: But is there a
- 12 written legal opinion? I don't know how HHS
- 13 counsel operates. I am not necessarily saying
- 14 we are asking for it. I am just trying to
- 15 understand.
- MS. HOWELL: An opinion was
- 17 issued to the Agency.
- 18 CHAIRMAN MELIUS: Thank you. Any
- 19 questions? Before you sit down, Emily, any
- 20 other Board Members have questions for Emily?
- 21 Brad?
- MEMBER CLAWSON: Well, as Paul was

1	talking	about	the	scientific	end	of	this,	I
---	---------	-------	-----	------------	-----	----	-------	---

- 2 would just like to bring up, too, that I have
- 3 a real heartache with using it, because you
- 4 are using two totally different facilities.
- 5 They keep calling up the phosphate plant in
- 6 Idaho which I am intimately knowledgeable
- 7 with, which looking at the designs of Blockson
- 8 and everything else, which is totally
- 9 different.
- 10 The processes are different. The
- 11 issues -- I just really, from my perspective,
- 12 cannot see how they can even use that. I know
- 13 the weaknesses of that facility. I know how
- 14 the process was run in there and so forth, and
- 15 I really personally -- it is just my personal
- 16 opinion -- have a hard time seeing how they
- 17 can even use it.
- 18 CHAIRMAN MELIUS: We will be
- 19 talking more about those issues in a second.
- 20 Is someone from the Senate Health staff on the
- 21 call? I wasn't given information on who might
- 22 be participating. So I know with the weather

-			
1		_	_

- 2 MS. LAM: Yes. It is Livia Lam.
- 3 CHAIRMAN MELIUS: Do you have
- 4 anything to add at this point?
- 5 MS. LAM: Not at this point.
- 6 CHAIRMAN MELIUS: Okay.
- 7 MR. MILLER: Dr. Melius, would it
- 8 be okay if I just jumped in for one last
- 9 point.
- 10 CHAIRMAN MELIUS: I was going to
- 11 call on you.
- 12 MR. MILLER: Regarding the
- 13 comments, we regard the legal opinion, whether
- 14 there is or there isn't one, of the
- 15 Department, we have not yet seen a legal
- opinion from the Department on this. We have
- 17 certainly received verbal ones. However, I
- 18 just wanted to bring to everyone's attention
- 19 that I think it is a very cramped reading of
- 20 the authorization for the Advisory Board to
- 21 presume what it can and cannot provide advice
- on, and I don't mean to publicly disagree with

	1	legal	counsel's	view	of	what	you	are	entitled
--	---	-------	-----------	------	----	------	-----	-----	----------

- or not entitled to provide advice on. But let
- 3 me just say this, that the duties of the Board
- 4 are to advise the President on the development
- of guidelines under 7384n(c).
- 6 Not that is the very specific
- 7 quideline we are talking about here, and that
- 8 quideline, as it has always been debated and
- 9 discussed, the dose reconstruction rule and so
- 10 forth, has constantly been a matter of a
- 11 mixture of law and policy.
- 12 Likewise, it also provides for
- 13 providing advice with regard to other matters
- 14 that may be deemed appropriate. So it is not
- 15 quite as cramped a set of authorities. I
- 16 would just encourage you to go look at the
- 17 Advisory Board section and look at the
- 18 specific tasking that you have received,
- 19 because I don't believe it is quite as limited
- 20 as was just defined by counsel. But that is
- 21 for you and your counsel to work out.
- 22 CHAIRMAN MELIUS: Thank you,

1	Richard.	Does	any	other	Board	Members	
---	----------	------	-----	-------	-------	---------	--

- 2 David Richardson, do you have questions?
- 3 MEMBER RICHARDSON: Yes. My first
- 4 question is: Is there a case currently under
- 5 our consideration in which the proposed method
- 6 for radiation dose assessment depends upon
- 7 exposure information from another facility, or
- 8 are there cases?
- 9 CHAIRMAN MELIUS: There are cases.
- 10 There are individual dose reconstructions
- 11 where surrogate data has been used, and there
- 12 are a number of pending SEC evaluations where
- 13 part of the NIOSH method for doing
- 14 reconstruction involves the use of surrogate
- 15 data.
- 16 MEMBER RICHARDSON: Could you list
- 17 those out, Dr. Melius?
- 18 CHAIRMAN MELIUS: Actually, it may
- 19 be a little bit out of date, but I know there
- 20 is a report from SC&A that is -- what? -- two
- 21 years old, John?
- 22 MEMBER RICHARDSON: Yes, that is

1	what	I	am	wondering,	because	for	example,

- 2 Blockson, it seems like we are focusing on.
- 3 My understanding now is that the use of the
- 4 surrogate data has been put aside, and there
- 5 is an exposure reconstruction model which is
- 6 based on source terms and kind of a set of
- 7 parameter assumptions.
- 8 So that is no longer drawing upon
- 9 the Florida phosphate data, for example.
- 10 CHAIRMAN MELIUS: I believe John
- 11 Mauro is getting to the microphone. He may be
- 12 able to --
- DR. MAURO: Yes. This is John
- 14 Mauro with SC&A. We have been asked to review
- 15 two Site Profiles from the perspective of
- 16 degree to which surrogate data was used and
- 17 was used in accordance with the draft criteria
- 18 that the Surrogate Data Work Group developed.
- 19 I am trying to think of the two
- 20 sites. One, I believe, was Texas City, and I
- 21 am drawing a blank on the other one, but there
- 22 are a number of sites where we explicitly

1	looked	at	it	from	the	perspective	of	the	use
---	--------	----	----	------	-----	-------------	----	-----	-----

- 2 of the surrogate data.
- 3 So, absolutely, surrogate data has
- 4 been and is being used on a number of Site
- 5 Profiles.
- 6 MEMBER RICHARDSON: Isn't
- 7 Bethlehem Steel one of those, Dr. Mauro?
- Bethlehem Steel, yes,
- 9 is one of those. At that site, data was used
- 10 from Simonds Saw and applied to supplement the
- 11 data that Bethlehem Steel had.
- I would say the one area that goes
- 13 to perhaps the heart of this issue is the use
- 14 of TBD-6000/6001. What this is is a generic
- 15 compendium of data collected from many, many
- 16 facilities dealing with uranium, and on many
- 17 occasions some of the old AWE facilities where
- 18 data -- where a dose reconstruction or an SEC
- 19 issue might arise or whereby the compendium of
- 20 data that is available in TBD-6000/6001 has
- 21 been drawn upon, which basically represents a
- 22 compendium of data from other sites that are

1	beina	brought.	in	and	applied	t.o	supplement
_	200 2 2 2 2 2 9	22 2 2 2 3 1 1 2		arra.	appirca		Dappromerro

- 2 data for a particular site under
- 3 consideration.
- 4 MEMBER RICHARDSON: Wasn't it also
- 5 the case, Dr. Mauro, that the neutron/photon
- 6 ratios that were at Lawrence Livermore at one
- 7 point were being used at Hanford?
- B DR. MAURO: Yes. Neutron/photon
- 9 ratio is another area. We have been
- 10 categorizing that as different. When we have
- 11 been looking at the surrogate data issue, we
- 12 have divided the matter from a scientific
- 13 perspective into what we would call Type 1
- 14 surrogate data.
- 15 This is where you take air
- sampling data, bioassay data, film badge data,
- 17 direct dosimetry data directly related to the
- 18 reconstruction of dose, and where that data
- 19 from one facility is used at another, that is
- 20 what we, SC&A, have been calling the term Type
- 21 1 application.
- There is also what we call Type 2

	1	where	it	is	more	indirect,	and	tŀ
--	---	-------	----	----	------	-----------	-----	----

- 2 neutron/photon ratios are what we consider to
- 3 be a Type 2. But, yes, in a way, if you want
- 4 to broadly interpret or define surrogate data,
- 5 the use of neutron/photon ratios that are
- 6 drawn upon from the experience of the industry
- 7 and the weapons complex where you have some
- 8 understanding of what those ratios might look
- 9 like for certain types of activities, and then
- 10 applying that ratio observed at one site or
- 11 facility to another.
- 12 I guess you could broadly
- 13 interpret that as a type of surrogate data
- 14 also, but we have been calling that a Type 2
- 15 surrogate data.
- 16 CHAIRMAN MELIUS: Stu has
- 17 comments.
- 18 MR. HINNEFELD: Yes, Stu Hinnefeld
- 19 from OCAS. I just wanted to offer one point
- 20 of clarification in response to Dr.
- 21 Richardson's question.
- 22 The Blockson SEC that has been in

	1	front	of	the	Board	does	not	use	surrogate	fo
--	---	-------	----	-----	-------	------	-----	-----	-----------	----

- 2 radon, but there is an application of
- 3 surrogate data in that. It is the particulate
- 4 exposure in -- I forget exactly where in the
- 5 plant. This is the Building 40 particulate
- 6 exposure model, relies on dust loading
- 7 measurements from the Idaho Phosphate Plant, I
- 8 think the one that Brad alluded to earlier.
- 9 So that surrogate use is in Blockson.
- 10 Then I think most of the other
- 11 uses that are in front of the Board are TBD-
- 12 6000 uses.
- 13 CHAIRMAN MELIUS: And, Stu, before
- 14 you sit down, I believe that either you or Jim
- 15 -- I can't remember who it was -- indicated
- 16 earlier today that NIOSH is also currently
- 17 reviewing your use of surrogate data in a
- 18 number of settings based on your criteria.
- 19 MR. HINNEFELD: Yes. It is our
- 20 judgment that there are some, but not a lot of
- 21 differences between this draft Work Group
- 22 document in our IG core guidance. So we are

1	proceeding	now	to	try	to	do	that,	but	that	is
---	------------	-----	----	-----	----	----	-------	-----	------	----

- 2 sort of different question. That is the
- 3 question of, if it is allowable, are we doing
- 4 it well? Are we doing it appropriately? That
- 5 is sort of a different question.
- 6 CHAIRMAN MELIUS: Okay. Thank
- 7 you, Stu. Yes, John?
- B DR. MAURO: In order to -- there
- 9 is a continuum of what might be considered
- 10 surrogate data. I just thought of another
- 11 perspective that may enrich the appreciation
- of the complexity of the subject.
- 13 There are OTIBs procedures. I am
- thinking of OTIB-0054. This is where you have
- 15 bioassay data from a person, a beta-gamma
- 16 bioassay urine sample, and you want to assign
- 17 what mix of radionuclides might be -- that
- 18 person may have taken in to have that result
- 19 in his urine.
- 20 What has been done in this OTIB is
- 21 to draw experience from what the mix of
- 22 radionuclides are in different types of

1	reactors	throughout	the	complex.	So	in	а	way,
---	----------	------------	-----	----------	----	----	---	------

- 2 one could argue the mix that you assign to a
- 3 person that you have bioassay data at one
- 4 facility -- you may say, well, we are going to
- 5 assign this mix based on experience at another
- 6 reactor, because we know this is the kind of
- 7 mix that we would expect this person to have
- 8 been exposed to.
- 9 It is important, I think. So
- 10 there is this degree and continuum of the use
- 11 of surrogate data.
- 12 CHAIRMAN MELIUS: Thank you. Any
- 13 more questions for Richard Miller? If not,
- obviously, Richard, you are welcome to stay on
- 15 the line as we discuss this issue more, but I
- am trying to move this into different parts.
- 17 Now all of you should have
- 18 received an updated set of criteria dated
- 19 January 2010 on draft criteria for the use of
- 20 surrogate data. This is based on some earlier
- 21 drafts that came from the Surrogate Data Work
- 22 Group, which I chair.

Τ	inis drait was updated based on
2	our last telephone call. I will say up front,
3	it does not represent a consensus of the group
4	nor is it a specific recommendation from the
5	Surrogate Data Work Group. This was something
6	that the the updates to this policy were
7	something I put together based on our
8	discussions at the Work Group meeting that we
9	had, and then circulated to the Work Group
10	and, after that, to the Board.
11	So much of this looks familiar. I
12	will say that the parts of it that are updated
13	are probably starting on page two to page
14	three. We expanded some of the discussion on
15	plausibility, and then tried to summarize how
16	I thought this was applied and some of the
17	considerations. It does not deal directly
18	with the sort of legal issues that were raised
19	with that. So I guess we would be open to
20	discussions of that, and we will start with
21	Wanda again.

MEMBER MUNN: I have no comments

22

of my own. Dr. Lockey, who had to leave us	1	of	mу	own.	Dr.	Lockey,	who	had	to	leave	us
--	---	----	----	------	-----	---------	-----	-----	----	-------	----

- 2 left a couple of comments that he asked I
- 3 relay.
- 4 On the first page, the last
- 5 sentence of the first paragraph, he indicates
- 6 the word "latter" should read "former." I
- 7 think he is correct.
- 8 CHAIRMAN MELIUS: Minor.
- 9 MEMBER MUNN: This reports focuses
- 10 on the former situation, Type 1. First
- 11 paragraph, last sentence.
- 12 Then on page 2, the first sentence
- 13 just under the four bullets under Item 3:.
- 14 Where it says "Surrogate data should not be
- 15 used if the equivalents are claimant
- 16 favorability of working conditions," he marked
- 17 through "are claimant favorability" and says
- 18 he is not sure what this means.
- 19 It does seem to be a little -- the
- 20 sentence itself seems a little clumsy.
- 21 Doesn't seem clear enough.
- 22 MEMBER ZIEMER: This is Ziemer.

1	Dr.	Melius	has	suggested	to	me	that	it	was	my
---	-----	--------	-----	-----------	----	----	------	----	-----	----

- 2 sentence. The only reason he knows that, he
- 3 doesn't see any dangling participles. So it
- 4 must be mine.
- I honestly don't recall why the
- 6 word claimant favorability would be in there.
- 7 I think, without that, the sentence is still
- 8 clear, that we are looking for equivalence in
- 9 terms of working conditions, source terms and
- 10 processes. If you couldn't establish those,
- 11 then you don't have a case.
- 12 I am not sure where that came in
- or if that got added later. I admit, it is
- 14 not even clear to me, if it is my sentence,
- 15 why it is in there.
- 16 MEMBER MUNN: I suspect that Dr.
- 17 Lockey would have suggested that those three
- 18 words be removed, but I am not certain that
- 19 would be his recommendation. It would be
- 20 mine.
- 21 On page 3 under the first bullet
- there, the end of the second line, "is based

	1	on."	Не	suggests	used	"when"	rather	than
--	---	------	----	----------	------	--------	--------	------

- 2 "based on." "Have the models been validated
- 3 when actual monitoring data collected in a
- 4 similar situation is available? " he would add.
- 5 Are available.
- 6 Second bullet, third line down,
- 7 the word "affect." He suggests that affect is
- 8 too broad or is not as appropriate as
- 9 "significantly impact." So that he would
- 10 suggest the sentence read: "Have all of the
- 11 factors that could significantly impact
- 12 exposure been taken into account," because
- 13 most anything could affect it. Whether it
- 14 affects it in the fashion that is of any
- 15 consequence is an issue.
- In the last paragraph, he suggests
- 17 on the third to the last line that "the rare"
- 18 be removed, and instead of "fully met" as the
- 19 last words of that sentence, the words
- 20 "address and documented in the Evaluation
- 21 Class."
- 22 So let me read that sentence, I

1	believe, as he is suggesting it. "Given the
2	difficulties in obtaining the comprehensive
3	information needed for validating the use of
4	surrogate data for individual dose
5	reconstruction and the inherent concerns about
6	its use by claimants, the Work Group
7	recommends that the use of surrogate data be
8	limited to circumstances where other
9	approaches are not feasible, and then only if
10	the above criteria have been addressed and
11	documented in the Evaluation Report."
12	That is the last of Dr. Lockey's
13	comments.
14	CHAIRMAN MELIUS: Dr. Lemen?
15	MEMBER LEMEN: As a new Member of
16	the Board, I was not on this Committee or even
17	addressed this issue previously, since this is
18	my first meeting. But I know that probably my
19	comments are going to be taken adversely by
20	the rest of the Board Members, but I feel
21	compelled to tell what I think about using
22	surrogate data, and I think that using

1	surrogate	data.	first	of	all.	is	absurd.
_		~~~,			~~~ <i>,</i>	_ ~	

- 2 I think that there are many
- 3 conditions in plants that you cannot control
- 4 for using data from another plant, such as
- 5 what type of protective measures were taken in
- 6 the other plant.
- 7 As I understood this issue with
- 8 the phosphate data, I happen to have done a
- 9 study in the phosphate industry in Florida,
- 10 and that is a completely outdoor facility. It
- 11 may have similar processes, but it is not
- 12 going to compare to an indoor facility, in the
- 13 first place, and there are a lot of
- 14 differences from plant to plant.
- So I find even considering the use
- of surrogate data for the purposes of doing
- 17 compensation a misguided approach, and I would
- 18 like to suggest that, instead of "rare," you
- 19 say "never."
- 20 That is my opinion, and I know
- 21 that that is adverse to the fact that you set
- 22 a Working Group up on this, but I have to

1	express	I	just	feel	that	the	use	of	surrogate
---	---------	---	------	------	------	-----	-----	----	-----------

- 2 data is inappropriate.
- 3 CHAIRMAN MELIUS: Other comments
- 4 from Board Members? Bill?
- 5 MEMBER FIELD: I guess I have a
- 6 little bit different take on it. I think, in
- 7 some cases, surrogate data can be very useful,
- 8 but I think that is the whole question. In
- 9 some cases, it goes back to the
- 10 representativeness of the surrogate data. How
- 11 representative is it to the site in question,
- which brings me back to the draft on page 2,
- 13 number 3, the bottom comment there.
- 14 "Do the surrogate data reflect the
- 15 type of operations or work practices in use at
- 16 the facility in question?" So I guess my
- 17 question would be how is that evaluated? Do
- 18 you need a whole new Site Profile for that
- 19 site to see if it -- that is my whole
- 20 question, is how representative is it, and how
- 21 far do you really explore it to assess its
- 22 representativeness?

1	CHAIRMAN MELIUS: Well, in the
2	circumstances that we have it is assessed,
3	and there are examples, and I guess Blockson
4	would be one that we talked about yesterday,
5	is that where NIOSH has proposed the use of
6	surrogate data based on the Florida phosphate
7	I guess this is for radon and so in
8	examining and evaluating that source of that
9	data, that information, we have determined
LO	that it was not an appropriate, basically, by
11	comparing the two facilities, and that it does
12	require some due diligence to do that.
13	I think, back to Dr. Lemen's
L4	comments earlier and Dr. Lockey's, another way
15	of thinking about the never/rare to just
L6	leaving it open is I think we also have to
L7	keep in mind that there is also both the
L8	statute and, obviously, the regulations allow
L9	the alternative approaches, which is the
20	Special Exposure Cohort.
21	That is really what we are
22	weighing. The use of "rare" in that, I will

1 not try to attribute that to Dr. Ziemer.	Tha	.at
--	-----	-----

- 2 is mine. I will be honest. But it was to try
- 3 to capture that we would be very stringent on
- 4 that.
- 5 Again back to your comment, maybe
- 6 this was developed assuming that surrogate
- 7 data is allowed to be used legally, but I
- 8 think we have to sort of capture some of the
- 9 balance there of, one, how you apply it.
- 10 I guess, again, assuming that it
- is legally permissible to use it, then I don't
- 12 know if I would agree with the comment that
- 13 there is never a circumstance, because there
- 14 may be one. Again, I am very loathe to use
- it, but I can't rule out that there would be a
- 16 circumstance where it might not be appropriate
- 17 to do that.
- I can tell you, the history of
- 19 this issue was it is something that was raised
- 20 by the Board. I don't recall it, but I guess
- 21 we did have a legal briefing when it was first
- 22 raised a number of years ago on it, and then

1 we developed the Working Committe	1	we	developed		the	Working	Committee
-------------------------------------	---	----	-----------	--	-----	---------	-----------

- 2 developed some criteria.
- 3 After we developed some draft
- 4 criteria, then NIOSH developed their criteria,
- 5 and we have gone back and forth, and we have
- 6 some, obviously, pending evaluations.
- 7 Some of those have been sort of --
- 8 Originally, the Work Group was focusing on
- 9 Blockson and Texas City as the examples that
- 10 we would sort of initially look at from the
- 11 surrogate data, and then NIOSH decided not to
- 12 use surrogate data at those sites, at least
- 13 preliminarily. I don't think you have reached
- 14 a final decision on Texas City yet, but at
- 15 least for the radon they went to a different
- 16 model.
- 17 So we start with the general and
- then try to see how it would apply, but it is
- 19 sort of difficult, and there is a long history
- 20 here that at least the new Board Members and
- 21 even some of the more recently appointed Board
- 22 Members have picked up on. Actually, Henry

1 p	robably	remembers	back	to	the	early
-----	---------	-----------	------	----	-----	-------

- 2 discussions of it.
- 3 MEMBER ANDERSON: I remember the
- 4 briefing.
- 5 CHAIRMAN MELIUS: Henry, and then
- 6 Dr. Ziemer.
- 7 MEMBER ANDERSON: Yes. I think,
- 8 one, I would -- as a new Member, I would
- 9 support the need to develop some kind of a
- 10 written set of guidelines, the major
- 11 challenges, but you would like to have, before
- 12 decisions are starting to be made, a set of
- 13 criteria. You can basically say does it meet
- 14 this or does it not, rather than wait until we
- 15 have a set of circumstances and then say, wow,
- 16 gee. Then it isn't consistently applied.
- Now coming up with that list is a
- 18 major challenge. So I don't know. I think
- 19 this does a good job kind of framing or, as we
- 20 have done in these meetings, bounding things.
- One thing I would think might be
- 22 worth putting in here, and this is just for

1	discussion,	its	kind	of	primary	use	versus

- 2 secondary use, that if you have no data -- I
- 3 mean, I could see surrogate data becoming the
- 4 driver for most of these SECs. You look --
- 5 there is not enough data to really do it.
- 6 Now surrogate data could be used
- 7 to, well, you don't have representative
- 8 samples from a site, but you have some values,
- 9 and you say are these likely to be on the low
- 10 end? Are they likely to be the high end, or
- 11 what? So then looking at beefing that up by
- 12 saying, gee, it is very similar to what we
- 13 have seen at other sites, gives you a better
- 14 confidence on how you might be able to use
- 15 those, versus we don't want to have any.
- So let's try to look at a site to
- 17 then assign those values to another. So I am
- 18 probably like Dick saying that, if you don't
- 19 have any measures to basically apply
- 20 everything to a -- use a surrogate set of data
- 21 to assign to a facility, I think that, to me,
- 22 would be very problematic and reaches the

1	boundaries	of	kind	of	zero	to	one,	while	it
---	------------	----	------	----	------	----	------	-------	----

- 2 covers the universe.
- 3 So a primary/secondary, I think,
- 4 is one way. I think it could be useful to
- 5 support describing activities, but I wouldn't
- 6 go beyond it as support data.
- 7 CHAIRMAN MELIUS: Initially with
- 8 SC&A, as John Mauro mentioned, he had built
- 9 sort of Type 1 and Type 2. As you heard from
- 10 even his earlier presentation, it is sometimes
- 11 hard to make even that distinction at times,
- 12 because there are things that fall in between
- 13 the two.
- 14 Generally, we are trying to focus
- just on Type 1, and I actually agree with you,
- 16 Henry. It may be, in some ways, more helpful
- to think about both Type 1 and Type 2 at the
- 18 same time, at least to capture some of the
- 19 criteria and how the application of the
- 20 criteria would sometimes ease up with a Type 2
- as opposed to a Type 1 where you have no data.
- 22 MEMBER ANDERSON: The other

1	comment	MAG	аt	SOME	noint	VO11	hawe	tο	aet
_	COMMETIC	wab	aı	SUILLE	POINC,	you	11a v C	LU	900

- 2 into a how much effort then needs to go into
- 3 looking for surrogates. I mean, once you say
- 4 you can use surrogate, how broad a search and,
- 5 therefore -- I mean, if one were limited to
- 6 say you want to look at data from the same
- 7 time period.
- 8 Since most of these where the data
- 9 is missing are the early years, you don't have
- 10 to search very hard, but going broader than
- 11 that, I think we need a limit as are we
- 12 looking -- you know, when we heard about on
- 13 the phosphate side, well, maybe there is some
- 14 data from Poland or wherever. Well, we ought
- 15 to have a set of criteria for when do we not
- 16 drag this out.
- 17 CHAIRMAN MELIUS: Thank you.
- 18 Paul?
- 19 MEMBER ZIEMER: I appreciate the
- 20 concerns that Dr. Lemen raised. I did want to
- 21 point out that in Item 4, which is temporal
- 22 considerations, part of the effort there was

1	to	point	out	that,	in	fact,	it	is	not	fair

- 2 game to use surrogate data if you don't meet -
- 3 it is not just a plant that is called the
- 4 same thing, but there are these other
- 5 considerations, what we call here temporal,
- 6 and that there are some criteria about
- 7 monitoring methods, the procedures used, the
- 8 working conditions.
- 9 So there is a lot of opportunity
- 10 for a mismatch, which would rule out the use
- of the data. So the criteria -- you know, it
- 12 can be fairly rigorous, and you would have to
- 13 determine which items are not critical to the
- 14 final outcome, but I think all of those things
- 15 have to be considered, and you have to make a
- 16 judgment on the extent to which the use is
- 17 appropriate.
- I would point out -- and I just
- 19 noticed here, you see an asterisk in there,
- 20 and the footnote, I think, from our early
- 21 draft dropped out, but that footnote spoke to
- the issue of what same general period means.

1	Same general period has different
2	meanings for different things. For example,
3	if you are talking about legal requirements,
4	the same general period might be the period
5	during which a certain dose limit was enforced
6	in some way versus later.
7	We have seen this in facilities
8	where the law changed in terms of dose limits
9	or something, and subsequently the approaches
10	and procedures changed. So that is one kind
11	of a general period limit.
12	Sometimes it has to do with
13	technology. Suddenly, you can do whole body
14	counting, and you couldn't before. So you
15	have those kinds of things. So the same time
16	period might be a year. It could be a decade.
17	So I think you have to look at that, and that
18	footnote had to do with sort of clarifying.
19	Time period does not necessarily
20	mean that same year, but what can you say in
21	terms of the equivalence of all of these
22	things, which may be a bigger or a smaller

1	time	period.
_	CTILL	PCITOU.

- 2 So there is a lot of those issues
- 3 that come up, and I kind of agree with what
- 4 Andy says here, that if you have the criteria,
- 5 aside from the legal issue which Dr. Miller
- 6 raised with us earlier, but if we have this
- 7 use, even in cases where there are SECs, you
- 8 have some cancers which are not covered, and
- 9 what do you do with claimants for whom there
- 10 is no data? Sometimes having surrogate data
- 11 helps you in even those cases where we have an
- 12 SEC.
- 13 So I will make the statement I had
- 14 made before. I think, in general in science,
- 15 there are cases where we use surrogate data.
- 16 It is used sometimes even in epidemiology, as
- 17 Dr. Field knows, and again you have to make
- 18 sure that you are using it appropriately.
- 19 Otherwise, you can distort or even invalidate
- 20 the outcomes.
- 21 So as a general approach, I don't
- 22 object to it at all. I think it is

- 1 appropriate. There are cases where it can
- 2 indeed help us. The legal issue might turn
- 3 out different, and it may be -- I think Dr.
- 4 Miller suggested that the Board could weigh in
- on 83.14 -- is it 83.14? Well, in any event,
- 6 the dose reconstruction rule.
- 7 Well, I don't want to get off on
- 8 that.
- 9 MR. HINNEFELD: The dose
- 10 reconstruction rule is 82. I think it might be
- 11 relevant to 83 as well, which is the SEC rule.
- 12 MEMBER ZIEMER: Well, in any
- 13 event, insofar as the Board would want to
- 14 weigh in on that separately, but otherwise the
- 15 legal part, I think, we may have to leave to
- 16 the legislature.
- 17 MEMBER LEMEN: Could I possibly
- 18 comment briefly on Dr. Ziemer's comment or did
- 19 you want to go to somebody else?
- 20 CHAIRMAN MELIUS: Well, Dr. Poston
- 21 has waited patiently. Okay, Dr. Lemen.
- 22 MEMBER LEMEN: I just wanted to

2	use surrogate data. As I understand our role
3	on this Committee, however, we are
4	compensating people based upon calculations
5	that we make for their radiation exposure in
6	the plant that they are in, and when you do an
7	epidemiological study, you are going to put
8	all the caveats together that Andy talked
9	about and you talked about, and you are going
LO	to publish that, and that is what the
11	epidemiology says in that study. So you can
L2	take that or leave it.
13	Here where we are using surrogate
L4	data, as I see it, we are talking about real
L5	people that are waiting to get compensated and
L6	using data that has multiple caveats to it,
L7	such as you might do in an epidemiological
L8	study, seems to me if I don't understand
L9	the role of the Committee, correct me, but
20	seems to me completely wrong.
21	When you are talking about
22	compensating people you don't play around

say that I agree that in epidemiology we often

1

- 2 That is where I am coming from.
- I don't deny that surrogate data
- 4 has been used in some cases in epidemiology,
- 5 but I think we have to divorce ourselves from
- 6 the role of epidemiology and look at our role
- 7 as Board Members, and is it really
- 8 scientifically solid to use surrogate data
- 9 when we are going to base that on whether or
- 10 not a person gets compensated or not? That is
- 11 where I am coming from.
- 12 CHAIRMAN MELIUS: I would just add
- 13 to that, that when the Work Group met and we
- 14 were discussing this issue with NIOSH, NIOSH
- 15 said they were not basing using the use of
- 16 surrogate data in epidemiological studies as a
- 17 justification in parallel to what is being
- 18 done for dose reconstruction.
- 19 So they are acknowledging that
- 20 distinction -- nor the use of surrogate data
- 21 in terms of radiation protection matters. I
- 22 think they recognize there is a difference

1 now. We may still have a difference in who	⊥ .	now. we	ınay	STIII	nave	a	allierence	ın	WIIa
--	-----	---------	------	-------	------	---	------------	----	------

- that difference is, but they are acknowledging
- 3 that.
- Dr. Poston, you have been patient.
- 5 MEMBER POSTON: Thank you, Dr.
- 6 Melius. I guess in general, I am in support
- of surrogate data, but I would like to go back
- 8 to your word, which would be rare.
- 9 I see the use of surrogate data or
- 10 the nonuse of surrogate data as equivalent to
- 11 asking all the NIOSH staff to have a lobotomy
- 12 and forget all the experience that they have
- in how do you apply the scientific principles
- and so forth to solve a problem.
- 15 I think what you have written here
- 16 is very important. The temporal
- 17 considerations and the plausibility, to me,
- 18 are the keys to this, and it falls not
- 19 necessarily to the Board, but it certainly, to
- 20 me, would fall to the Work Group to make a
- 21 determination of whether NIOSH has used
- 22 surrogate data appropriately.

1	So if I were doing dose
2	reconstruction for a facility, the first
3	question I would ask is, is this plausible?
4	Does this make sense? Is this appropriate? If
5	the answer is no, then it is clear what you
6	do.
7	So somehow NIOSH has to justify
8	that to the Work Group, and it is up to us,
9	before it comes to the main Committee, to
LO	decide whether or not they have done things
11	appropriately, and that is what SC&A, that is
L2	what the Work Group is charged to do, in my
L3	opinion.
L4	CHAIRMAN MELIUS: Thank you.
15	David Richardson, do you have anymore
L6	questions or comments?
L7	MEMBER RICHARDSON: I do.
L8	Firstly, I agree with the comment that
L9	epidemiology is different than what we are
20	doing here, and in epidemiologic study it is
21	fine to break people into groups of three or
22	four or five categories, and those categories

1	can i	have	lots	of	variation	within	them,	and	if
---	-------	------	------	----	-----------	--------	-------	-----	----

- 2 you are -- you want to draw a contrast between
- 3 groups of people.
- 4 So you are not trying to estimate
- 5 an individual's dose, and it is fine to have
- 6 lots of error there. You want to characterize
- 7 kind of the average value for the group, and
- 8 contrast those groups.
- 9 So here, I think the framework is
- 10 sort of coming from job exposure matrices or
- 11 the kinds of things that industrial hygienists
- do to characterize the exposure conditions for
- 13 people in different areas or in different
- 14 times, and they may draw analogies to other
- 15 plants. But those are -- I mean, those sort
- of methods are used not to assign scores to
- 17 individuals. They are to characterize the
- 18 mean value for a group and maybe its variance.
- 19 I think, to me, that is kind of starts to get
- 20 to kind of where the discomfort is.
- 21 One specific question about this
- 22 document. Item 1 is hierarchy of data. I was

1	surprised in reading that, because my
2	impression was the hierarchy of data would be
3	at a given facility, for an individual, if you
4	have monitoring data, that would be
5	preferable.
6	If you have workplace monitoring
7	data, not individual level monitoring data,
8	that would second in the hierarchy, and then
9	below that would be surrogate data. But the
LO	way the document is written is surrogate data
11	should not be used to replace available data
12	from the site in question that is at the same
13	or at a higher level in the hierarchy, which
14	would imply that you might have workplace
15	monitoring data for your facility, but there
L6	is surrogate data at the individual level that
L7	in some sense would be preferable to the
L8	actual data you have for area monitoring for
L9	your facility.

are you actually imagining that

situations where, even though you have data

Am I reading the document wrong or

20

21

22

there are

1	for	а	facility,	you	would	want	to	replace	it
---	-----	---	-----------	-----	-------	------	----	---------	----

- 2 with surrogate data?
- 3 CHAIRMAN MELIUS: The intention of
- 4 what is written there is consistent with what
- 5 you just said. Maybe we just need to clarify.
- 6 Maybe sort of which way it goes in the
- 7 hierarchy is confusing. Let me try to clarify
- 8 that, but we are not talking about trying to
- 9 use surrogate process data to replace when
- 10 there is lots of workplace monitoring data or
- 11 something. So let me try to clarify that.
- 12 MEMBER RICHARDSON: Yes, because
- it sort of brings a bunch of scenarios where,
- if it is equal or -- I was surprised. I guess
- 15 I wasn't surprised by that.
- I started to think about it.
- 17 There are a number of situations where
- 18 surrogate data must be used all the time, like
- 19 for the medical X-rays. I think what is being
- 20 done right now is there is almost never
- 21 individual measurements or even workplace
- 22 measurements of the dose delivered by a chest

X-ray	
	X-rav

- 2 So you are assigning a dose under
- 3 an assumption of an annual screening practice
- 4 or something like that. Is that correct?
- 5 CHAIRMAN MELIUS: That is correct,
- 6 and we may have tried to call it Type 2. As I
- 7 said, I think it is a gray area, but is easily
- 8 interpreted as surrogate data for the Type 1.
- 9 MEMBER RICHARDSON: Yes, and it
- 10 leads to thinking about one way that dose
- 11 reconstruction is being done, which is there
- is an average intensity of exposure which is
- 13 applied to a group or often to the whole
- 14 cohort, and then the exposure that is assigned
- 15 to that population is just the integral over
- 16 time of that exposure intensity.
- 17 So the only distinction that you
- 18 are getting between people in the cohort is
- 19 length of employment. It sort of parallels, I
- think, in Blockson what is done. You say that
- 21 there is, either based on surrogate data from
- 22 another plant or a model, you are going to

1	assiqn	an	exposure	intensity,	and	then	you	are

- 2 just going to integrate that up, and everybody
- 3 is going to get that exposure intensity.
- 4 That is sort of where I was again
- 5 feeling like, okay, you probably can have some
- 6 sort of bounding, but where do you stop with
- 7 this? You want to have a high level -- you
- 8 know, you don't have -- I mean, you could do
- 9 this at the Nevada Test Site, too, I suppose,
- if you wanted to consider some extremely high
- 11 level of average intensity, and then we are
- 12 just going to integrate up over that and say
- 13 that the maximum exposure somebody got to an
- 14 agent. Whether it is inhalation of radon,
- 15 inhalation of uranium dust or medical X-ray
- 16 exposures. We are going to give an upper
- 17 bound of the exposures.
- 18 So I don't have an answer to that,
- 19 but it seemed to me that this question,
- 20 really, is pretty much always falling into
- 21 these scenarios where you are not going to
- 22 actually attempt to do any individual exposure

1 reconstruction other than just some	integral
---------------------------------------	----------

- 2 of their time on site.
- Maybe you do have examples where
- 4 you have finer distinctions than that, but I
- 5 haven't seen them.
- 6 CHAIRMAN MELIUS: That is correct.
- 7 Any other questions by Board Members? We are
- 8 pushing up to lunchtime here.
- 9 Why don't we actually break for
- 10 lunch, and then when we come back, I think we
- 11 can briefly talk about some follow-up on the
- 12 Surrogate Data Work Group, and I also want to
- 13 talk briefly about Texas City and clarify that
- 14 from that Work Group, and then we will go on
- 15 to our other reports. So let's, I think, come
- 16 back at 1:30.
- 17 MR. KATZ: Thanks, everybody, for
- 18 calling in, and we will reestablish the line
- 19 at 1:30.
- 20 (Whereupon, the above-entitled
- 21 matter went off the record at 12:02 p.m. and
- 22 resumed at 1:34 p.m.)

1	AFTERNOON SESSION
2	(1:34 p.m.)
3	CHAIRMAN MELIUS: Why don't we
4	reconvene. I would just like to briefly
5	finish a couple of issues with the Surrogate
6	Data Work Group.
7	One is sort of what are next
8	steps. Step number one, I think, is to make
9	some revisions to this document, and bring it
LO	back to the Board at our next conference call
11	meeting. So we can do that.
L2	Secondly, I think it might be
L3	helpful I actually think it would be
L4	helpful to have SC&A update their document and
L5	list the use of surrogate data in the Type
L6	1/Type 2 issues. I think that would inform
L7	some of our discussions and some of the
L8	questions that came up today.
L9	I don't think it is a large task
20	to do, because most of it has been done, but
21	there have been some changes in it that, I
22	think, would help us when we are thinking

	1	about,	well,	where	has	surrogate	data	been
--	---	--------	-------	-------	-----	-----------	------	------

- 2 used, and how has it been used in the
- 3 document, and then have them update, then
- 4 circulate that to the Board.
- 5 I think the other issue
- 6 outstanding, we have at least two, probably
- 7 more, SECs that are, in some ways, awaiting
- 8 some resolution by the Board on how we are
- 9 going to handle surrogate data.
- 10 The one that, in some ways, is
- 11 immediate -- our next meeting is in Buffalo,
- 12 and that is the Bethlehem Steel SEC Petition
- 13 that is up.
- 14 For those of you that are new on
- 15 the Board, Bethlehem Steel is particularly --
- 16 I won't say particularly. It is somewhat
- 17 problematic in the sense Bethlehem Steel, the
- 18 use of surrogate data, and the dose
- 19 reconstructions done there were done before
- 20 the SEC Evaluation regulations were written.
- 21 So it is out there, and I think as
- 22 we were dealing with that issue as a Site

1	Profile	review	issue	and	discussing	а	number

- of changes made in NIOSH's approach for dose
- 3 reconstruction there as a result of Board
- 4 input, but that was all done without reference
- 5 to the possibility they could be in the
- 6 Special Exposure Cohort. After that, the
- 7 group of workers there or worker
- 8 representatives have filed for an SEC
- 9 Petition, which was qualified and so forth.
- 10 So we have not evaluated that
- 11 pending the Surrogate Data work Group. I
- 12 think it would be helpful to apply our
- 13 criteria to that situation there, what is
- 14 being done, because it is a use of surrogate
- 15 data, and inform that. So we can, hopefully,
- 16 try to reach some conclusion on how to deal
- 17 with that SEC Petition by our May meeting.
- I think, in order to do that, I
- 19 think SC&A needs to do some -- needs to be
- 20 tasked to do that.
- 21 The other SEC that is potentially
- 22 involved here is the Texas City SEC. Again,

1	that	has	been	on	hold	for	а	while	pending	the

- 2 Board reaching some conclusion on how to deal
- 3 with surrogate data.
- 4 The confusion there -- and again,
- 5 some of this is also the radon issue, I
- 6 believe, there, but it is also NIOSH has sort
- 7 of been holding back on their Evaluation
- 8 Report, possibly modifying that, pending how
- 9 the Board decides to deal with the Blockson
- 10 radon issue.
- 11 Then I heard LaVon say that you
- 12 were -- I thought you said you were moving
- 13 ahead with a report. So I guess I am trying
- 14 to get updated on -- okay.
- 15 MR. RUTHERFORD: This is LaVon
- 16 Rutherford. We actually -- the report is held
- 17 up internally, and it is internally because of
- 18 the radon modeling and some discussion on
- 19 surrogate data --
- 20 CHAIRMAN MELIUS: Right.
- 21 MR. RUTHERFORD: -- look back at
- 22 ensuring consistency with IG-004.

1	CHAIRMAN MELIUS: Okay. So that
2	is still on hold then. So I think we then
3	in that case, I think we need to move on that,
4	but I don't think it is a little bit
5	different situation.
6	So what I would like to do is task
7	SC&A with the update on their document, the
8	use and abuse of surrogate data, how it is
9	being used, and then secondly, look at the
10	Bethlehem Steel which, I think, would sort of
11	be a focused SEC Evaluation, because it has
12	been an extensive evaluation of that situation
13	already by SC&A.
14	Why don't we go through the
15	Subcommittees and Work Group reports. While
16	we are doing that, if people can be looking
17	through just the five letters that have been -
18	- either four or five that have been passed
19	out.
20	For those of you that are new on
21	the Board, our normal procedure, usual
22	procedure, is that we sort of approve the

	1	motion,	and	then	we	do	the	letter	to	the
--	---	---------	-----	------	----	----	-----	--------	----	-----

- 2 Secretary, and then the Board then approves
- 3 the letter. It takes time to write the
- 4 letter. This is sort of our standard format
- 5 for the letter. When we go into it, I will
- 6 explain some of it to you. We go over those,
- 7 but you can be looking at those, dangling
- 8 participles and other significant -- yes?
- 9 MR. KATZ: Just one note. For
- 10 those of you that have a conflict for a site,
- obviously, you don't review that letter, and
- 12 you will recuse yourself from that discussion.
- 13 That is all, but those are relatively brief,
- 14 those discussions, and we will bring you back
- 15 in.
- 16 CHAIRMAN MELIUS: Did NIOSH staff
- 17 and Emily get the letters?
- 18 MR. KATZ: Yes.
- 19 CHAIRMAN MELIUS: Okay, good.
- 20 Dose Reconstruction Subcommittee, Mark?
- 21 MEMBER GRIFFON: Yes. We have had
- 22 a meeting since the last Advisory Board

1	meeting.	I	think	the	only	one	we	had	was	а
---	----------	---	-------	-----	------	-----	----	-----	-----	---

- 2 telephone meeting, and the main thing to
- 3 report, we are continuing on our progress with
- 4 the regular case reviews, just out of -- I
- 5 think we are up to the 12th set of cases.
- 6 Usually, we do pretty much batches of 20.
- 7 There is a little variation there, but just
- 8 for the new Members, we have done a -- the
- 9 first five sets we completed altogether, and
- 10 we released the report to the Secretary on the
- 11 first 100 cases, to sort of wrap-up findings
- 12 from the first 100 cases.
- We were then asked by the Advisory
- 14 Board to the full Board to go back to those
- 15 first 100 cases and, given the deficiencies,
- 16 make a determination of what impact they had,
- 17 and if we had any recommendations at this time
- 18 to give to NIOSH as far as program
- 19 modifications.
- 20 So we are in the process of doing
- 21 that follow-up, and we have been working with
- 22 a couple of, I guess, draft White Papers to

1	bring	back	to	the	Board.	Αt	this	point,	we
---	-------	------	----	-----	--------	----	------	--------	----

- 2 have -- we have been looking at identifying
- 3 deficiencies or categories of deficiencies
- 4 that were considered critical factors in
- 5 assuring scientific validity and quality of
- 6 dose reconstruction, and got a couple of
- 7 categories from those first 100 cases.
- We need to do some follow-up,
- 9 especially on -- we had several findings that
- 10 fit into the sort of quality assurance
- 11 category, and on the Subcommittee we have
- 12 asked SC&A to go back and do a sampling of
- 13 some of the cases that involved quality
- 14 assurance findings, to sort of do drill-downs
- 15 and see what was the nature of the quality
- 16 control finding. Was it dose reconstructor
- 17 error or was it something more systemic.
- 18 So we have asked SC&A to do that
- 19 follow-up. So our report back to the Board --
- 20 we are kind of waiting. We think it would be
- 21 much more meaningful if we could include some
- 22 of that information in the report. Then we

1	could	have	more	specific	recommendations,
---	-------	------	------	----------	------------------

- 2 theoretically.
- 3 The other two areas are
- 4 consideration of information from workers, and
- 5 this is the CATI. This is the worker
- 6 interviews when they do Site Profiles,
- 7 different aspects of considering the worker
- 8 information.
- 9 This one, I have to coordinate a
- 10 little bit with the Worker Outreach Work
- 11 Group, because I think some of the draft
- 12 recommendations that I sort of was throwing on
- 13 the table at our Subcommittee meeting
- 14 overlapped with some things that the Worker
- 15 Outreach Work Group is still looking into, but
- 16 we have at least identified that as a
- 17 category. Once we flesh it out a little more,
- 18 we will bring it to the full Board.
- 19 The last one was case
- 20 documentation and reporting, and I think this
- 21 speaks to both the DR report from the claimant
- 22 standpoint, but also from the auditor's

1	standpoint,	our	standpoint	in	terms	of	havi	ng
---	-------------	-----	------------	----	-------	----	------	----

- 2 a sufficient auditable trail, so to speak,
- 3 having the case files including all the work
- 4 that makes it something that will last the
- 5 test of time and people can go back to these
- 6 at a much later date, or if claimants have
- 7 expertise, helping them review cases. There
- 8 is enough there that they can actually follow
- 9 along how the calculations were conducted.
- 10 Those were the three categories
- 11 kind of. The last thing that we are including
- 12 in this letter is -- again, this is a letter
- 13 back to the full Board, not to the Secretary.
- 14 The last thing we are including in this is
- 15 some things, areas, that have resulted --
- 16 areas of change in NIOSH's program that are,
- 17 at least in part, a result of the audit of the
- 18 first 100 cases.
- 19 For instance, one example would be
- 20 the Dose Reconstruction Report format. There
- 21 have been some modifications, and they did
- that early on. They weren't going to wait for

1	us	to	go	through	100	cases	and	do	it.	They
---	----	----	----	---------	-----	-------	-----	----	-----	------

- 2 recognized it early on in the first 30 or 40,
- 3 we were having a similar finding several
- 4 times, and NIOSH proactively made some
- 5 modifications to their report form to the
- 6 claimants. So we are also trying to note some
- 7 of those.
- 8 Another area is the Program
- 9 Evaluation Reviews. There have been some
- 10 Program Evaluation Reviews that -- again, I am
- 11 being careful with the words here -- at least
- in part were a result of the audit process for
- 13 the first 100 cases. So we are going to
- 14 identify those and describe what -- so that is
- 15 sort of what was the value of doing those
- 16 first 100 cases.
- 17 That report -- hopefully, we will
- 18 have that ready for the next probably full
- 19 meeting, not the phone call meeting. It might
- 20 be ready to bring that back to the full Board.
- Other than that, we are proceeding
- on the case reviews. We are working with the

	1	I	think	we	actually	wrapped	up	the	sixth
--	---	---	-------	----	----------	---------	----	-----	-------

- 2 matrix. The seventh and eighth set of cases,
- 3 which are all, again, batches of 20, kind of
- 4 are in progress, somewhere in our finding
- 5 resolution process between SC&A and NIOSH,
- 6 which is what we do at the Subcommittee level.
- 7 I believe all those -- I am asking
- 8 now, Ted. All those -- at least the final
- 9 matrices and things like that, they are all
- 10 available somewhere where the new Board
- 11 Members can see them. Right?
- 12 MR. KATZ: I would have to ask
- 13 OCAS about that.
- 14 MEMBER GRIFFON: I know they are
- 15 somewhere on there. We will have to make sure
- 16 we can point you in the right direction. At
- 17 least for the first five sets, the finalized
- 18 report, that's got to be available for new
- 19 Members.
- 20 MR. HINNEFELD: I'm sorry. What
- 21 was the question?
- 22 MEMBER GRIFFON: The matrices of

1	all	the	findings,	the	ones	that		I	mention
---	-----	-----	-----------	-----	------	------	--	---	---------

- 2 this, because I was thinking that the new
- 3 Members would certainly be interested in
- 4 seeing the matrices and how we go through this
- 5 resolution process, and I am wondering if
- 6 those are collected in any one area on the 0:
- 7 drive or maybe we need to make that happen.
- 8 MR. HINNEFELD: We would have to
- 9 make that happen. So you are talking about
- 10 the first five matrices with the final
- 11 resolution?
- 12 MEMBER GRIFFON: Well, actually, I
- 13 need to work with NIOSH on this anyway,
- 14 because we have talked about putting an area
- 15 similar to the Procedures Work Group, having
- 16 an area where we have the findings altogether
- in one spot, and possibly in a database
- 18 format.
- 19 So I will keep people apprised on
- that one, because I think you need to see that
- 21 and see how the resolution process is working.
- 22 It is sometimes slow, and if there is one

issue that we are all aware of that is t	:here
--	-------

- 2 are concerns going forward, I think, with a
- 3 lot of our Work Groups is the sort of tracking
- 4 of the findings, because often it will turn
- out that the resolution is that NIOSH agrees,
- 6 and the procedure is being revised, but that
- 7 falls under the Procedures Work Group.
- 8 So we don't want to shuffle
- 9 something to another Committee and forget
- 10 about it. We want to make sure it was
- 11 completely closed out. So tracking is going
- 12 to be an issue going forward for several of
- 13 our Committees. I will certainly let people
- 14 know where -- when we get this all in one
- 15 spot, I will let you know where it is and make
- 16 sure it is available for you.
- 17 CHAIRMAN MELIUS: Thanks, Mark.
- 18 Any questions from Board Members? Yes, Paul?
- 19 MEMBER ZIEMER: Mark, could you or
- 20 John remind us where we are on the 12th set of
- 21 cases? I believe all of the teams have
- reviewed the 11th set, and I believe the 12th

- 1 set had been picked.
- 2 DR. MAURO: The 11th set is
- 3 completed and delivered.
- 4 MEMBER ZIEMER: Right. Is your
- 5 team still looking at the 12th set?
- DR. MAURO: The 12th set, we are
- 7 about halfway done with the batch. So, yes, I
- 8 would say that it will be a couple of months
- 9 before we will be ready for one-on-ones on the
- 10 12th set we are on.
- 11 My guess is the next batch may be
- 12 May. It might be put on the agenda to fill
- 13 the pipeline up. That will be probably a
- 14 perfect time.
- 15 MEMBER ZIEMER: Well, the reason I
- 16 asked that question, we don't have teams
- 17 assigned, and this is a good opportunity to
- 18 get the new Members now involved on the review
- 19 team. So I suggest that --
- 20 MEMBER ANDERSON: We got the
- 21 copies of the 11th emailed to us.
- 22 MEMBER GRIFFON: You did? Oh,

1	okay	•
	01101	ľ

- 2 MEMBER ZIEMER: And you have --
- 3 Did we assign you to any --
- 4 MEMBER ANDERSON: No.
- 5 MEMBER ZIEMER: No, I didn't think
- 6 so. You got the copies, right. I guess you
- 7 have the opportunity, if you want it, to
- 8 listen in, but we need to make sure, and I
- 9 know the Chair will take care of that, but I
- 10 just wanted to emphasize it. That is coming
- 11 up fairly soon, and not only to see the
- 12 previous matrices but now become involved in
- 13 reviewing cases.
- 14 MEMBER GRIFFON: Just to be clear
- what we are talking about, we have always had
- 16 Board teams, two or three individuals, get
- 17 case assignments, and we have had the Chair
- 18 doing that, because there is the conflict
- 19 concern. So we have to kind of sort through
- 20 who can be reviewing what.
- 21 That is your opportunity to sort
- 22 of weigh in on SC&A's findings in a

	1	preliminary	fashion.	Then	SC&A	brings	all
--	---	-------------	----------	------	------	--------	-----

- 2 that information back to the Subcommittee, and
- 3 the Subcommittee Members have another crack at
- 4 it, along with NIOSH, to discuss it. So that
- is sort of how the process has been working.
- 6 CHAIRMAN MELIUS: Any other
- 7 questions for Mark? Wanda, Procedures Review
- 8 Subcommittee.
- 9 MEMBER MUNN: Although we usually
- 10 meet every six or eight weeks, we have not met
- 11 since November. Both the Agency and the
- 12 contractor were heavily involved in activities
- 13 preparing for this particular meeting we are
- in today, and so we did not meet in January,
- 15 as we ordinarily would.
- November was our last meeting. We
- 17 are now scheduled to meet immediately
- 18 following the Dose Reconstruction
- 19 Subcommittee's meeting on March 23, I believe
- 20 it is, in Cincinnati.
- 21 Our letter to Secretary Sebelius
- 22 giving a report on -- our second annual report

1 of our acti	lvities, as	you	approved	it	during
---------------	-------------	-----	----------	----	--------

- 2 our Port Jefferson meeting, was mailed on
- 3 January 29 and is now gone.
- We have somewhere between 15 and
- 5 20 very specific issues that we have
- 6 outstanding and are in various degrees of
- 7 being resolved between NIOSH and SC&A.
- At our last meeting, we spent just
- 9 about half the day, possibly even more than
- 10 that, wrestling with the issues that are
- 11 surrounding PERs and how they need to be
- 12 handled.
- 13 SC&A has given us their review of
- 14 potential protocol, and we are going to have
- 15 to work through how we approach these, simply
- 16 because they involve a lot of cross-
- 17 responsibilities with the Dose Reconstruction
- 18 Subcommittee. So that will be a major issue
- 19 on our upcoming agenda. We are going to have
- 20 to do that.
- 21 If you would like to take a look
- 22 at where we are, I have -- hold on just a

1	moment,	Ι	am	aoina	up	to	the	podium.	I	had
_		_	OLLLL	50-115	\sim r	~ ~	0110	Pour am.	_	

- 2 thought we might want to take a look again at
- 3 our spread of information with respect to
- 4 where our cases are.
- 5 You have seen this before. This
- 6 is what is on the database right now, the
- 7 status of all of the procedures at which we
- 8 are looking. As you can see, we have a total
- 9 of 538 total findings that we are dealing
- 10 with, of which we still have 104 open, which
- means they have not been addressed yet.
- 12 The others, we are addressing in
- 13 some fashion. We have closed almost half of
- 14 the findings that have been placed before us,
- 15 but we are not quite there yet.
- We are hoping that in the next
- 17 couple of meetings, we will be able to move
- 18 through some of those fairly quickly, because
- 19 we are close on a half-dozen or so.
- 20 So this material, the data that
- 21 you see here, is accessible to you through the
- 22 database on O: drive. If you don't know how

1	to	get	to	it	and	want	to	get	to	it,	I	can	give
---	----	-----	----	----	-----	------	----	-----	----	-----	---	-----	------

- 2 it to you.
- 3 It is not ordinarily updated
- 4 except during our meetings, at which time we
- 5 try to keep our database literally as close to
- 6 today's findings as possible, but of course,
- 7 these things are only closed in our meetings
- 8 or when we bring something specifically to
- 9 you.
- 10 So that is all I have unless you
- 11 have questions.
- 12 MEMBER ANDERSON: What is the
- 13 findings? I mean, to go to this table, how do
- 14 I see what you are really looking at?
- 15 MEMBER MUNN: In order for you to
- see what I am really looking at, you will have
- 17 to go to the full database, and in our full
- 18 database you would need to sort.
- 19 If you want a little tutorial on
- 20 how to do that, Henry, I will be glad to do
- 21 that for you offline, or any of the other new
- 22 Members who are interested in doing that. We

_							' -	
1	can	give	you	some	written	instructions,	, lİ	you

- 2 would like. Once you are a little more
- familiar with the O: drive, you can get to it.
- 4 What those indicate is groups of
- 5 specific procedures that had a number of
- 6 findings in each case, and the individual
- 7 findings are listed on the left side. That is
- 8 not the number of procedures we are looking
- 9 at. It is the number of findings.
- 10 MEMBER ANDERSON: I know, but
- 11 where does one get what the procedure is and
- 12 what the findings are?
- 13 CHAIRMAN MELIUS: That is the full
- 14 database.
- 15 MEMBER MUNN: That is the full
- 16 database that lists everything on it, and
- 17 needs to be sorted to find what you want at
- 18 any given time. We can show you how to do
- 19 that.
- 20 CHAIRMAN MELIUS: And there are
- 21 periodic reports from SC&A.
- 22 MEMBER ANDERSON: That is what I

	1	thought.	That	is	what	I	meant.
--	---	----------	------	----	------	---	--------

- 2 CHAIRMAN MELIUS: They are
- 3 compiled, and then -- but the database doesn't
- 4 -- correct me if I am wrong, Wanda, which I
- 5 know you will. It just sees where we are in
- 6 terms of resolving the findings between SC&A
- 7 and NIOSH under the direction of the
- 8 Procedures Subcommittee.
- 9 MEMBER MUNN: Right.
- 10 CHAIRMAN MELIUS: Did I get it
- 11 right, Wanda?
- 12 MEMBER MUNN: You got it right.
- 13 CHAIRMAN MELIUS: Hey, you taught
- 14 me well.
- 15 MEMBER MUNN: Gold star for the
- 16 Chair. Thank you.
- 17 CHAIRMAN MELIUS: Any other
- 18 questions for Wanda? Brookhaven, Josie?
- 19 MEMBER BEACH: Brookhaven, as you
- 20 recall, in October we tasked SC&A to do a
- 21 focused review for that Evaluation Report. At
- 22 this time, it is with DOE. Once it has been

1	released,	then	I	will	work	with	Ted	and	the
---	-----------	------	---	------	------	------	-----	-----	-----

- 2 other Work Group Members to schedule a
- 3 meeting.
- 4 CHAIRMAN MELIUS: So you expect a
- 5 meeting between now and May?
- 6 MEMBER BEACH: Well, it depends on
- 7 how long that report is with DOE, and maybe
- 8 Joe might have a better idea of how long until
- 9 that report is released from DOE.
- 10 MR. FITZGERALD: I don't think it
- 11 is going to take very long.
- 12 MEMBER BEACH: So once that is
- 13 complete, we will talk to Ted.
- 14 CHAIRMAN MELIUS: Okay. Fernald?
- 15 MEMBER CLAWSON: The Work Group -
- we met January 29, 2010. We have basically
- 17 got six outstanding issues that we are dealing
- 18 with, bioassay data, to assure that the
- 19 database that they are using can be used for a
- 20 coworker model.
- 21 NIOSH and OCAS has recently put
- several papers on, ranging from radon for body

1 burden and thorium body burde	en. SC&A is
---------------------------------	-------------

- 2 reviewing those, and several other issues with
- 3 K-65, and one of the ones that you heard last
- 4 night that a Fernald individual brought up is
- 5 how this would work -- the coworker model
- 6 would work for the construction workers. This
- 7 has been tasked to NIOSH and SC&A, and we are
- 8 waiting to hear back from them.
- 9 CHAIRMAN MELIUS: Any questions
- 10 for Brad? Hanford -- I am Chair of the Work
- 11 Group for Hanford.
- 12 At the last meeting before this
- one, we approved a large petition to the SEC
- 14 Cohort for Hanford as a result of sort of a
- 15 reevaluation by NIOSH, and a lot of new data
- 16 that they collected from Hanford on that site.
- So in response to that, we have --
- 18 the Board approved NIOSH's recommendation on
- 19 that. So that has moved forward. We now have
- 20 to sort of revise our issues matrix, which
- 21 Arjun has done, and I think we are just sort
- of waiting on NIOSH, some other work to go on.

1	I	d	lon '	t	know	if,	Sam	and	Arjun,	i1	E
---	---	---	-------	---	------	-----	-----	-----	--------	----	---

- 2 you want to give us a brief update on where
- 3 that is.
- 4 DR. GLOVER: Yes. As I have been
- 5 speaking with Arjun, essentially we have
- 6 completed our research, focusing a lot mostly
- 7 on 1972. It is essentially in the Board's
- 8 hands at this time. We are working on the
- 9 matrix, and there are a few data captures that
- 10 are open, and we are interacting with SC&A.
- 11 So they are fully aware of that. I am also in
- 12 the process of updating the Advisory Board's
- website, so you have access to our previous 28
- 14 data capture efforts. So you will have all
- 15 that information, so you can proceed.
- 16 CHAIRMAN MELIUS: Okay. Thank
- 17 you. Arjun.
- 18 DR. MAKHIJANI: Yes. We haven't
- 19 had a three-way conversation since NIOSH has
- 20 put up their revised Site Profiles to reflect
- 21 all of the recent information, and basically,
- 22 as I understand our informal conversations,

1	that	NIOSH	is	essentially	saying	the	rest	are
---	------	-------	----	-------------	--------	-----	------	-----

- 2 Site Profile issues, and we are going to
- 3 review, if we have SEC issues, they will come
- 4 up as part of our review of the revised Site
- 5 Profiles.
- 6 So, basically, as I understand it,
- 7 going forward we are going to follow the
- 8 matrix issues through the revised Site
- 9 Profiles from 1972 onward. I have got to
- 10 create a work plan for our team and run it by
- 11 you.
- 12 CHAIRMAN MELIUS: Okay. Thank
- 13 you. Idaho. Phil.
- 14 MEMBER SCHOFIELD: A couple of
- 15 things. One, we are trying to get a tour set
- 16 up before the meeting in Idaho for the full
- 17 Board.
- 18 The other thing is there has been
- 19 some movement on the Idaho and Argonne
- 20 National Labs West information. Pete Darnell
- 21 will give us an update.
- 22 MR. DARNELL: My name is Pete

1 Darnell. With Idaho, the Oak Ridge A	Associated
--	------------

- 2 Universities has updated the issues matrix for
- 3 SC&A, and it is currently under review at
- 4 OCAS. Once we get that, we will be turning it
- 5 over to SC&A to update responses.
- 6 We have also received from Oak
- 7 Ridge Associated Universities the internal and
- 8 external Technical Basis Document sections.
- 9 The internal section has been reviewed by
- 10 OCAS, and comment resolution is in process.
- 11 The external Technical Basis Document is still
- 12 under review.
- 13 That is pretty much where things
- 14 stand. We expect more sections of the
- 15 Technical Basis Document in accordance with
- 16 the procedures in our Gantt chart over the
- 17 next couple of months.
- 18 CHAIRMAN MELIUS: Any questions on
- 19 Idaho? For that matter, Hanford? I realize
- 20 that I tried to avoid questions myself there.
- 21 MR. DARNELL: One thing I forgot
- 22 to mention, the Idaho update Technical Basis

1	Document	update	is	also	the	Argonne	national

- 2 Laboratory West update. Those two sites are
- 3 being combined.
- 4 CHAIRMAN MELIUS: And that has
- 5 been part of the hold-up in moving us forward.
- 6 Good. Thank you. Linde.
- 7 MEMBER ROESSLER: We have had two
- 8 Work Group meetings since the last Board
- 9 meeting. The first one was face to face in
- 10 Cincinnati, and there are two things from that
- 11 I will mention.
- 12 One might be of interest to the
- 13 Outreach Group. Our claimant's
- 14 representative, [identifying information
- 15 redacted], had mentioned earlier that it is
- 16 very difficult for the claimants to read the
- documents that are put out by NIOSH and SC&A.
- 18 Intentionally, they go into a lot of
- 19 scientific detail and so on.
- 20 She said it would be very helpful
- if a summary of the Evaluation Report could be
- 22 written so the claimants could understand the

1	whole	process	better.
_	*****	Process	ZCCCT.

- 2 Chris Crawford from NIOSH, who is
- 3 our Linde NIOSH person, wrote about a three
- 4 and a third page summary of the Linde ER,
- 5 which I think was very helpful. [identifying
- 6 information redacted], I think, was pleased
- 7 with it. In fact, I find as a Work Group
- 8 Member it is helpful myself. That might be
- 9 something other groups would want to look at
- 10 doing.
- 11 The other thing at that meeting in
- 12 December, SC&A agreed -- we had resolved all
- 13 the issues that we had on the table. SC&A
- 14 agreed that NIOSH's approach to bounding doses
- 15 was satisfactory. However, at that meeting
- 16 [identifying information redacted] brought up
- 17 some other issues.
- 18 We had some other discussions. So
- 19 we decided to have another Work Group meeting
- 20 by teleconference, which we did on January
- 21 25th.
- 22 We went over these issues. A

1 r.	number	of	them	were	raised	by	the	claimants,
------	--------	----	------	------	--------	----	-----	------------

- 2 in fact. So we still have a few more things
- 3 to do. NIOSH has a list of a few things to
- 4 accomplish. SC&A is supposed to look at a few
- 5 more things that NIOSH has done, just to see
- 6 that they feel that they are done
- 7 appropriately.
- 8 So our goal is to have another
- 9 Work Group meeting, and then at the May
- 10 meeting, Board meeting in Buffalo, which is
- 11 in the Linde territory, [identifying
- information redacted] is hoping that we will,
- 13 as a Work Group, come and present our
- 14 findings. So I hope we can pull these last
- 15 things together and present to you our Work
- 16 Group's conclusions.
- 17 CHAIRMAN MELIUS: Okay. Any
- 18 questions for Gen? Yes, Brad?
- 19 MEMBER CLAWSON: Just one thing
- 20 that I was thinking when she was talking about
- 21 that brief rundown. Ted has requested that
- 22 SC&A and NIOSH, after each Work Group, that

1	they	give	а	brief	summary	of	what	the	issues
---	------	------	---	-------	---------	----	------	-----	--------

- 2 are and so forth. I received mine from John.
- 3 Just in short sentences, it is kind of
- 4 telling what the issue is and where they are
- 5 going with it, and I found that quite
- 6 interesting. It may be able to help them a
- 7 little bit.
- 8 MR. KATZ: Yes. These are the
- 9 action items. So we agreed, and OCAS as well,
- 10 that SC&A and OCAS after every meeting would
- issue as quickly as they can the action items,
- 12 just so that everybody is clear about who is
- 13 doing what.
- 14 MEMBER ROESSLER: In our Work
- 15 Group, SC&A's Steve Ostrow has done a very
- 16 good job of keeping track of everything we do
- on a nice table in very understandable format.
- 18 CHAIRMAN MELIUS: Good. Thank
- 19 you, Gen. Los Alamos.
- 20 MEMBER GRIFFON: Los Alamos is, I
- 21 guess, the only -- right now, the ball is in
- 22 SC&A's court, really. SC&A is reviewing

1	NIOSH's	Evaluation	Report,	and	they	did	
---	---------	------------	---------	-----	------	-----	--

- 2 since the last meeting, my understanding is
- 3 that Joe and the team went out and did some
- 4 interviews as well as some classified
- 5 documents review for about a week.
- I am not sure if you have the
- 7 timing on when you might be ready, but as soon
- 8 as they come out with their report, then we
- 9 will schedule a Work Group meeting, but we
- 10 haven't met yet.
- 11 So, I don't know, Joe, if you have
- 12 a time frame on that.
- 13 MR. FITZGERALD: We just got the
- 14 redacted notes back on the interview about two
- 15 weeks ago. So we are going through and doing
- 16 summaries of that. So I think we are getting
- 17 relatively close to having a response, a first
- 18 response. We have two on-site reviews, a lot
- 19 of interviews, a classified review, and we had
- 20 -- I think ORAU staff was on that site visit.
- 21 So I think we are getting close, another
- 22 month or so.

1	MEMBER GRIFFON: So we may be able
2	to schedule a meeting before the May full
3	Board meeting.
4	CHAIRMAN MELIUS: Thank you. Any
5	questions for Mark? Okay. Mound? Josie.
6	MEMBER BEACH: Thank you. Mound
7	last met for a two-day meeting in January on
8	the 5th and the 6th. Of the 16 remaining
9	issues, the Work Group has unanimously agreed
10	to close the following matrix items, Issue 13,
11	which is the buried records. This was an
12	issue specifically addressed in the petition
13	related to the burial of Mound records at Los
14	Alamos and the Nevada Test Site.
15	Issue 16 was our R-beta shallow
16	dose issue, and also 21, the PAAA violations
17	where inadequate bioassay sampling was done.
18	This issue is being addressed further under
19	Issue 11 and 12. That is our adequacy and
20	completeness of internal dose. So while that
21	is closed, we will still have some issues to
22	follow-up on.

1	The Work Group has assigned
2	actions to the following issues, Issue 9 is
3	the high-fired Pu-238. NIOSH is reviewing the
4	Type L versus Type J solubility models as
5	bounding options, and it will establish for
6	the Work Group what approach will be taken for
7	dose reconstruction and the rationale behind
8	it.
9	What we call the Roadmap is an
10	integrated issues 1, 3, 4, 7 and 8. The Work
11	Group has agreed that the Roadmap mirrors the
12	King report and is not responsive to original
13	data adequacy issues. These issues are being
14	addressed again under Issues 11 and 12.
15	Issue 10 is the D&D era. NIOSH
16	will review and report back to the Work Group
17	the availability of information regarding rate
18	of conformance by former D&D workers for
19	providing termination bioassays upon departure
20	from Mound work sites.
21	If the information is available
22	and the rate of conformance is low, we will

1 have to determine	the	feasibility	of
---------------------	-----	-------------	----

- 2 conducting validation reviews of the internal
- 3 dose, coworker model application to D&D
- 4 workers.
- 5 These topics are SEC relevant
- 6 issues remaining that have been addressed --
- or, excuse me, have been assigned actions from
- 8 the Work Group for both NIOSH and SC&A.
- 9 The first one is Issues 14 and 15,
- 10 neutron dose reconstruction. Concerns remain
- over NIOSH's use of the MCNP model application
- 12 and the validity and application of NIOSH's
- 13 coworker dose data in NIOSH's dose
- 14 reconstruction approach.
- The next one is Issue 6, the
- 16 stable tritium compounds. A secure meeting
- 17 has been scheduled for February 18th to review
- 18 classified documents pertinent to establishing
- 19 scope of workers potentially exposed to Type S
- 20 tritides.
- 21 Based on the results of that
- 22 meeting, we are going to establish for the

1	Work	Group	what	approach	will	be	taken	for
---	------	-------	------	----------	------	----	-------	-----

- 2 dose reconstruction for both Type S and the
- 3 intermediate solubility of the STCs.
- 4 The other one is Issue 11 and 12,
- 5 adequacy and completeness of internal dose.
- 6 More work is needed to identify and
- 7 substantiate radionuclides for which exposure
- 8 potential existed, but where bioassay data is
- 9 lacking.
- 10 We need to define a basis for
- 11 judging exposure potential and whether NIOSH
- 12 can still reconstruct the missing doses with
- 13 sufficient accuracy.
- 14 There is one last topic, and I was
- 15 hoping maybe Jim would mention this at this
- 16 meeting. I am not sure if he can speak on it,
- 17 but SEC actions under consideration, Issue
- 18 Number 2, was our radon issue, and NIOSH is
- 19 working with DOL on a proposed scope of the
- 20 postulated SEC.
- I didn't know if you would want to
- 22 mention anything more on that.

1	DR. NETON: LaVon might be able to
2	fill in a little more detail, but we had
3	identified in the review of the petition a
4	portion of the time where radon couldn't be
5	reconstructed at the Mound Site.
6	That was a very unusual
7	combination of events that occurred that had
8	exposure potential to these three different
9	isotopes of radon gas, radon-219, radon-220
10	and radon-222 in extremely large
11	concentrations.
12	So because of that, we are going
13	to modify our Evaluation Report to recommend
14	addition of a separate Class of workers for
15	that one facility for I believe it is one
16	building. I forget which building it is now,
17	but this is a very confined exposure to one
18	building, and we feel that those workers could
19	be adequately identified as to who was in
20	those buildings.
21	MEMBER BEACH: And I believe it
22	was possibly two buildings, but that hasn't

- 1 been worked out.
- DR. NETON: Yes, I think they were
- 3 somewhat connected by some kind of walkway.
- 4 There may be two buildings.
- 5 MEMBER BEACH: Right. Yes. so,
- 6 hopefully, we will be hearing from NIOSH on
- 7 that soon. That is all I have.
- 8 CHAIRMAN MELIUS: Questions for
- 9 Josie? Nevada Test Site? We have heard from
- 10 them yesterday.
- 11 MEMBER PRESLEY: As everybody
- 12 knows, we did get our SEC passed yesterday.
- One thing that I would like to
- 14 bring up today to see if we could go ahead and
- 15 vote on is the NTS Site Profile.
- 16 MR. KATZ: Bob, can you speak
- 17 closer to the microphone, please? Thanks.
- 18 MEMBER PRESLEY: One thing that I
- 19 would like to bring up today and vote on was
- 20 the Board accepting the NTS Site Profile.
- In the last three or four years,
- 22 NIOSH has made a tremendous amount of changes.

1 We have gotten a lot of feedback from SC&.	Ĺ		gotten	lot	of	feedback	from	SC&I
--	---	--	--------	-----	----	----------	------	------

- 2 Their changes have been implemented. The Site
- 3 Profile, about six or eight items have been
- 4 rewritten and implemented.
- 5 What I would like to do is make a
- 6 motion that we accept the Site Profile as it
- 7 stands today. Everybody needs to realize that
- 8 this is a living document, and as changes come
- 9 up and as information comes up, it will be
- 10 added in.
- 11 The one thing that the Working
- 12 Group would ask is that, when things of this
- 13 nature happen, that we are immediately
- 14 apprised of the change so that, if it is
- 15 deemed that we need to go back and re-look at
- 16 this, that we will have the chance to comment
- and so that things don't fall by the wayside.
- 18 That is all I have, but I think we
- 19 do need to go ahead and accept the Site
- 20 Profile as it is today.
- 21 CHAIRMAN MELIUS: Bob and I talked
- 22 about this a little yesterday. It was sort of

1	in	the	context	of	more	disbanding	the	Work

- 2 Group, because there is no activity for the
- 3 Work Group going forward.
- In the promise Bob sort of puts it
- 5 is, yes, the Site Profile keeps changing, to
- 6 some extent. I guess the question would be --
- 7 I guess one is we can sort of disband the Work
- 8 Group or put it in mothballs or something,
- 9 whatever.
- I don't know how people feel about
- 11 accepting a Site Profile review that they
- 12 aren't really -- isn't in front of them to
- 13 see. That would be my question. I don't want
- 14 to force that issue, and I don't know that we
- 15 really have a procedure for this. In fact,
- 16 Mark reminded me that there are some old, real
- 17 old, Work Groups that dealt with some SEC
- issues, and we have sort of don't have any
- 19 Site Profile -- a Work Group to really deal
- 20 with some of the Site Profile issues.
- 21 Any comments? Yes, Brad?
- 22 MEMBER CLAWSON: Part of my issue

1	is	and	what	I	am	nervous	about	is	I	understand
---	----	-----	------	---	----	---------	-------	----	---	------------

- 2 that the Site Profile is a living document,
- 3 but as a Work Group I don't know how it is
- 4 going to work, because -- I wonder how it is
- 5 going with Rocky Flats, because there is a lot
- 6 of changes. It seems like Mark is kind of
- 7 spearheading quite a few of those, since the
- 8 SEC kind of stopped.
- 9 I don't want to lose so many --
- 10 anything, because there's many things that are
- 11 still going on, like [identifying information
- 12 redacted] said yesterday, with Yucca Mountain
- and the 25 Area of how this is going to work
- in and so forth, like that.
- I would like to be able to somehow
- 16 make sure that we are still in the loop for
- 17 these issues that come up with Nevada Test
- 18 Site. That is the only thing I am nervous
- 19 about.
- 20 CHAIRMAN MELIUS: Jim?
- DR. NETON: I would just like to
- 22 make a couple of comments. I see Bob Presley

1	stepped	out	for	а	second.	So,	hopefully,	he

- 2 will be able to -- well, I'll repeat when he
- 3 comes back, I quess.
- 4 We are certainly going to have to
- 5 revise the Site Profile now to pull out all
- 6 the internal monitoring reconstruction or
- 7 basically to revise it, so that we don't do
- 8 internal dosimetry calculations through 1992
- 9 now. So all of those findings related to
- 10 internal dosimetry prior to '92 go away. I
- 11 mean, we have agreed that we can't do dose
- 12 reconstruction.
- So what is left, or the balance of
- 14 what is left is the external dosimetry
- 15 reconstructions through '92, and then full
- 16 dose reconstructions after '92. But we have
- 17 not revised the Site Profile.
- We have agreed in principle with
- 19 SC&A on virtually all the remaining issues, to
- 20 my knowledge, but we have not yet produced the
- 21 final report that contains that -- those
- 22 agreed upon paths forward, if that is helpful.

1	CHAIRMAN MELIUS: So that would be
2	that there is if I understand you, there
3	would be some point in the future I want to
4	say near future, but I don't want to try to
5	pin you down, but that there would be a
6	revised Site Profile that would address all
7	these issues in the context of what has been
8	approved for the SEC and so forth, and then
9	there would really be a need to review and
10	ascertain that that
11	DR. NETON: I would think so.
12	CHAIRMAN MELIUS: Yes. Then I
13	guess the question would be whether we
14	maintain the same Work Group and have it ready
15	to do things or do we try to come up with a
16	new Work Group or wait until the time? I will
17	ask you, what is the time frame for that,
18	because I guess that would make a difference
19	in terms of
20	DR. NETON: I have learned my
21	lesson not to give very definite time
22	schedules. I really can't say when it is

1	going	to	be	done.	I	would	have	to	confer	with

- others who are more privy to the schedule than
- 3 I am.
- 4 CHAIRMAN MELIUS: That is fine,
- 5 Jim. Other Board Members? Bob, while you
- 6 were out, Jim sort of updated us. They are
- 7 revising the Site Profile. I think there is
- 8 general agreement there would be possibly some
- 9 need or probably some need to review the
- 10 revisions, see do they address all the issues
- 11 satisfactorily. I guess the question is do we
- 12 disband the Work Group while NIOSH is doing
- 13 that, then maybe reconvene it in some way at
- 14 the time, or what.
- 15 MEMBER CLAWSON: Maybe we could
- 16 put it in emeritus status or something.
- 17 CHAIRMAN MELIUS: We have some
- 18 that are -- the Security one.
- 19 MEMBER PRESLEY: I just want
- 20 everybody to understand, you know, that when
- 21 we were tasked with this, what we were tasked
- 22 with doing was taking care of the Site Profile

1	and	the	SEC.

- 2 CHAIRMAN MELIUS: And I think we
- 3 can say, up to date, you have taken care of
- 4 those two overarching tasks, and now there is
- 5 maybe a third task coming up, which will be
- 6 the Site Profile revision, which will reflect
- 7 what has happened so far. Why don't we just
- 8 say it is on, have a latent or whatever we
- 9 want to call it, Work Group. Thank you.
- 10 MEMBER ZIEMER: Did I understand
- 11 from Dr. Neton that the only change would be
- to basically remove or change that part of the
- internal dose calculation in accordance with
- 14 what basically has been agreed to?
- DR. NETON: No. There will also
- be some changes that we have agreed to through
- 17 the Working Group process in the external
- 18 dosimetry area as well. Like I said, we have
- 19 agreed in principle through these Working
- 20 Group deliberations on the path forward, but
- 21 we have yet to revise the Site Profile to
- 22 completely address our proposed path forward.

1		M.	EMBEF	R ZIEMER:	Okay	<i>Y</i> ,	but	ın
2	essence	all	the	proposed	changes	are	thi	ngs
3	that hav	re bee	en ag	reed to.				

- 4 DR. NETON: Correct.
- 5 MEMBER ZIEMER: So the only point
- 6 in the review, as I could see it so far, would
- 7 be simply to confirm that those have actually
- 8 occurred. So it would not be -- it is not
- 9 like you are completely revising things now.
- 10 All the revisions in principle have been
- 11 agreed to.
- DR. NETON: Correct.
- 13 MEMBER ZIEMER: Thank you.
- 14 CHAIRMAN MELIUS: Pantex?
- 15 MEMBER BEACH: So do we need to
- 16 pull that motion from the table or table it,
- 17 because he did make a motion.
- 18 MEMBER PRESLEY: It was never
- 19 seconded.
- 20 CHAIRMAN MELIUS: It was never
- 21 seconded.
- 22 MEMBER BEACH: Oh, so it doesn't

1 matter? Okay. Thank yo	Thank you.
--------------------------	------------

- 2 MEMBER CLAWSON: At the request of
- 3 the petitioners -- they have been getting many
- 4 different conflicting information on Pantex.
- 5 So they asked me, instead of just saying that
- 6 we haven't met, that I kind of lay out where
- 7 the issues are at and where we are, and I want
- 8 to make something clear.
- 9 This is not to point blame or to
- 10 say anything. I know that Stu has stepped
- into this position and has inherited a lot of
- 12 these things, but this is more so the
- 13 petitioners know exactly where we are at, and
- 14 as requested. As they said, it might be a
- 15 good idea, Brad, if you write this stuff down
- 16 so you don't get lost.
- 17 So here is where we are at. Just
- 18 so you know, Pantex Evaluation was issued by
- 19 NIOSH in December 2008. The Board asked me
- 20 and my Working Group to review the ER back
- 21 then. Petitioners and members of the public
- 22 are increasingly asking me what is happening,

1 why no findings, no recommendations have	: been
--	--------

- 2 rendered to date in the Board's review after
- 3 some 14 months after the SEC was filed.
- 4 Quite frankly, I share their
- 5 concerns. Since the ER was issued and SC&A
- 6 presented in the early 2009 what it considered
- 7 to be the key SEC issues, the Work Group and
- 8 NIOSH have not been able to meet and have not
- 9 even been able to tour the site.
- 10 Why are many of these reasons?
- 11 One of the ones that is a big one is security,
- 12 which we understand and we accept from our
- 13 national security standpoint. However,
- 14 security alone is not the only issue.
- The tour that I mentioned has been
- 16 requested for over a year and a half and has
- 17 been under consideration by both DOE
- 18 Headquarters and Pantex during that time.
- 19 Simple interview notes have taken over six
- 20 months to clear and to be returned to SC&A,
- 21 and even in some standpoints longer.
- 22 Each on-site visit requires a lead

1	time	of	about	three	months.	Workers	are
---	------	----	-------	-------	---------	---------	-----

- 2 apprehensive about being interviewed at
- 3 Pantex, which I would like to thank DOE for
- 4 issuing a letter on worker retaliation, which
- 5 I hope will bring a little bit of peace to the
- 6 workers.
- 7 A list of issues were identified
- 8 by SC&A in its 2007 Site Profile and has been
- 9 carried forward into the March 2009 Issue
- 10 Matrix. To date, despite repeated requests by
- 11 me, no cleared response has been forthcoming
- 12 from NIOSH. Apparently, the Work Group cannot
- 13 meet at this time until we have these back.
- 14 This is why the Work Group has not been
- 15 meeting.
- 16 The bottom line is that Pantex SEC
- 17 review is hardly off to square one due to the
- 18 proceeding implementations at times dragging
- 19 on. It is incumbent on the Board to press
- 20 both agencies of DOE and NIOSH to respond in a
- 21 timely manner. However, at this pace the
- 22 Pantex review -- and these are just my

1 calculations may take well over the thre
--

- 2 to five years if we don't get under it a
- 3 little bit better.
- 4 At this time, Stu has told me that
- 5 we have a review that is finally being sent
- 6 back to us, but at this time I still have not
- 7 received anything.
- 8 I hope that this allows the
- 9 petitioners to understand what many of our
- 10 problems are and that we are trying to deal
- 11 with these things. That's it.
- 12 CHAIRMAN MELIUS: Any comments,
- 13 Stu, updates?
- 14 MR. HINNEFELD: Well, just a
- 15 little bit in terms of our -- I believe the
- 16 product that Brad is talking about is our
- 17 response to the findings. I believe these are
- 18 the Site Profile findings. Isn't that right?
- 19 MEMBER CLAWSON: And there was SEC
- 20 issues. When we first started out, it was the
- 21 Site Profile, and the SEC came. So they kind
- of are combined.

1	MR. HINNEFELD: So that they are
2	combined. Okay. Our response the way the
3	process works on these is that, when the team
4	responding to those findings prepares their
5	product, their initial product, that goes to
6	the Department of Energy for clearance for
7	sensitive material before anybody else, even
8	in the project, sees it.
9	So there was some amount of time,
10	and then there was a double clutch on the
11	preparation of that, because as the team was
12	preparing the response, in the middle of the
13	preparation we received a large number of
14	documents that we had requested from our site
15	research like months earlier from the
16	Department of Energy.
17	So once we received those, then we
18	looked at those, and we felt that they would
19	either change or strengthen our responses. So
20	that then delayed the response some more. The
21	preparation of the response took longer.

That response has been reviewed

22

1	now	and	released.	You	will	recall	that	that

- 2 was the team's initial draft of the response,
- 3 and it came to us to review, and we felt that
- 4 there should be some strengthening of it. So
- 5 we made some comments, and those comments are
- 6 now being resolved.
- 7 I would think that it is not that
- 8 far from being available, but our experience
- 9 has been that this has been a really tough
- 10 site to keep things moving through. So I
- 11 don't really have a prediction for a date
- 12 right here today.
- 13 MEMBER CLAWSON: And I just wanted
- 14 to make sure, because the petitioners -- you
- know, many times when they have called in, and
- 16 this is why they asked that I do this, is
- 17 because they get conflicting points. They
- 18 want to know what is going on, and I really
- 19 don't blame them.
- 20 As I wrote this down, I forgot one
- 21 thing. I already talked to Stu about it
- 22 earlier, but that is the data retrieval plan

1	that	we	still	to	date	have	not	seen,	and	per

- 2 the procedures we are supposed to both be
- 3 issuing these, so that both sides know what we
- 4 have.
- 5 I talked to Greg and Regina before
- 6 they left, and I have made them very much
- 7 aware of where we are at. They have promised
- 8 me that they are starting somewhat of a new
- 9 process, that whenever anything goes into
- 10 Pantex, requests and so forth, that they will
- 11 also go to DOE headquarters to somewhat assist
- 12 with this. But this is dragging on.
- 13 CHAIRMAN MELIUS: Thank you, Brad.
- 14 Questions for Brad? I would just add, as I
- 15 have said, I think, many times now, I just
- 16 question whether, given the nature of the
- 17 security issues with Pantex, whether we can
- 18 have a meaningful and appropriate SEC
- 19 evaluation process. Let's see where we are by
- 20 the next meeting.
- 21 MEMBER CLAWSON: I am giving it my
- 22 best shot.

1 CHAIRMAN	MELIUS:	We	understand
------------	---------	----	------------

- that, and I think NIOSH and everybody and,
- 3 hopefully, DOE headquarters is going to step
- 4 in a little bit more on that.
- 5 Pinellas.
- 6 MEMBER SCHOFIELD: We still
- 7 haven't had a meeting, and right now we are
- 8 still on schedule. Hopefully, we will be
- 9 ready by August. It is way down in the queue.
- 10 Because of all these SEC Petitions, NIOSH has
- 11 been quite busy, but they are still hopeful
- 12 that maybe by August we will be ready.
- 13 CHAIRMAN MELIUS: Okay, thank you.
- 14 Piqua Power Reactor. John?
- 15 MEMBER POSTON: The Piqua Working
- 16 Group was established at our last meeting, and
- 17 consists of Phil Schofield, mark Griffon, and
- 18 Bill Field, and myself.
- 19 I was advised not to have a
- 20 meeting until our new Members were baptized in
- 21 fire. So we will try to have a meeting soon.
- We do not have anyone from SC&A appointed to

1	the	Working	Group	so	far.

- 2 I think the first meeting will
- 3 probably be a telephone conference, because we
- 4 need to sort of outline how we are going to go
- 5 about it, and I think the expense of traveling
- 6 to Cincinnati and holding a face to face
- 7 meeting is probably not justified. So I will
- 8 be contacting the Members, and we will try to
- 9 have a teleconference.
- 10 CHAIRMAN MELIUS: Okay. Thanks,
- 11 John. SC&A can get somebody assigned. You
- 12 don't need to -- just do it, unless you have
- 13 something else.
- DR. MAURO: This is one of the --
- 15 a bit unusual in terms of the process. I just
- 16 want to make sure I understand.
- 17 SC&A is not to take any action in
- 18 terms of reviewing the Piqua material until
- 19 the Work Group meets. As long as you are in
- that position, I am going to be the person.
- 21 So just let me know when you want to get
- 22 together, and I will certainly bring aboard

	_	
-	- 1 7	Members.
	$\Delta E D \Delta V$	Wampara
	COLLICI	MCHINCIS.

- 2 So as of this date, we have not
- 3 billed an hour to Piqua.
- 4 MEMBER POSTON: I wanted to give
- 5 especially Bill a chance to read the report
- 6 that was issued at the last meeting, and then
- 7 for the four of us to get together and talk
- 8 about what we think needs to be done and how
- 9 to proceed.
- 10 CHAIRMAN MELIUS: That is fine,
- 11 and helpful. Now we've got an SC&A contact.
- 12 So we have accomplished something.
- 13 Rocky. Mark?
- 14 MEMBER GRIFFON: Rocky Flats is
- 15 essentially inactive. We do have open Site
- 16 Profile issues, though. So we are not
- 17 complete with our work, but have really been
- 18 trying to resolve this implementation of the
- 19 Class issue before we move forward with any of
- 20 the Site Profile -- outstanding Site Profile
- 21 issues.
- 22 So we are still waiting for

1	information	from	DOL	on	that,	and	you	heard
---	-------------	------	-----	----	-------	-----	-----	-------

- 2 the brief report two days ago that they are
- 3 still working with University of Colorado
- 4 database. They are considering that and its
- 5 impacts on the implementation of the Class as
- 6 established.
- 7 So we will schedule a Work Group
- 8 meeting soon. I know there are lots of other
- 9 priorities, but we haven't forgot about
- 10 closing out the Site Profile issues.
- 11 CHAIRMAN MELIUS: Santa Susana,
- 12 Mike Gibson.
- 13 MEMBER GIBSON: Yes. Dr. Melius,
- 14 we have not met recently. Dr. Hughes is
- 15 providing periodic updates on OCAS response,
- 16 and the last indication from OCAS is that they
- should be ready to have a meeting sometime in
- 18 the April time frame.
- 19 CHAIRMAN MELIUS: Okay, excellent.
- 20 Any questions for Mike? Okay, thanks, Mike.
- 21 Savannah River?
- 22 MEMBER GRIFFON: Yes, Savannah

1	River,	we	did	have	а	Work	Group	meeting.	Ιf

- 2 you remember, the last couple of reports I
- 3 have given, NIOSH was in the process of
- 4 getting quite a bit more data, especially
- 5 related to thorium exposures.
- They have that data now, and along
- 7 with several other -- I won't list them all,
- 8 but there are several other radionuclides
- 9 where they are going to have to do coworker
- 10 models. They believe they can accomplish the
- 11 coworker models, but they are still pulling
- 12 this data together.
- 13 They did at the last Work Group
- 14 meeting give us a time line. I believe most
- of those coworker models will be completed by,
- 16 at least according to the time line, if my
- 17 memory serves me, sometime in May/June time
- 18 frame of this year.
- 19 So we are waiting to reconvene
- 20 until some of these outstanding actions are
- 21 further along, but we did have a Work Group
- 22 and made some progress.

1	We also have an open issue on data
2	adequacy that we are looking into, and
3	construction worker model, and I think that is
4	a quick summary of where we are at, but the
5	Work Group continues to work.
6	I guess I will make one note on
7	this is that we do want to strike while the
8	iron is hot, so to speak, with Savannah River.
9	We had a Work Group meeting well, I don't
10	know if that was the right term, but we I
11	guess keep the momentum is more the phrase I
12	am looking for.
13	The last Work Group meeting
14	when we have these things spaced so far apart,
15	we find ourselves going over the same ground
16	again and again, and to the extent we can I
17	know we have the problem now is we have so
18	many SECs in front of us, and major sites, but
19	my goal is to keep the momentum with Savannah
20	River. So working closely with Tim Taulbee to
21	do that.

CHAIRMAN MELIUS:

22

Thanks, Mark.

1 5	SEC	Issues?	This	is	my	Work	Group.
-----	-----	---------	------	----	----	------	--------

- We had a meeting last Friday
- 3 regarding two particular issues for that
- 4 meeting. One was the Dow Madison Site, which
- 5 had been assigned to that group. We have a
- 6 number of issues there. We are basically
- 7 trying to outline what the issues were and
- 8 what needed to be done in terms of follow-up.
- 9 There were also some issues
- 10 longstanding for the petitioner to get
- 11 information they had requested from DOL and
- 12 from NIOSH and so forth. I think we have
- 13 finally resolved those. I just got an email
- 14 from [identifying information redacted]
- 15 indicating that he had received or was about
- 16 to receive a lot of the information that he
- 17 had recently requested from DOL.
- 18 So our plan is to have a meeting
- 19 and try to resolve and come to some conclusion
- 20 on that SEC Evaluation Report shortly. The
- 21 meeting will take place as part of another
- 22 meeting.

1	The other half of our meeting on
2	SEC issues concerned the 250-day issue where
3	we have been talking about a long time in what
4	situations or circumstances will we qualify
5	people for the SEC when they don't have a 250
6	work day requirement and basically when there
7	are short term, very high exposures, and how
8	to resolve how to interpret that in terms of
9	the regulation, the situations that we
10	encounter which are varied, depending on the
11	site and amount of information we have,
12	involve a number of the specific sites, the
13	NTS, Ames, among others. The Met Lab was the
14	other one.
15	I think we made good progress in
16	our conference call on that, and we plan on
17	another probably full day Work Group meeting
18	or at least an in-person Work Group meeting
19	sometime before the May meeting, and hope to
20	be able to report back with some
21	recommendations to the Board by the May
22	meeting.

1	TBD-6000?
2	MEMBER ZIEMER: TBD-6000 Work
3	Group met in December, and our main focus at
4	that time was still on General Steel
5	Industries, although we have the TBD-6000 and
6	6001 matrices themselves to completely
7	resolve, as well as the now three newer sites
8	that we have basically not looked at yet. But
9	our prime focus is still on GSI.
10	There is a SEC Petition as well as
11	the main Appendix B, which serves as the Site
12	Profile.
13	After our meeting in December, at
14	which time [identifying information redacted]
15	had reported to us that he had identified the
16	source of information that would help
17	characterize the workplace much better, which
18	included the actual AEC/NRC licenses,
19	inspection reports, and some related
20	materials, and these now have been provided to
21	NIOSH, and we are awaiting their review of
22	these materials. Dave Allen has informed me

1	just	this	past	week	that	he	is	still	going
---	------	------	------	------	------	----	----	-------	-------

- 2 through those materials.
- 3 Then the other important piece of
- 4 information we are still awaiting is the
- 5 outcome of the search for Picker X-ray
- 6 records, which perhaps may be present in the
- 7 Landauer records repository, and NIOSH has
- 8 actually entered into a contract with Landauer
- 9 to search the Picker records, not only for GSI
- 10 information but for film badge records
- 11 possibly from other locations as well.
- In any event, we are hopeful that
- 13 those efforts will provide a better
- 14 characterization of the workplace for GSI, and
- 15 as soon as NIOSH has completed their
- 16 evaluation of those materials, the Work Group
- 17 will schedule its next meeting.
- 18 CHAIRMAN MELIUS: To put you on
- 19 the spot, Dr. Ziemer, we talked on, I believe,
- 20 our first day of these meetings, whether --
- 21 maybe it was yesterday -- whether we should
- 22 add another SEC Evaluation to your Work Group

1	or	whether	we	should	form	а	new	Work	Group
---	----	---------	----	--------	------	---	-----	------	-------

- 2 relative to that. I don't know if you have
- 3 had time to give it some thought.
- 4 MEMBER ZIEMER: I have tried not
- 5 to think about it too much. I suppose, in
- 6 fairness, we should at least pick it up
- 7 initially, because although if you feel like
- 8 you have some people who need more Work Group
- 9 activities -- a lot of this ends up being the
- 10 same people, but I don't have a good --
- 11 MEMBER GRIFFON: Is United Nuclear
- 12 then the one?
- 13 MEMBER ZIEMER: Yes, United
- 14 Nuclear. But it is fairly clear to me that
- our next meeting is probably going to have to
- 16 be a two-day meeting. We cannot do General
- 17 Steel Industries plus these others. So either
- 18 way, if we have a new Work Group, they will
- 19 have to meet. Some of this is the same
- 20 people, but in any event, if we don't have
- 21 people available to do that individually, I
- 22 guess we will add it to our workload, but --

1	MEMBER BEACH: What if we add
2	another alternate to that?
3	MEMBER ZIEMER: I think it would
4	be excellent to have at least
5	MEMBER CLAWSON: What are you
6	offering?
7	MEMBER ZIEMER: Lunch at the
8	Cincinnati Marriott. Perhaps at least one of
9	the new Members might want to participate in
10	that, but we can talk further, I suppose,
11	after we get the other reports.
12	CHAIRMAN MELIUS: Okay. Is there
13	some way it is just a thought. Is there
14	some way of having a sub-Work Group that would
15	just focus on a particular site that would
16	sort of ease some of the burden on you to keep
17	track of all this, and also at the same time
18	take into account what is going on and then be
19	able to understand it?
20	MEMBER ZIEMER: Like a Work Group
21	of the Work Group?
22	CHAIRMAN MELIUS: Yes.

1	MEMBER ZIEMER: Well, one of the
2	things that ties these together is they all
3	are subsets of TBD-6000 or 6001, as the case
4	may be. So the work of whatever group is
5	handling this still has to tie in with TBD-
6	6000, which as was indicated earlier, is a
7	type of surrogate data situation. But even in
8	that framework, places like General Steel
9	Industries, although it comes under that
10	category, still have their own dataset.
11	So we are not doing what you would
12	call surrogate data there, in any event, but I
13	see no reason why we couldn't have a separate
14	group, for example, for this new one, maybe
15	with some overlapping membership, and have the
16	Work Groups back to back, and maybe the folks
17	who aren't on both can sit in if they want to
18	on the other. That might be a way to do it.
19	CHAIRMAN MELIUS: Thank you.
20	Worker Outreach, which I believe is the last
21	one on our list. Mike Gibson, do you want to
22	give us an undate on Worker Outreach? T

1	believe	the	information	that	the	Work	Group
---	---------	-----	-------------	------	-----	------	-------

- 2 had compiled has been circulated to the Board
- 3 and has also been made available here at the
- 4 meeting. So, Mike, if you want to --
- 5 MEMBER GIBSON: Thank you, Dr.
- 6 Melius. When the Work Group was established,
- 7 you know, we were charged with looking at
- 8 worker outreach and how worker input was given
- 9 due diligence to the program, when
- 10 appropriate. This turned out to be a
- 11 complicated task.
- 12 There were many avenues to look
- 13 at. So it has taken us some time, but we
- 14 provided the Board with a mission statement on
- 15 a previous meeting, which was adopted, and we
- 16 also told the Board we would bring forth an
- implementation plan, which is before you now.
- By procedure, I don't know if this
- 19 needs to be adopted by a motion, but we did
- 20 want to present it to the Board, because it
- 21 potentially could have some impact on the
- 22 agencies, the Board and other Work Groups, and

1	we	just	wanted	to	make	sure	that	it	is
---	----	------	--------	----	------	------	------	----	----

- 2 comprehensive but it is not too burdensome on
- 3 the process.
- 4 So the presentation itself is kind
- of lengthy. So I just felt it was better to
- 6 send it out to the Board in advance, giving
- 7 them time to review it, and maybe we could
- 8 just have a short discussion on questions on
- 9 what the Board feels right now.
- 10 CHAIRMAN MELIUS: Okay. So for
- 11 the Board Members, there's two documents. One
- is a PDF of a PowerPoint presentation. That
- is on your memory sticks, and then there was
- 14 another document that was handed out that
- 15 supplements that. Ted, do you want to add?
- 16 MR. KATZ: Yes. The other handout
- 17 is the actual plan, which I think Mike's
- 18 presentation very closely follows. So you
- 19 don't necessarily have to read both, but some
- 20 of you may have read it already, because we
- 21 distributed it before a prior Board meeting.
- 22 David, just to let you know, I

	1	emailed	this	to	you,	if	you	want	to	see	the
--	---	---------	------	----	------	----	-----	------	----	-----	-----

- 2 actual plan, but again Mike's presentation, I
- 3 think, covers it pretty closely.
- 4 MS. ROBERTSON-DeMERS: This is
- 5 Kathy Robertson-DeMers. I think it is not the
- 6 actual implementation plan. I think that was
- 7 the options to be considered for the Board.
- 8 MR. KATZ: We are talking about
- 9 two different things, Kathy. That is coming
- 10 up next. We are just talking about the plan
- 11 for evaluating outreach right now.
- MS. ROBERTSON-DeMERS: Okay.
- MR. KATZ: Thanks.
- 14 CHAIRMAN MELIUS: So do people
- 15 have comments on that, or questions? Dr.
- 16 Ziemer?
- 17 MEMBER ZIEMER: Well, I certainly
- 18 want to compliment the Work Group on the
- 19 preparation of this plan, Mike. You and your
- 20 colleagues have really done a fine job in
- 21 scoping out the work.
- 22 I must say, it looks very

1	ambitious	to	me,	and	my	thought	was	that

- 2 probably you need to try some of this out and
- 3 then refine it later, if it needs refining.
- 4 But I think it has got a lot of items in it
- 5 which seem to be appropriate, if we can do
- 6 them, that would be helpful if we could do
- 7 them.
- 8 Again, I think it is very
- 9 ambitious, but you won't have a full grasp, I
- 10 don't think, of the extent of this effort --
- it looks extensive to me -- until you start to
- 12 try some of it. It is not always obvious if
- 13 you are asking fully the right questions, but
- 14 this is one of those areas, like many others,
- that we have had in the past where we have to
- 16 try things and then modify them or improve
- 17 them or get rid of them, as the case may be.
- 18 So that is my comment. I did have
- one question, which is on objective 4. This
- 20 is a question that you will probably put in
- 21 the same category as my typical dangling
- 22 participles, because another thing that always

1	dangles	is	the	use	of	et	cetera.

- I am pretty good at figuring out
- 3 what et cetera means when somebody says it is
- 4 1, 3, 7, 9, et cetera. I know that the next
- 5 thing is 11. But when they list a number of
- 6 things such as here, I have no idea what the
- 7 next thing is.
- 8 So what I am wondering is, did the
- 9 group have anything specific in mind or was
- 10 this just a place holder in case something
- 11 else emerged? What is the next thing on the
- 12 list represented by et cetera in objective 4?
- 13 MEMBER GIBSON: Dr. Ziemer, I
- 14 totally agree with you. This is a much bigger
- 15 task, we are finding out, than what we
- originally thought, and we do intend on trying
- 17 to take baby steps and maybe do one or two
- 18 things at a time, and just work through the
- 19 process and see how it works.
- 20 Et cetera is just that. It is a
- 21 place holder. We were just trying to be
- 22 comprehensive. If we left something out, we

just wanted to make sure we weren't limited t

- that. We weren't trying to necessarily expand
- 3 into other areas.
- 4 CHAIRMAN MELIUS: Okay. Thanks,
- 5 Mike. Any other Board comments on this?
- I have one comment, and I don't
- 7 know how much of this you could hear and
- 8 appreciate from over the telephone, but at the
- 9 beginning of our meeting Lew Wade outlined
- 10 NIOSH's plans for their own evaluation, and
- 11 that evaluation includes some evaluation of
- 12 worker outreach.
- I think it is fine to have -- I
- 14 think the Board should be doing what we are
- 15 doing through this Work Group. I don't think
- that is a problem, but certainly in terms of
- 17 what steps, where we start and so forth, it
- 18 would probably be better if we focusing on
- 19 different areas or at least complement what is
- 20 done, so we are not sort of duplicating --
- 21 they are not duplicating what the Work Group
- 22 is doing, and vice versa.

1	So some coordination on that would
2	be helpful, I think. If you talk to Lew, he
3	can fill you in on what is going on and be
4	able to work that out.
5	MEMBER GIBSON: Sure. We would be
6	glad to, Jim.
7	CHAIRMAN MELIUS: Good. Thanks.
8	But again, I compliment the Work Group on your
9	efforts here in developing this plan, and we
10	look forward to its implementation.
11	Are there more comments? Okay.
12	The other piece we have, which is
13	what has caused some of our confusion here
14	today is this discussion on tracking public
15	comments and issues to the Advisory Board,
16	which is a four-page document that is in front
17	of us.
18	As I understand it, this is from
19	the Work Group, and it is in response to some
20	comments that Dr. Ziemer made at the last
21	meeting. It outlines this is the one that
22	lists a number of different options and so

1	forth	for	doing	that.	I	don't	know	if	peopl	e
---	-------	-----	-------	-------	---	-------	------	----	-------	---

- 2 have input on that.
- Mike, do you have anything you
- 4 want to say?
- 5 MEMBER GIBSON: Well, basically --
- 6 and again, I know this is wordy. Dr. Ziemer
- 7 had made a comment in our New York meeting
- 8 about that the Work Group might consider
- 9 looking into public comments and how they are
- 10 tracked or responded to.
- 11 As we looked at that, we tried to
- 12 determine -- not only at public meetings, but
- 13 there are times at Work Group meetings that
- 14 the workers, the advocates might comment. So
- 15 we have tried to just -- basically, what I
- 16 think this breaks down to is we want to be
- 17 able to track comments, and we are trying to
- 18 find a way that at public meetings, either
- 19 Worker Outreach Work Group, SC&A, whoever we
- 20 designate, would track those comments, but we
- 21 are not necessarily involved in Work Group
- 22 meetings.

1	So that perhaps the Work Group
2	Chairs could track comments, and we need to
3	find a mechanism to maybe follow them back to
4	this Work Group when appropriate and just find
5	a way to determine whether they are site
6	specific, issue specific, whether they are
7	programmatic-wide, whether it is something
8	that is appropriate for a Work Group to
9	respond to or whether it is something that is
10	appropriate for the full Board to discuss
11	before the comment is responded to, is
12	basically what this is trying to say.
13	CHAIRMAN MELIUS: Okay. Any
14	questions?
15	MEMBER BEACH: No questions, but I
16	do have a comment. If you look at this
17	document and if you look at the scope, option
18	1, 2 and 3, basically lays out in very simple
19	language what each of those options are. If
20	you go into the body of the document, it just
21	that is where it gets a little wordy, but
22	it gives you how, how the scope is going to be

1	accomplished.
_	

- I guess we as a Work Group wanted
- 3 to give as many options as possible. During
- 4 NIOSH's presentation, they did talk about a
- 5 tracking system, and I believe they put -- it
- 6 is on our memory stick of how they are
- 7 tracking, and it is something we asked SC&A to
- 8 maybe look at tracking in that format also.
- 9 So something to look at.
- 10 MEMBER GRIFFON: I quess I am
- 11 struggling with to what end? What are we -- I
- 12 mean, is this task to begin tracking -- I
- 13 think I understand the different options,
- 14 although they may not be as clear as you think
- 15 they are to others. But is it a goal?
- I don't understand why the Work
- 17 Group would be setting up a tracking system?
- 18 Are you evaluating whether the current --
- 19 whether past comments have been tracked and
- 20 have been considered by NIOSH or are you
- 21 proposing to begin tracking? I guess I am not
- 22 exactly sure what the options are or to what

Τ	end. What are you trying to get at with this
2	proposal?
3	MEMBER GIBSON: Mark, I think what
4	we are trying to do is we want to review the
5	current policies and procedures on how the
6	meetings are conducted. We want to take a
7	limited slice in time back at the past to see
8	how that has worked, not go back to day one,
9	but then see how that is working and see if,
LO	in the future, that the current policies and
11	procedures and conduct of meetings serves our
12	purpose and gives due diligence to the
L3	questions and the responses and the input to
14	the program that the workers give.
15	MEMBER GRIFFON: I actually think
L6	that makes sense to me. You are talking about
L7	a sample retrospectively, and then if you find
18	some concerns or flaws, making recommendations
L9	going forward. Is that sort of
20	MEMBER GIBSON: Yes.
21	MEMBER GRIFFON: I am not sure I

see that in option 1, 2, 3 or 4, but I accept

22

1	that.	Т	think	that	is	not	а	bad	idea.
_	CIIC C •			CIICC	+ D	1100	o.	\mathbf{z}	± u c u •

- 2 CHAIRMAN MELIUS: I think it is in
- 3 there. It was just, there are other options,
- 4 and it was a little hard. Actually picked
- 5 that as option 1, as I understood it. Yes,
- 6 Kathy DeMers from SC&A.
- 7 MS. ROBERTSON-DeMERS: I just
- 8 wanted to kind of clarify. The goal was to
- 9 kind of be accountable for the comments that
- 10 the public was making and follow through on
- 11 those comments. What the Working Group tried
- 12 to present here was various options for
- 13 various portions of that process that you
- 14 should consider.
- They range from very minimal to
- 16 very detailed, and we are looking for guidance
- 17 from the full Board on how they want it done.
- 18 MR. KATZ: Maybe just recollecting
- 19 the Work Group meeting, I could shed some more
- 20 light on this.
- 21 OCAS already has sort of put in
- 22 place a program to sort of track that they are

	1	responding	to	comments	that	sort	of	they	find
--	---	------------	----	----------	------	------	----	------	------

- 2 are in their domain to respond to, whether it
- 3 is to refer on to DOL or because it is a dose
- 4 reconstruction issue with a particular dose
- 5 reconstruction or what have you. So they have
- 6 set up this tracking system to make sure they
- 7 are doing their job diligently when it is
- 8 their issue from a Board meeting.
- 9 So the Work Group liked that model
- 10 and wanted sort of accountability for the
- 11 Board's responses to issues that really belong
- in front of the Board.
- 13 So it wasn't so much to monitor
- 14 that OCAS is doing its piece correctly,
- 15 although that model is nice, and certainly
- 16 they want to look at that, at how OCAS is
- 17 doing with their responses, but also I think
- 18 the intent -- and, Mike, correct me if I am
- 19 wrong, but this is how I sort of understood it
- 20 all -- was to make sure that the Board itself
- 21 covered those issues that had been put before
- it, gave some response to the public.

4	actually been following through. Maybe that
5	is part of the
6	MR. KATZ: That is the evaluation,
7	that other stuff that you already dealt with.
8	Mike, so does that do you justice?
9	MEMBER GIBSON: We wanted to make
10	sure the Board fulfills what we believe its
11	responsibility is to the workers, but I think
12	part of our task is also to monitor NIOSH. We
13	don't want to make this a burdensome task that
14	pulls down the Board, the Work Groups and OCAS
15	and everything else, but I do think we have a
16	responsibility to monitor OCAS, how they
17	collect the comments and how they respond to
18	them, too.
19	CHAIRMAN MELIUS: Go ahead, Dr.
20	Ziemer.
21	MEMBER ZIEMER: I just wanted to
22	comment that, actually, when I brought this
	NEAL D. CDOSS

MEMBER GRIFFON: I guess I totally

misinterpreted it. I thought it was to look

at NIOSH's past activities and see if they had

1

2

3

1	issue to the Board last time, I wasn't fully
2	aware that NIOSH was formally tracking any of
3	this, but it had seemed to me important to
4	recognize that there are reoccurring themes
5	that come to this Board from public comment.
6	Now we often hear individual cases
7	or information and stories about individual
8	experiences that are very individual specific,
9	and those are handled by staff people, claims
LO	people, and so on. But I am talking about the
11	other kinds of things that we hear that have
L2	to do with people's experiences with the CATI,
L3	as an example.
L4	We actually in the past have
15	followed up on many of those things, but the
L6	concern was that there could be issues that
L7	fall through the cracks. We get so many
L8	comments, and superimpose that on all the
L9	things we cover in the Board meeting, and it
20	is very easy to forget some of those things.

said, yes, we are going to keep track of this

The idea was, if we formalize and

21

22

1	information,	and	if	we	can	categorize	it	
---	--------------	-----	----	----	-----	------------	----	--

- they have given some examples. Well, I guess
- 3 NIOSH gave examples of how they would do it --
- 4 but categorize them, and then determine
- 5 whether or not some follow-up or action should
- 6 be taken.
- 7 Now there are many that are Work
- 8 Group specific. For example, in General Steel
- 9 Industries, I have a whole lot of comments
- 10 that have come out from the petitioners, and I
- 11 feel that is something the Work Group has to
- 12 track in the sense that we are responsible not
- 13 necessarily to have a matrix, but at least to
- 14 track what the issues are for the petitioner,
- and we do that, but we have a lot of people
- that call in, and we have had some that aren't
- 17 necessarily petitioners, but they have some
- 18 concern about something in the program. That
- 19 was kind of genesis in my mind.
- 20 As was indicated, some of these
- 21 are issues as to -- they are Board related
- 22 issues. Now none of our Board related issues

1	are	really	separate	from	NIOSH.	We	don '	't
---	-----	--------	----------	------	--------	----	-------	----

- 2 operate in a vacuum. So there is a lot of
- 3 overlapping things, and we need to recognize
- 4 that. From my point of view, if NIOSH tracks
- 5 it all, that's great, as long as somebody is
- 6 tracking it.
- 7 CHAIRMAN MELIUS: This may help or
- 8 it may confuse, but I know I have seen this
- 9 someplace. But if you go to our memory
- 10 sticks, under the NIOSH program update, the
- 11 folder, there are -- I believe this is the
- 12 list of the issues that they are tracking, the
- 13 comments they are tracking from, I think, the
- 14 last two Board meetings, under that.
- I guess what I am a little
- 16 confused on is what are the criteria for what
- 17 they track versus what they are not tracking,
- 18 and what was -- maybe, Stu, you can address
- 19 that, because I think that -- then I think, if
- 20 I understand it right, then what the Outreach
- 21 Work Group is doing is proposing setting up a
- 22 tracking and follow-up of issues that NIOSH

	1	isn't	tracking,	because	they	are	Board	issues.
--	---	-------	-----------	---------	------	-----	-------	---------

- 2 So the Board needs a way of
- 3 keeping track of that and assuring that those
- 4 are being followed up. Stu?
- 5 MR. HINNEFELD: Well, I want to
- 6 offer a little information, just so everybody
- 7 knows this isn't a historical practice that we
- 8 have been doing all along. It was discussed
- 9 at the October Board meeting, as I recall, as
- 10 it would be desirable that we keep track of
- 11 these comments that are made in public comment
- 12 in some fashion.
- 13 Following that meeting then, we
- 14 embarked -- you know, we took the action to do
- 15 that, and we did it just for the previous
- 16 meeting, because those transcripts were
- 17 available. We started right after the October
- 18 meeting. The transcripts for the July meeting
- 19 were available, and we reviewed those
- 20 transcripts to record the comments.
- 21 We had our Worker Outreach
- 22 contractor do this task. I believe our

	1	instruction	to	them	was	to	record	the	comments
--	---	-------------	----	------	-----	----	--------	-----	----------

- 2 that were a response -- that were essentially
- 3 respondable to.
- 4 You know, there are a number of
- 5 public comments, there is really nothing to
- 6 respond to. People recount their history and
- 7 the difficulties they have encountered in the
- 8 history, but there is not really a lot to
- 9 respond to those. I believe we asked our
- 10 contractor to record the comments that it was
- 11 possible to respond to.
- 12 This was sort of a pilot thing,
- 13 just to get started. We have not finalized
- 14 anything. We have not written -- I believe we
- 15 just gave the contractor verbal instructions
- 16 from their contract's technical monitor.
- 17 So there is nothing really
- 18 formalized about what we had proposed to do.
- 19 I think we can, in fact, provide responses for
- 20 things that reflect our activities, to the
- 21 extent we can.
- I don't want to be presumptuous in

_	, ·					7.0	
1	makina	an	assignment	ATTAN	$\pm \circ$	myza l t	thouah
_	manting	an	abbiginicht	$C \lor CII$		III Y D C T T ,	CIIOUGII

- 2 for these comments that we would really
- 3 consider essentially in the domain of the
- 4 Board, since these are public comments made to
- 5 the Board. By doing it, by going ahead and
- 6 writing some responses, it provides some
- 7 timeliness that wouldn't be there if it were
- 8 sort of a Board deliberated thing, because we
- 9 could -- once we had compiled them, we could
- 10 assign and start working on it.
- 11 This is embryonic here. We just
- 12 started this, and we have not really done much
- of anything on how to proceed yet.
- 14 CHAIRMAN MELIUS: I would just add
- 15 to that that there are also, I can imagine,
- 16 comments that need to be followed up by both
- 17 NIOSH and the Board. If someone reports on
- 18 some particular circumstance or something
- 19 about a particular site, obviously, NIOSH is
- 20 going to be -- it is relevant to NIOSH's work
- 21 on that site. It is also relevant to the
- 22 Board and SC&A's review of that site. So it

1	ought	to	be	tracked	bу	both,	and	I	think	at
---	-------	----	----	---------	----	-------	-----	---	-------	----

- least communicated to both, obviously. So,
- 3 therefore, a tracking system for either is
- 4 appropriate. Josie?
- 5 MEMBER BEACH: I would like to
- 6 propose -- this was actually brought up at the
- 7 last Board meeting for our Work Group to bring
- 8 these recommendations to the Board so that the
- 9 Board could decide how they wanted to track
- 10 public comment.
- 11 So that is what we did here. What
- 12 I would like to recommend, if Mike is in
- 13 agreement and the Work Group, is -- I know
- 14 SC&A took comments during all the public
- 15 meetings, this meeting -- if we could get
- 16 together as a Work Group and put those into a
- 17 tracking system and present it to the Board at
- 18 the May meeting to give you an idea of how it
- 19 would look from the Work Group, if that would
- 20 be --
- 21 CHAIRMAN MELIUS: I think that
- 22 would be fine, and also some coordination with

1 NIOSH on that. So if we are going to	ao t	tnis,
--	------	-------

- 2 let's make sure we have some coordination and
- 3 understand what each party is doing.
- I would add, if my memory is
- 5 correct, that once upon a time a long time
- 6 ago, ORAU was tasked to do this also, and
- 7 somehow that got stopped. So we are starting
- 8 again.
- 9 MEMBER GIBSON: Jim, again this is
- 10 -- as we started out this discussion, these
- 11 are just our first baby steps. We may be a
- 12 little overarching right now, but just, let's
- 13 take a little time and see how it works, and
- 14 we can always modify what we are doing. We
- 15 just want to make sure that, again, worker
- 16 comments are given due diligence, and their
- input is looked at in the program in the right
- 18 perspective when appropriate.
- 19 CHAIRMAN MELIUS: I think we
- 20 understand. I think it is helpful to have
- 21 sort of a big framework for it, which is what
- 22 you have done. So it is broad. I think, at

1	the	same	time,	the	implementation	is
---	-----	------	-------	-----	----------------	----

- 2 implemented in steps, and that is what you are
- 3 proposing. I think that is helpful.
- 4 Kathy, did you want to say
- 5 something?
- 6 MS. ROBERTSON-DeMERS: I just
- 7 wanted to say something that might clarify
- 8 something. We gave you a presentation on the
- 9 implementation plan, and then you have a copy
- of the full implementation plan that we talked
- 11 about earlier.
- 12 That implementation plan is for
- 13 evaluating NIOSH worker outreach activities.
- 14 The options that are presented for data-
- 15 tracking are for Board comments that are
- 16 received.
- 17 CHAIRMAN MELIUS: We understand
- 18 that, but I think that on the worker outreach
- 19 part, I think, now that we understand this
- 20 better, all of us, that we need to read this
- 21 over. I would like to put this -- a report
- 22 from this Work Group in an update, and maybe

-			- 1		- · ·			
1	$\triangle IMI$	can	reach	acme	decisions,	$\alpha 1 770$	acme	20111 CE
	W C	Can	T Cacii			910	שווט	$aav \pm cc$

- 2 to the Work Group at our next Board call,
- 3 which would be at the end of March.
- 4 Meanwhile, I think we should go ahead with
- 5 what Mike proposed on the public comment
- 6 follow-up. Is that satisfactory with
- 7 everybody? Okay.
- 8 Thank the Work Group for their
- 9 work on this.
- 10 You have an item here: managing
- 11 conflicts on tasking and TBDs and PERs.
- MR. KATZ: I do have that, and I
- 13 can go into that, although it is not pressing
- 14 right now, and I am just worried about your
- 15 time.
- 16 CHAIRMAN MELIUS: I am worried
- 17 also.
- 18 MR. KATZ: I could address that at
- 19 the teleconference.
- 20 CHAIRMAN MELIUS: Okay. That
- 21 would be fine.
- I think let's do additional --

1	well,	let	me	ask	the	Board,	would	people	like
---	-------	-----	----	-----	-----	--------	-------	--------	------

- 2 to take a 15 minute break?
- 3 (A chorus of yes.)
- 4 CHAIRMAN MELIUS: Yes. We will
- 5 take a 15-minute break.
- 6 (Whereupon, the above-entitled
- 7 matter went off the record at 3:15 p.m. and
- 8 resumed at 3:33 p.m.)
- 9 CHAIRMAN MELIUS: Okay, Ted, you
- 10 want to check the lines?
- 11 MR. KATZ: Yes. Dr. Richardson
- 12 and Mr. Gibson, are you with us?
- 13 MEMBER GIBSON: Yes, I am here,
- 14 Ted.
- 15 MR. KATZ: David?
- 16 (No response.)
- 17 CHAIRMAN MELIUS: It is very late
- 18 there. We have five items left. We have SC&A
- 19 tasking to do and some issues relative to
- 20 that. Following that, we have some Work Group
- 21 --
- 22 MEMBER RICHARDSON: Just for the

1 red	ord, I	am	here.	I'm	sorry.	couldn't	get
-------	--------	----	-------	-----	--------	----------	-----

- 2 the mute off.
- 3 CHAIRMAN MELIUS: Okay. Both you
- 4 and Mike have been very good. We understand
- 5 it is not easy.
- 6 Work Group assignments,
- 7 volunteering, and then we have the letters to
- 8 approve. We have some letters, correspondence
- 9 kinds of issues to respond to. Finally, we
- 10 have to do some meeting scheduling.
- 11 So we will start with SC&A. So,
- 12 John, if you want to come to the microphone
- and sort of give us an update. John, I think,
- 14 provided to us -- I don't believe it was on
- 15 the memory sticks, but it was through an
- 16 email, a document that was his sort of status
- 17 report, I quess you would call it, material
- 18 for consideration by the Board at the meeting.
- 19 DR. MAURO: I sent out two
- 20 packages, not expecting it to be anything
- 21 formal but just for the information of the
- 22 Board and, certainly, the new Members of the

1 Board.

2	Two packages went out. One is a
3	complete listing of everything that we have
4	done or are actively doing on this contract
5	since 2003. Basically, so it is almost a
6	laundry list. In that same package, the items
7	that are still active where we have been
8	tasked and we are doing things, and we are
9	billing time, I put down an estimate of what I
10	believe it is going to cost to finish up the
11	work that we have been tasked to date, so that
12	everyone has a sense of the amount of
13	resources that have effectively been committed
14	and how much is basically available to the
15	Board.
16	So it sort of sets the stage of,
17	okay, here is the work that is ongoing, this
18	is what was completed and done, and here is
19	the work that currently is ongoing and it will
20	require this much resources to finish, which
21	effectively puts you in a good position to
22	judge, to know, okay, we have this much

1 re	esources	available	to	us	to	task	SC&A	as	we
------	----------	-----------	----	----	----	------	------	----	----

- 2 see fit.
- 3 The other package is a listing of
- 4 all of the Site Profiles, PERs, that we have
- 5 not yet reviewed. In effect, it is a menu,
- 6 and what they cost. If you want us to review
- 7 this one, it will be this much.
- 8 So in effect, I am trying to put
- 9 you in a position to help judge where you
- 10 would like us to be tasked.
- Now it does not include anything
- 12 related to SECs. The SEC issues emerge from
- 13 these meetings. So in effect, what this is,
- is a listing of, basically, Site Profiles that
- 15 you may or may not want to task us with and
- 16 how much they would cost.
- 17 So, basically, I am trying to put
- in front of you the information you might need
- 19 to task us, which is over and above any
- 20 tasking that might emerge as a result of the
- 21 SEC discussions.
- 22 I quess that is it. Now we could

1 go through it. I could put it up on	tne
---------------------------------------	-----

- 2 screen or -- I don't know really where to go
- 3 from here.
- 4 CHAIRMAN MELIUS: I think we would
- 5 like to not go through it in great detail. We
- 6 have had it, but I think we need to have
- 7 enough understanding to be able to make
- 8 assignments.
- 9 We traditionally make assignments
- 10 sort of incrementally from meeting to meeting,
- 11 because the information changes and so forth,
- and it changed over this particular meeting.
- I would also add that there are
- 14 things that -- there are also changes that
- 15 SC&A has been assigned to do Site Profile
- 16 reviews, but there are some Site Profiles that
- 17 there are not Work Groups formed for yet.
- DR. MAURO: That is true.
- 19 CHAIRMAN MELIUS: And once we form
- the Work Group, then there's costs associated
- 21 with the SC&A contract for the resolution
- 22 process.

1	DR. MAURO: You make a very
2	important point. In the table where I list
3	the things that have been completed and how
4	much resources to that well, have not been
5	used, there are many Site Profile reviews that
6	we have completed over the last five years
7	that have no Work Group, and in the table I
8	put zero dollars there, because we have not
9	yet been tasked. There is no Work Group, and
10	we have not been tasked to do anything with
11	that Work Group.
12	So I am not assuming there will be
13	money, because we may never get to that. So
14	the dollars that are in there that I am saying
15	are sort of committed, these are really
16	committed. They are not anticipating that
17	maybe someday a Work Group will form to look
18	at Weldon Spring or to look at X-10 or K-25.
19	These are all Site Profiles that we have
20	completed, but there really is no active Work
21	Group. So I did not put any dollars in.
22	If I did that, if I were to assume

1	that	there	would	be	а	Work	Group	opened	on
---	------	-------	-------	----	---	------	-------	--------	----

- 2 every single one of these that are Site
- 3 Profiles that we have already performed, I
- 4 would say that we would probably be very close
- 5 to have already have committed all the dollars
- 6 available to SC&A.
- 7 CHAIRMAN MELIUS: So, John, do you
- 8 want to -- I don't know if you have slides
- 9 ready or what, just as a way of putting these
- 10 up in front of people. I am not sure that
- 11 everybody has them in front of them.
- 12 DR. MAURO: We have a stick here
- 13 with that on it. I am trying to track it
- 14 down.
- MR. KATZ: While John is getting
- 16 ready, let me just check on the line. Chris
- 17 Cox, are you on this line, by any chance? Oh,
- 18 okay, no need. I am just getting a signal
- 19 from the audience. Thank you.
- 20 CHAIRMAN MELIUS: While they are
- 21 working on that, I will address two other --
- 22 bring up two other things that I think we have

1	identified	in	terms	of	Work	Groups.
_	Taciicii			-	MOT 12	OF Capp.

- One is Lawrence Berkeley where we
- 3 did approve an SEC. We have a Site Profile
- 4 review that, I believe, is undergoing
- 5 classification review but should be -- if my
- 6 memory is right, it should be back shortly,
- 7 and the question is do we want to try to form
- 8 a Work Group to go through that Site Profile
- 9 and resolve that. So I think that is one we
- 10 need to assign.
- 11 The second one is United Nuclear,
- 12 which would be sort of the subgroup that --
- 13 what we are calling that sub-Working Group --
- 14 would coordinate with Paul's committee.
- 15 MEMBER ZIEMER: One possible
- 16 suggestion that came up, actually, during the
- 17 break was that it might be worth thinking
- about splitting the TBD thing and do TBD-6000
- 19 and its facilities, the Appendices, and TBD-
- 20 6001.
- 21 So the suggestion would be, for
- 22 example, to take the current Work Group and

1	make	it	the	TBD-6000	Work	Group,	and	it	wou.

- 2 continue to have General Steel Industries, and
- 3 then to appoint a new Work Group for TBD-6001
- 4 and the Appendices that come under it.
- 5 A further suggestion would be to
- 6 take some of the -- have some overlap in
- 7 membership, so that there is some continuity,
- 8 so maybe a couple of Members, perhaps, and
- 9 certainly include a couple of the new people.
- 10 That would be the suggestion.
- Was United a 6000?
- 12 MEMBER MUNN: It is 6000.
- 13 MEMBER ZIEMER: 6001. So that
- 14 would fall under the new Work Group.
- 15 MEMBER MUNN: It is?
- DR. NETON: TBD-6001 is uranium
- 17 production type facilities, and I believe that
- 18 would be United Nuclear. TBD-6000 is uranium
- 19 metalwork type operations.
- 20 CHAIRMAN MELIUS: I think the
- 21 general consensus is that that is a good idea.
- 22 So that would be the second Work Group that

- 1 we need to form.
- 2 MEMBER ZIEMER: Right, and I would
- 3 point out Electro Metallurgical is also a
- 4 6001. That is Appendix C, I believe, of 6001.
- 5 I don't know if LaVon can confirm that.
- 6 DR. NETON: I believe that
- 7 Electro-Met -- I believe that is a 6001,
- 8 because that was a uranium recovery.
- 9 MEMBER ZIEMER: Right. I have it
- down as Appendix C of 6001.
- DR. NETON: Okay. Yes, I think
- 12 that is correct.
- 13 MEMBER ZIEMER: So Electro
- 14 Metallurgical would also join that, whereas
- 15 Bliss & Laughlin, I believe, is a 6000.
- 16 CHAIRMAN MELIUS: John, while we
- 17 have you up there, before we start this, off
- 18 the top of your head, are there other finished
- 19 Site Profiles where you have not had Work
- 20 Groups assigned yet? There are a number.
- DR. MAURO: Oh, yes. They are in
- 22 the -- one of the packages I gave you lists

1 all	the	Site	Profiles	that	we	have	done.	The
-------	-----	------	----------	------	----	------	-------	-----

- ones in bold in the copy that you have -- the
- 3 ones in bold are the Site Profile reviews that
- 4 have been completed, but there is no Work
- 5 Group. Is it apparent on your copies?
- 6 CHAIRMAN MELIUS: I am trying to
- 7 see if I have the right copy here or if it is
- 8 on the other. Well, rather than hold up, why
- 9 don't I ask. I am going to ask for volunteers
- 10 first for the new 6001 Work Group, an idea of
- 11 who would be interested in serving on that.
- 12 MEMBER GRIFFON: I would offer to
- be an overlapping member of that.
- 14 MR. KATZ: So, Mark, you said yes?
- 15 MEMBER ANDERSON: As long as there
- is somebody else who is overlapping. I don't
- 17 want to be lead on anything.
- 18 MEMBER ZIEMER: Well, I will
- 19 overlap, too, if we need another overlap.
- 20 MEMBER ANDERSON: I would be happy
- 21 to do that.
- 22 CHAIRMAN MELIUS: I think, at this

1	point	we	are	not	going	to	assign	any	of	the	
---	-------	----	-----	-----	-------	----	--------	-----	----	-----	--

- 2 we are not going to make new Members of the
- 3 Board as Work Group Chairs yet, and we will
- 4 take into account overlapping, try to get who
- 5 is willing, so to speak, on that.
- 6 MEMBER ANDERSON: The 6000 group?
- 7 CHAIRMAN MELIUS: This would be
- 8 the new 6001 group. It would overlap. So I
- 9 have got that filled.
- 10 MR. KATZ: Okay, that is four.
- 11 CHAIRMAN MELIUS: And Mark.
- 12 MR. KATZ: Who would Chair?
- 13 CHAIRMAN MELIUS: We will see
- 14 where we are with that and so forth. Then for
- 15 Lawrence Berkeley.
- 16 MEMBER ANDERSON: Do you meet at
- 17 Berkeley? I'll take that.
- 18 CHAIRMAN MELIUS: Wanda? David or
- 19 Mike, if you are still on the phone, are you
- 20 interested?
- 21 MEMBER GIBSON: Jim, this is Mike.
- 22 If you need someone for one of the Work

1 Groups, I will volunte	eer.
--------------------------	------

- 2 CHAIRMAN MELIUS: Okay. What I
- 3 will do is also follow up with Jim Lockey, and
- 4 then I will figure this out later, and then do
- 5 the assignments.
- DR. NETON: There are three people
- 7 on that one?
- 8 CHAIRMAN MELIUS: We may just do
- 9 three or something. John?
- DR. MAURO: We ready? Thank you.
- I wasn't expecting to go through this. So I
- won't take up too much of your time.
- I put up -- you folks have all
- 14 received this email report dated February 6th.
- I know you receive a lot of material, but I
- 16 sent this, basically, I thought it would be
- 17 helpful, given that we have been -- our budget
- is fully approved for this year as of January
- 19 1st, and it turns out that that budget is
- 20 always about \$3.4 million, \$3.5 million.
- 21 So what we are looking at is the
- 22 big picture right now. Stay with me, and I

1	will	aet	this	under	control.	There	it	is.

- 2 Okay.
- 3 As of January 1st -- and you can
- 4 think of it as the project manager for SC&A --
- 5 we have \$3.4 million available to us or
- 6 available to the full Board to task us. Now
- 7 it is important to recognize that, as of this
- 8 date, we have a lot of work that we are still
- 9 working on.
- 10 We have work that was tasked last
- 11 year. There is a lot of -- there are Work
- 12 Groups active. So what, in effect, the second
- line says is, well, we have work in progress
- 14 right now that we are already involved in, and
- 15 we have work products that we owe you. As of
- 16 today, that is \$1.3 million as of today. So
- 17 we already have a backlog where we have
- 18 deliverables that I estimate will cost \$1.3
- 19 million.
- Now the third line says, I
- 21 anticipate that this upcoming year we are
- 22 going to require -- SC&A will require, sort of

1	like	effectively	committed,	\$360,000	to
---	------	-------------	------------	-----------	----

- 2 support program management. What program
- 3 management is, SC&A -- whenever we come to
- 4 these meetings, that is part of program
- 5 management, and it is basically my time. So
- 6 it is supporting meetings, but that is
- 7 effectively committed. So that is really not
- 8 available, so to speak.
- 9 The next is: we also expect that
- 10 you will be assigning us this year 60 new DR
- 11 reviews. That has sort of been a staple. So
- 12 I am making the assumption that during the
- 13 course of this year we will be asked to
- 14 perform 60 new dose reconstructions. It is a
- 15 presumption.
- 16 On that basis, as of today we have
- 17 committed -- we are effectively committed to
- 18 \$2.3 million out of the \$3.5 million. So the
- 19 Board has what I would call discretionary
- 20 funds of \$1.15 million available to it to task
- 21 us. So that is sort of where we are right
- 22 now.

Τ	so, in theory, you could task us
2	to do today to do some work, and the
3	purpose of that is to set the stage to say,
4	okay, that is the resources available to the
5	Board to task SC&A.
6	Now you folks probably have a
7	sense regarding the degree to which there is
8	any new SEC work that you think might be
9	needed that you might want us to task us. I
LO	am not addressing those here. I am just
11	simply what I am doing now is saying in the
12	past historically, the places beside Dose
13	Reconstruction Reviews, which seem to be very
L4	consistent year after year after year, we
15	do 60 a year. That is why I have put them in.
L6	I am just assuming you are going to want us
L7	to do that.
L8	So that money is effectively
L9	committed. But tasking us to do Site Profile
20	Reviews is sort of like I call it a
21	judgment that you make from time to time,
22	whether you would like us to do any Site

_		
7	Drotila	Reviews.
	ETOTITE	I/C A T C M P .

- What you are looking at here is a
- 3 list of all of the Site Profiles that are out
- 4 there that we have not reviewed, SC&A has not
- 5 reviewed. There may be some of them now, in
- 6 light of where the developments are, that
- 7 might be of interest that you might want us to
- 8 task, and I have put down the price. It is a
- 9 menu.
- 10 So a judgment could be made.
- 11 Effectively, you have \$1.5 million available
- 12 to you. For example, if you wanted us to do
- 13 all the Site Profile Reviews that are out
- 14 there right now, I totaled it all up. It
- 15 would require almost half the budget we
- 16 currently have left.
- By the way, these are relatively
- 18 inexpensive. Your experience in the past is
- 19 that they were a lot more expensive, because
- 20 we were doing the big ones: Hanford, Savannah
- 21 River. What is left are what I consider to be
- 22 relatively small ones.

1	So that	is why	these a	re
2 relative	ely inexpensive	e, but I w	ould like	to
3 put you	in a positio	n and t	hat is why	I
4 presente	ed this to you	that, if	you elect	to
5 task us	to do any Sit	ce Profile	Reviews, he	re
6 is how	much they will	cost, and	you will s	ee
7 what it	does to the bu	dget.		
8	You may no	t want to d	do that. Y	ou
9 may wan	it to save th	e resources	s to do SE	C-
10 related	work. Beside	es Site Pro	file Review	s,
11 there a	lso are some p	rocedures t	hat you mig	ht
12 want rev	viewed. There	aren't very	many left.	
13	We have ba	sically rev	viewed all	of
14 them.	We have review	ed about 13	0 procedure	s,
15 and we	e are well	along in	the issu	es
16 resoluti	ion, but there	are a few	remaining.	I
17 listed t	those and their	price.		
18	Finally, P	ERs: this	is somethi	ng
19 that is	s emerging.	To date,	we have on	ly
20 performe	ed three PER re	eviews. We	did Blocks	on
21 PER, t	thoracic lymp	homa, and	l high-fir	ed
22 plutoniu	um, and we have	e delivered	those repor	ts

1 to you.

2	These are a list of all of the
3	PERs that are out there, and the number of
4	cases that they affect. In other words, you
5	may decide that, yes the way I am starting
6	to look at it is there really aren't very many
7	procedures, but maybe there are some PERs that
8	you might be interested in having reviewed.
9	These are all the PERs, and the
10	number of cases that might be are impacted
11	that were reevaluated. In other words, every
12	one of these PERs resulted in a reevaluation
13	of the cases. So the second column tells you
14	how many cases were reevaluated. That will
15	help you make a judgment which ones might be
16	important to look at, and I have put down the

price that we estimate it would cost to do it.

So in effect, this is a listing of here's the resources that are available to the Board, and here are all of the different kinds of things you might want SC&A to do or not do, bearing in mind that I think your greatest

1	interest	has	been,	and	probably	continues	to
---	----------	-----	-------	-----	----------	-----------	----

- 2 be, SEC-related activities.
- 3 So I guess I will leave it at that
- 4 point. That is, you can make a judgment on
- 5 some SECs, and I am going to try to keep you
- 6 apprised of where we stand, because if we
- 7 start to open up, let's say, a lot more Work
- 8 Groups to look at many of the old Site
- 9 Profiles we reviewed, the burn rate will start
- 10 to increase, and I could see a situation
- 11 arising where SC&A will run out of money
- 12 before the end of the year.
- We have been very fortunate, I
- 14 have to say, over the last six years that the
- 15 way in which the work has unfolded is we have
- 16 been in budget. We have never been in a
- 17 situation where we ran out of money by the end
- 18 of the year.
- 19 Given that we have new Board
- 20 Members, given that there may be more Work
- 21 Groups, more Site Profiles that are going to
- go through issues resolution, the burn rate of

1 SC&A may	increase.	I	will	keep	you	apprised
------------	-----------	---	------	------	-----	----------

- on a routine basis of when I think we might be
- 3 in trouble. I think that is what I was hoping
- 4 to explain.
- 5 CHAIRMAN MELIUS: Thank you.
- 6 Don't leave there. Can you go back to the
- 7 Site Profile page?
- 8 As I said earlier, what we have
- 9 traditionally done is we've tried to do this
- 10 incrementally, recognizing that, again, we
- 11 don't want to have an important SEC evaluation
- 12 that we can't address. At the same time, we
- don't want to let things -- we don't want to
- 14 end up with essentially a lot of money left in
- 15 the contract, unused resources, and find that
- 16 we haven't dealt with issues, and they stay
- 17 around for too long.
- 18 I think what we have tried to do
- 19 in terms of prioritizing the Site Profiles and
- 20 so forth is basically a sense of what the
- 21 number of cases there, so how important are
- 22 they for that? I think that, given these

1	costs,	we	can	make	some	assignments	on,	again
_	,						,	

- off the top of my head, four or five of these
- 3 Site Profiles to do.
- 4 Ted, do you want to comment on
- 5 that?
- 6 MR. KATZ: No. Before we actually
- 7 get into the dialogue about which, I would
- 8 like to discuss what I was planning to discuss
- 9 about tasking in this sort of situation.
- 10 CHAIRMAN MELIUS: Okay.
- MR. KATZ: Is this the time to do
- 12 that?
- 13 CHAIRMAN MELIUS: That is the time
- 14 to do it, before it is too late.
- 15 MR. KATZ: Okay. Thank you. So
- 16 this came up with the PER tasking the last
- 17 Board meeting, and I have gotten some
- 18 guidance. I want to make it clear, this
- 19 guidance is interim guidance, because the
- 20 source of this guidance needs to consult with
- 21 others who are expert for this sort of
- 22 situation.

1	The guidance for now, when we have
2	a situation like this with PERs or Site
3	Profiles where there are multiple sites, and
4	it is really not practical for Board Members
5	to leave because they might be conflicted with
6	one site; but if you have a whole bundle of
7	sites that we will be discussing all at once,
8	the practice would be, when the discussion
9	comes around to a site that you are conflicted
10	at, for you to just state for the record that
11	you are recused from the discussion, to put
12	that on the record at that point that it comes
13	up, and then, of course, not engage in that
14	discussion at all.
15	Then if it is decided by the rest
16	that that is a site for which we want to task,
17	then there needs to be an individual we
18	need to do a roll-call type vote as opposed to
19	in the past, I think we have often just
20	sort of done a general consensus, a verbal
21	tally that everybody agrees, but in this case,
22	we actually need to make it clear on the

1 record that the person with the conflic	t did
---	-------

- 2 not vote in favor of that tasking for that
- 3 site.
- 4 MEMBER GRIFFON: What do we do for
- 5 like high-fired -- and this came up before
- 6 with high-fired plutonium PER where we would
- 7 not retain -- I am not sure we would retain a
- 8 quorum? Maybe we will, but I think a lot of
- 9 people would have to -- could be conflicted on
- 10 that one because it affects so many sites.
- 11 MR. KATZ: And that particular,
- 12 for example, one -- and there are not that
- many that, I think, fall in that bucket, but I
- 14 would suggest we don't deal with that right
- 15 now.
- 16 MEMBER MUNN: Ted is our man.
- 17 CHAIRMAN MELIUS: It would cut
- down on the number of Board comments, though.
- 19 That is for sure. Actually, John Poston had
- 20 a question or a comment.
- 21 MEMBER POSTON: We may be asking
- 22 the same question. John, I noticed on the

1 t	ınreviewed	projected	cost	for	the	Site
-----	------------	-----------	------	-----	-----	------

- 2 Profiles that West Valley is on there twice.
- 3 DR. MAURO: Is it?
- 4 MEMBER POSTON: Yes.
- 5 CHAIRMAN MELIUS: At least, the
- 6 cost didn't change.
- 7 MEMBER POSTON: That is the
- 8 question. Should we reduce the cost by
- 9 60,000?
- DR. MAURO: That is it exactly. I
- 11 am sorry about that.
- 12 CHAIRMAN MELIUS: Wanda?
- 13 MEMBER MUNN: In looking at those
- 14 Site Profiles, Canoga and De Soto jump out at
- me because of the discussion that we had about
- 16 them during this very meeting. It may be only
- 17 my sense, but it seems that it is going to be
- 18 very difficult for us to segregate the Canoga
- 19 and De Soto sites from the other Santa Susana
- 20 activities. They appear to be so intertwined.
- 21 It would appear logically to me
- 22 that that particular pair of Site Profiles

	1	would	be	amongst	those	that	we	would	choos
--	---	-------	----	---------	-------	------	----	-------	-------

- With respect to the PERs, if there
- 3 is nothing --
- 4 CHAIRMAN MELIUS: Maybe, can we do
- 5 it maybe Site Profiles, then procedures, then
- 6 PERs?
- 7 MEMBER MUNN: I wasn't even going
- 8 to address individual PERs.
- 9 CHAIRMAN MELIUS: Okay, then.
- 10 MEMBER MUNN: What I was going to
- 11 suggest is that, because we have had such a
- lengthy discussion about it in Procedures, we
- 13 have just about beaten this to death, but we
- 14 have not yet worked out the final thinking
- 15 with respect to how we really should address
- 16 the business of who has what responsibility
- 17 for reviewing the PERs and how we were going
- 18 to do it.
- 19 We intend to do that at our March
- 20 meeting, and if we can, in fact, bring that
- 21 information to the Board so that you can have
- the Subcommittee's recommendation on how to

1	deal	with	PERs,	then	that	might	give	us	а
---	------	------	-------	------	------	-------	------	----	---

- 2 better handle on how to go forward choosing
- 3 our group.
- 4 CHAIRMAN MELIUS: Excellent.
- 5 Good. Then that would be something we could
- 6 take up on our March 31st phone call.
- 7 MEMBER MUNN: Correct.
- B DR. MAURO: May I say something
- 9 regarding the PERs? We have delivered three
- 10 PER reports, but they are not complete. The
- 11 last part of them is the review of selected
- 12 cases. So that is one of the places where,
- once a judgment is made on the responsibility,
- one of the first things that will need to be
- 15 done would be identification of cases that
- should be reviewed to see the degree to which,
- in fact, the PERs were implemented.
- 18 So that is something that is not
- 19 on this chart, but that remains to be done.
- 20 One of the things I had mentioned is, we could
- 21 identify some that we think might be useful to
- 22 test or we just could wait until the Board

1	points	out	which	cases	you	would	like	us	to

- 2 review.
- 3 MEMBER GRIFFON: Is that
- 4 considered in your cost estimate, John,
- 5 reviewing the cases?
- 6 DR. MAURO: The review of the
- 7 cases is included in the cost estimate. I
- 8 assumed three cases, but the last one we did -
- 9 turns out that one of the most recent
- 10 reviews we just completed, which was the
- 11 thoracic -- no, I forget which one -- one of
- the last ones we just completed, we think it
- is going to take more than three cases. There
- 14 may be as many as 10, because there are so
- 15 many dimensions to the problem.
- 16 MEMBER MUNN: Yes. You had
- 17 originally -- when you were talking to us in
- 18 Procedures, you said probably a minimum of
- 19 seven, and more than likely more.
- 20 DR. MAURO: On that particular
- 21 one.
- 22 MEMBER MUNN: Yes, on that

1	particular	one.
_	Parcicalar	0110.

- DR. MAURO: But in general, we
- 3 felt we will do three just to confirm that it
- 4 was done, but this one had lots of dimensions
- 5 to it. I just don't recall which.
- 6 MEMBER MUNN: Just another one of
- 7 those things that we hadn't finished working
- 8 through in Procedures.
- 9 CHAIRMAN MELIUS: I understand.
- 10 Good point. Brad?
- 11 MEMBER CLAWSON: I guess, looking
- 12 at this, I am looking for a little bit of a
- 13 bang for my buck, because Clarksville and
- 14 Medina, 90 percent of the information on those
- 15 facilities is at Pantex, plus on numerous
- 16 petitioners a large amount of the people came
- 17 from Clarksville and Medina to Pantex.
- 18 I feel they are kind of important
- 19 to get in place for the main site that I am
- 20 working with now. All the information that
- 21 was in those facilities went down to where we
- 22 are at now. So I think, just to be able to

1	make	it	easier,	it	sure	would	be	nice	to	get
---	------	----	---------	----	------	-------	----	------	----	-----

- 2 those going. They are a part of it.
- 3 CHAIRMAN MELIUS: Are we going to
- 4 be able to get the information, I guess, is my
- 5 question.
- 6 MEMBER CLAWSON: That is another
- 7 question, but in some of the information that
- 8 I have already reviewed -- and also a majority
- 9 of the petitioners that I have ran into,
- 10 numerous ones of them have already come from
- 11 Clarksville and Medina, and this is part of
- 12 their issues: where did everything go? We
- 13 haven't reviewed those.
- 14 CHAIRMAN MELIUS: The only
- 15 hesitation I would have is that we -- if I
- 16 understand this right -- so we would make the
- 17 assignment to SC&A. Nothing could be done,
- 18 because in terms of getting information back
- 19 and so forth, and we would have all this money
- 20 committed that we might need for other uses.
- 21 I guess we can readjust it at some point.
- 22 MEMBER CLAWSON: I think that we

1	are	getting	at	the	door	right	now	with	the

- 2 issues that DOE has committed to assist us
- 3 with and so forth. I think we are going to
- 4 get there, and I understand your concern. It
- 5 is just that, while we are already there, we
- 6 might as well be pulling this other stuff,
- 7 kind of a bigger bang for our buck.
- 8 CHAIRMAN MELIUS: My question
- 9 would be the top two on the list there that
- 10 have the most cases, and I think we have put
- off on Pacific Northwest for a while, and the
- 12 same on Kansas City. It has come up before,
- 13 and we should address those.
- So I guess we will do the
- 15 6000/6001. You have separate lists for those,
- 16 I believe, John.
- 17 DR. MAURO: Yes. What I did here
- 18 --
- 19 CHAIRMAN MELIUS: Just sum them.
- 20 DR. MAURO: Yes. The actual
- 21 individual ones are listed later on in the
- 22 write-up, and you can see, the individual ones

1	are	relatively	inexpensive.	Quite	frankly,
---	-----	------------	--------------	-------	----------

- 2 many of them have already gone through what I
- 3 would call a mini-review, because I have done
- 4 a lot of cases where, when I review the case,
- 5 I have to review the Appendix. Now it is not
- 6 a very thorough review. It is only reviewed
- 7 to the extent to which it applies to the case.
- 8 That is why you could see there
- 9 are 15 AWEs, and the total price of the 15 is
- whatever that number there is, \$72,000.
- 11 CHAIRMAN MELIUS: So if my quick
- 12 math is correct, for the six that we have
- 13 talked about, Pacific Northwest, the Kansas
- 14 City plant, the Clarksville-Medina, Canoga, De
- 15 Soto, that would be about \$270,000 or so to
- do? Let's do the 6000/6001 separately.
- 17 So if we got those going now in
- 18 terms of assignments, is that reasonable with
- 19 everybody? Now the conflicts and then the
- 20 vote, but --
- 21 MEMBER GRIFFON: Those six?
- 22 CHAIRMAN MELIUS: Those six, yes.

1	So could we have a motion from somebody on
2	the Board?
3	MEMBER ANDERSON: So moved.
4	CHAIRMAN MELIUS: So moved. Thank
5	you.
6	MEMBER LEMEN: I will second.
7	CHAIRMAN MELIUS: Second from
8	Dick. All in favor?
9	(A chorus of ayes.)
LO	Opposed?
11	(No response.)
12	Abstain?
13	(No response.)
L4	Okay. I think Wanda proposed that
L5	we on Procedures and PERs, we hold off
L6	until the March 31st call, when we will hear
L7	from the Subcommittee. So that then would
18	leave any assignments on the 6000 and 6001. I
L9	don't know, Paul, if you have any comments on
20	what would are priorities on those? It is
21	quite a long list.

MEMBER ZIEMER: Well, John, remind

22

- 1 me. On Appendix BB, which is General Steel,
- 2 you have already covered that in the existing
- 3 budget.
- 4 DR. MAURO: Yes.
- 5 MEMBER ZIEMER: So that is not an
- 6 issue.
- 7 DR. MAURO: These are exposure
- 8 matrices that we have not yet reviewed.
- 9 MEMBER ZIEMER: Now on both
- 10 Electro Metallurgical and Bliss & Laughlin,
- 11 last time what we said was something similar
- to what has been said on Piqua, that we wanted
- 13 the Work Group to look at it first to see
- 14 whether or not -- no, one of those we did
- 15 task. That is right.
- 16 DR. MAURO: We are almost done
- 17 with both of those.
- 18 MEMBER ZIEMER: Oh, we did that.
- 19 That's right. I know we had talked about
- 20 that, and then we did task them both. So
- 21 those are --
- 22 DR. MAURO: Those are close to

- 1 being delivered.
- 2 MEMBER ZIEMER: Right, and I don't
- 3 have a feel on the new ones, whether we would
- 4 want to task those now or authorize the
- 5 tasking and let the Work Group, the new Work
- 6 Group look at the new one or not.
- 7 CHAIRMAN MELIUS: I would say,
- 8 given the process, let's authorize the
- 9 tasking. At least, I would be comfortable
- 10 with that.
- 11 MEMBER GRIFFON: For all the
- 12 6000/6001?
- 13 CHAIRMAN MELIUS: Yes.
- 14 MEMBER ZIEMER: That would be
- 15 United Nuclear.
- 16 CHAIRMAN MELIUS: Yes.
- 17 MEMBER ZIEMER: On United Nuclear,
- 18 let's see, you also mentioned that that is
- 19 being revised -- right -- that Appendix. So
- 20 we need to clarify the status before we have
- 21 them --
- 22 MR. RUTHERFORD: Yes. It is being

1	revised.	I	don't	have	а	date	for	when	it	will

- 2 be completed, but that Appendix is being
- 3 revised.
- 4 MEMBER ZIEMER: I am not sure we
- 5 want to authorize --
- 6 MR. RUTHERFORD: I could give the
- 7 Board an update at the Board conference call.
- 8 MEMBER ZIEMER: That would be
- 9 good. Then if it is revised, then we could
- 10 immediately begin the tasking.
- 11 CHAIRMAN MELIUS: And then that is
- 12 also going to affect the SEC.
- 13 MEMBER ZIEMER: Right.
- 14 CHAIRMAN MELIUS: So your
- 15 suggestion is a motion?
- 16 MEMBER ZIEMER: Well, the
- 17 suggestion is to defer the tasking. If we
- don't task, we don't need a motion anyway. We
- 19 don't need a motion to not task, I don't
- 20 think, unless we need to stop it.
- 21 CHAIRMAN MELIUS: By the way, I
- 22 want to introduce one person. The new CDC

1	Contracting	Officer	has	been	here	with	us.	I
---	-------------	---------	-----	------	------	------	-----	---

- think many of you have seen him. Ruben Cruz
- 3 is there. Welcome, and glad to be able to
- 4 work with you, and look forward to doing that.
- 5 I also worked with him on World Trade Center
- 6 medical program. So he has quite a challenge
- 7 in terms of sort of different programs, I
- 8 guess you would call them, the large and
- 9 complicated.
- 10 Good. Anything else?
- DR. MAURO: Thank you. Thank you
- 12 very much.
- 13 CHAIRMAN MELIUS: Thank you. I
- 14 don't know what order I said we would do it
- 15 in, but we have the five letters to do.
- 16 Counsel's office is sick of hearing me. So
- 17 Emily has given us permission not to read the
- 18 letters into the record, but we will be
- 19 providing them to the Court Reporter. So they
- 20 will be in the record, but we will do that.
- There are five of them. One that
- 22 somehow the heading got left off, that is,

1 0	bviously,	the	Nevada	Test	Site;	LLNL;	Santa
-----	-----------	-----	--------	------	-------	-------	-------

- 2 Susana; Lawrence Berkeley; and Westinghouse.
- 3 Are there comments or changes? I
- 4 believe Emily wanted to make some corrections.
- 5 MR. KATZ: Are we doing these one
- 6 by one, LLNL to start with?
- 7 CHAIRMAN MELIUS: Yes, I quess. I
- 8 was hoping we could do a motion as a group and
- 9 adopt them with the changes.
- 10 MEMBER ANDERSON: Just a question,
- 11 what is the supporting documentation? Is
- 12 that just transcripts?
- 13 CHAIRMAN MELIUS: That is
- 14 transcripts of -- petition reports, all the
- 15 information, yes.
- 16 MEMBER ANDERSON: So it is a big
- 17 pack?
- 18 CHAIRMAN MELIUS: Yes.
- 19 MS. HOWELL: I think, due to
- 20 conflict of interest concerns, we may need to
- 21 separate them.
- 22 CHAIRMAN MELIUS: That is a good

- 1 point.
- 2 MR. KATZ: That is what I was
- 3 going to say. It is just that we have two
- 4 people who have conflicts, one -- two of
- 5 these, one for Lawrence Livermore and then one
- 6 person is conflicted for Berkeley. So we
- 7 can't do these as a group.
- 8 CHAIRMAN MELIUS: Okay. So why
- 9 don't we start -- what is on top of your pile
- 10 there?
- MS. HOWELL: NTS.
- 12 CHAIRMAN MELIUS: Okay, let's
- 13 start with NTS.
- 14 MS. HOWELL: I will clarify. I
- 15 gave Dr. Melius a copy of some minor, more
- 16 grammatical --
- 17 MEMBER ZIEMER: A point of order,
- 18 if I might. We have already approved this.
- 19 All that we are doing is editing the material.
- 20 So I just want to make sure it is editing.
- 21 MR. KATZ: I do understand that.
- 22 I understand, but --

1	MEMBER ZIEMER: We are not going
2	to vote on anything.
3	MR. KATZ: I understand we are not
4	voting, but we are discussing, and it is
5	discussing the substance of one of the sites.
6	Even though it is just editing, it is just
7	safe
8	MEMBER ZIEMER: I wasn't sure that
9	we were discussing substance so much as
LO	editing.
11	MS. HOWELL: So I gave Dr. Melius
12	earlier copies of each of the letters that had
L3	some grammar issues and places where the
L4	language in the Class Definition did not
L5	exactly track with the Class Definition
L6	language in the NIOSH SEC Evaluation Report.
L7	Those are all pretty minor changes. The only
L8	things I am going to talk about are a few
L9	bigger issues. I will leave that to you, and
20	I did not have any comments regarding NTS.

for NTS, it is a little different from some

CHAIRMAN MELIUS:

21

22

I would just add

1 other letters. Some of this was taken	as	а
---	----	---

- 2 paragraph there, under the bullets. It was
- 3 something we had commented on with the
- 4 previous above-ground testing, about people
- 5 working on-site, actually living on-site, and
- 6 asking Department of Labor to take note of
- 7 that, which I believe they do. So it is not
- 8 an unusual request but, otherwise, it is
- 9 relatively standard.
- 10 Any comments on that? If not --
- 11 MEMBER MUNN: I have only one
- 12 question. I am assuming that counsel and
- 13 someone else has double-checked the dates in
- 14 each of these letters. I did not take the
- 15 time to check the dates. They are correct.
- 16 CHAIRMAN MELIUS: I did okay on
- 17 the dates.
- 18 MEMBER MUNN: Good. Thank you.
- 19 MR. KATZ: Just for the record,
- 20 Mark can rejoin the table.
- 21 CHAIRMAN MELIUS: Yes.
- 22 MS. HOWELL: The next one in my

1	pile	is	Santa	Susana.	In	Santa	Susana,	I
---	------	----	-------	---------	----	-------	---------	---

- 2 requested that the language in the second
- 3 paragraph be changed to delete Section 83.13
- 4 and the word and from the fourth line down,
- 5 since this is an 83.14 SEC Petition.
- I also requested that the location
- of Ventura County, California, be deleted from
- 8 the Class Definition, since it doesn't appear
- 9 in the NIOSH Class Definition. We have had
- 10 some concerns in the past with physical
- 11 locations being included.
- 12 Then a third issue: the second
- 13 bullet on the page, second line, if you could
- 14 change the word laboratories to facilities, so
- 15 that it reads, radiological operations at
- 16 these facilities, in order to be able to
- 17 complete accurate individual dose
- 18 reconstructions, et cetera.
- 19 CHAIRMAN MELIUS: Anybody else
- 20 have comments? Dr. Ziemer?
- 21 MEMBER ZIEMER: Well, one comment.
- 22 If you delete Ventura County, California, is

1	there	an	address	location	that	can	be	used

- 2 other than just the title?
- 3 MS. HOWELL: My concern with the
- 4 location -- I don't have a problem --
- 5 MEMBER ZIEMER: I know the Ventura
- 6 County part was probably the issue, though.
- 7 Right?
- 8 MS. HOWELL: That would be fine.
- 9 My concern is that the location -- that
- 10 sentence -- that Ventura County, California,
- 11 appears in is actual Class Definition. If you
- would like to put a location in the very first
- 13 sentence, then that is better, but in the
- 14 Class Definition, the concern was if there is
- 15 any tiny part of the facility that falls
- outside of Ventura County, we don't want DOL
- 17 to have an issue with the implementation.
- 18 CHAIRMAN MELIUS: And actually,
- 19 when we did the first one there, we had that
- 20 particular question. There was uncertainty
- 21 about location, because things had moved
- 22 around or something. I can't remember the

1 d€	etails,	but	that	was	what	we	did.	I	just
------	---------	-----	------	-----	------	----	------	---	------

- 2 forgot to take it out there. Next?
- MS. HOWELL: The next one in my
- 4 stack is Lawrence Berkeley. MR. KATZ:
- 5 And for the record, Dr. Field is recusing
- 6 himself.
- 7 MS. HOWELL: In this letter,
- 8 again, on the second paragraph, fourth line
- 9 down, if you could remove the reference to
- 10 83.13 and that phrase, since it is an 83.14,
- 11 and those were the only comments I had for
- 12 that one.
- 13 CHAIRMAN MELIUS: Everybody else
- 14 okay?
- 15 MEMBER ANDERSON: Is it okay with
- 16 Berkeley, California?
- 17 MS. HOWELL: The next one in my
- 18 stack is Westinghouse. Again, if you could in
- 19 the second paragraph, fourth sentence, remove
- the reference to Section "83.13 and."
- 21 MEMBER ANDERSON: It is just a
- 22 generic letter, right?

1 CHAIRMAN MELIUS: At one point	we
---------------------------------	----

- 2 had both in, on advice of counsel. Now we
- 3 have better counsel.
- 4 MS. HOWELL: And that was all I
- 5 had on that one.
- 6 The next one -- I believe the last
- 7 one in my stack is Lawrence Livermore.
- 8 MR. KATZ: And for the record, Dr.
- 9 Poston has recused himself.
- 10 MS. HOWELL: We wanted to make
- 11 sure that Board Members had an opportunity to
- 12 stretch their legs.
- 13 On that one, the second paragraph,
- 14 fourth line down, once again just remove
- 15 "83.13 and." That was all. All of the dates
- 16 were correct.
- 17 CHAIRMAN MELIUS: Dr. Ziemer had a
- 18 correction under the second bullet, just to
- 19 say that at the end of that, the Board concurs
- 20 with this determination. It has sort of
- 21 become our standard language in that area.
- 22 MEMBER MUNN: What?

1 CHAIRMAN MELIUS: End of	LIUS: End of the
---------------------------	------------------

- 2 second bullet, add as the last sentence, "The
- 3 Board concurs with this determination, " for
- 4 the second bullet.
- 5 MEMBER MUNN: So we will be saying
- 6 twice, "The Board concurs"?
- 7 MEMBER ZIEMER: Excuse me. We
- 8 have on all of these letters except for this
- 9 one.
- 10 MEMBER ANDERSON: We got to show
- 11 some independence here. That's fine.
- 12 CHAIRMAN MELIUS: We have Board
- 13 correspondence. Dr. Poston, you are welcome
- 14 back. Ted, you are going to have to help
- 15 here.
- MR. KATZ: Correspondence?
- 17 CHAIRMAN MELIUS: Correspondence,
- 18 yes.
- 19 MR. KATZ: So we have the letter
- 20 from ANWAG, the beefiest one.
- 21 CHAIRMAN MELIUS: There is a
- 22 letter from the ANWAG group that actually

	1	precedes	the	meeting	that,	I	believe,	Lew	Wade
--	---	----------	-----	---------	-------	---	----------	-----	------

- 2 talked about that, or John Howard, earlier.
- 3 So some of their issues have been discussed at
- 4 that meeting and, Dr. Ziemer, you attended, I
- 5 believe.
- 6 MEMBER ZIEMER: Yes.
- 7 CHAIRMAN MELIUS: You spoke of
- 8 that. I guess the question is were there
- 9 issues there that -- in terms of answering
- 10 their letter, are there issues that weren't
- 11 addressed there. Some, clearly, we are, like
- we are addressing the surrogate data issue in
- 13 terms of follow-up.
- 14 MEMBER ZIEMER: I was looking for
- 15 the letter itself. One of the issues, my
- 16 recollection is that ANWAG had requested
- 17 automatic tasking of NIOSH -- not of NIOSH --
- 18 of SC&A whenever NIOSH produced an Evaluation
- 19 Report for which they indicated that they
- 20 could reconstruct dose with sufficient
- 21 accuracy that the Board not wait to do the
- tasking, that it be done automatically.

Т	I am looking for the letter.
2	MEMBER ROESSLER: From
3	[identifying information redacted] to you?
4	MEMBER ZIEMER: Yes, and it was
5	distributed. Oh, here it is, I believe.
6	I think Dr. Melius was asking me
7	if all of the issues had been covered, and let
8	me just identify the issues. One of the
9	issues was the use of surrogate data. They
10	were concerned about that, and of course, that
11	is being addressed.
12	I believe I am looking at the
13	letter now to see basically, a concern on
14	the use of surrogate data and the parameters
15	there; urges the Board to reverse their
L6	position, and it says to advise the President
L7	that the use of surrogate data is inconsistent
18	with the spirit of EEOICPA.
L9	I think, in the context of our
20	discussion earlier today, beginning with the
21	discussion by Dr. Miller and then the work of
22	the Surrogate Data Group, I think that is

T DCTIIG AGGICDDCG	1	being	addressed.
--------------------	---	-------	------------

- 2 Another issue was the
- 3 confidentiality issue on the disclosure of
- 4 worker identity when workers talk to people,
- 5 particularly at the sites where there were
- 6 classified information. I am not quite sure
- 7 where that stands now.
- 8 There was concern that the
- 9 identity of those that SC&A spoke to was being
- 10 revealed to the federal agencies. That was
- one of the concerns that was raised. Again, I
- 12 leave it to the Chair, to the extent we
- 13 discuss that.
- 14 There was also concern about SC&A
- 15 having to turn over their documents to OCAS,
- 16 again, I think, related to those -- all of the
- 17 things that SC&A retrieved, and the issue of
- 18 who owns the work product.
- 19 Oh, and then she talks about the
- 20 joint meeting and invites us to participate,
- 21 which we did. So those were the issues
- 22 raised.

2	Board Members and my recollection, the letters
3	for the Board, other than simple
4	acknowledgments, are all discussed with the
5	Board before they go out. In this case, I
6	think we could respond, if it is okay with
7	people, respond informationally to them that,
8	yes, we have attended the meeting, we followed
9	up, and we are taking these issues under
10	consideration and will at future meetings. If
11	that is okay with people, I will send that
12	letter out, and then circulate that.
13	We have a second letter. This is
14	dated December 3 from I don't believe this
15	is in the package, or not. I can't recall,
16	but it is relatively short. It is from
17	Senator Durbin in Illinois: "Writing on
18	behalf of my constituents who"
19	MEMBER ZIEMER: That is under
20	miscellaneous.
21	CHAIRMAN MELIUS: Oh, that is
22	under miscellaneous, basically about General

CHAIRMAN MELIUS: For the new

1

1 Steel Industries. I think a re	esponse back to
----------------------------------	-----------------

- 2 Senator Durbin would be to the effect that we
- 3 have an active Work Group that is considering
- 4 this and is following up on it, and we expect
- 5 to take action in the near future. I think
- 6 that that -- is that kind of response
- 7 appropriate?
- 8 MEMBER ZIEMER: My only comment
- 9 here: I originally didn't think this letter
- 10 called for a response, simply because he was
- 11 simply indicating that he supported this
- 12 petition. At a minimum, probably it would be
- 13 good to indicate that we have received his
- 14 letter. It has been distributed to the Board,
- in addition to the suggestion you have made
- 16 that the Working Group is developing a
- 17 recommendation for the Board.
- 18 CHAIRMAN MELIUS: Right. I think
- 19 we should try to acknowledge the letter.
- 20 The other letter we have is from -
- 21 that was read yesterday when we discussed
- 22 NTS -- from Senator Reid, I think, which we

1 have obviously taken care of the SEC. H	1	have	obviously	taken	care	of	the	SEC.	Η
---	---	------	-----------	-------	------	----	-----	------	---

- 2 asked for follow-up on three other issues, and
- 3 I think you heard me respond to his staff
- 4 person with what we were doing on those
- 5 issues. I would just write an acknowledgment
- 6 letter back just saying, thanks for the
- 7 letter; we have done the SEC, and the other
- 8 three issues that you raised, we are following
- 9 up on -- or, actually, NIOSH is addressing two
- 10 of them. So is that satisfactory? Okay.
- I think that is our last letter.
- 12 The only other letter we have is when we talk
- 13 about what I believe is our final item, the
- 14 next meeting. Checking with Ted to make sure
- 15 I didn't miss anything.
- MR. KATZ: Yes. Not a letter, but
- 17 the next item is future meetings.
- 18 CHAIRMAN MELIUS: Next item. It
- 19 is also a letter, too, because we have a
- 20 request regarding a meeting place.
- MR. KATZ: We do.
- 22 CHAIRMAN MELIUS: Well, let's talk

1	about	the	meeting	first.	Scheduled	for	March
---	-------	-----	---------	--------	-----------	-----	-------

- 2 31st.
- MR. KATZ: Yes. So presently we
- 4 have a teleconference on March 31st, and then
- 5 -- sorry, let me go to my records here. We
- 6 have our meeting at INL in Idaho, and that is
- 7 in August. Let me find my dates here, August
- 8 10-12 in Idaho Falls, and given how much -- we
- 9 might want to query the Board at this point,
- 10 given how much work there will be at that
- 11 meeting, as to whether we are going to be able
- 12 to do it in three days.
- 13 CHAIRMAN MELIUS: It was scheduled
- 14 for two days, right? Three days?
- 15 MR. KATZ: The schedule is three
- 16 days, yes. I am just wondering if three days
- 17 is going to be big enough. This is for Idaho
- 18 Falls, August 10-12.
- 19 CHAIRMAN MELIUS: We have a May
- 20 meeting.
- 21 MR. KATZ: Oh, I'm sorry. Excuse
- 22 me. I did skip a lot. I'm sorry. May 19th

1	through	the	21st	is	Buffalo,	New	York.	How
---	---------	-----	------	----	----------	-----	-------	-----

- 2 did I do that?
- 3 CHAIRMAN MELIUS: And I think, due
- 4 to various schedules, as I recall, this ended
- 5 up being doing a Wednesday, Thursday and
- 6 Friday, and I think there was a problem with
- 7 Tuesday, and I can't remember, among some
- 8 Board Members. So I think there we are --
- 9 MR. KATZ: We will have to squeeze
- 10 in.
- 11 CHAIRMAN MELIUS: -- we will have
- 12 to squeeze in, in three days.
- 13 MEMBER GRIFFON: What was the
- 14 date?
- MR. KATZ: May 19th through 21st,
- and following that we have July 14th. That is
- 17 French Independence Day. That is a
- 18 teleconference.
- 19 CHAIRMAN MELIUS: Nancy is going
- 20 to correct.
- MS. ADAMS: This is Nancy Adams.
- 22 Ted, there was some confusion. It is really

- 1 not Buffalo. It is Niagara Falls, is actually
- 2 the location.
- 3 MR. KATZ: Yes. We call it
- 4 Buffalo, I guess, but it is Niagara Falls.
- 5 CHAIRMAN MELIUS: Where are we in
- 6 Niagara Falls?
- 7 MS. ADAMS: We are at the Crowne
- 8 Plaza Hotel.
- 9 MR. KATZ: Thank you, Nancy.
- 10 CHAIRMAN MELIUS: There is an
- 11 airport in Niagara Falls they have been trying
- to get someone to fly to for a long time. I
- 13 better not say anything more or I will get in
- 14 trouble, a letter from the Niagara Falls
- 15 Board.
- MR. KATZ: Okay. So everyone has
- 17 that July 14th teleconference. That is a
- 18 teleconference.
- 19 Then we have August 10th through
- 20 12th. That was what I was -- Idaho Falls.
- 21 MEMBER LEMEN: Do you know the
- 22 hotel where that is at?

1 M	MR. KA	ATZ: I	don'	t	know.	Ιt	may
-----	--------	--------	------	---	-------	----	-----

- 2 be set, but we will get information to you on
- 3 that. I don't know that we have that set yet.
- 4 CHAIRMAN MELIUS: I would say, on
- 5 the Idaho Falls meeting -- and, Brad, don't
- 6 take offense, but given the time and how long
- 7 it takes to get in and out of there, I think
- 8 we would all be leaving on the morning --
- 9 Friday morning. I don't think -- maybe Josie
- 10 and, obviously, Brad. Wanda might be able to
- 11 get out. I don't even know if you can easily
- 12 that night. So I think we will have three
- 13 full days of meetings there.
- 14 MR. KATZ: I would also note, for
- 15 that we are going to try to set up a tour of
- 16 INL.
- 17 CHAIRMAN MELIUS: On the 9th?
- 18 MR. KATZ: Yes, that is right,
- 19 whatever, that fits, the 9th, a tour of INL
- 20 and Argonne West, I think that is.
- 21 MEMBER GRIFFON: That won't take
- 22 long. It is a small site.

1	MR.	KATZ:	Thank	you,	Mark.	Then
---	-----	-------	-------	------	-------	------

- we have a teleconference on October 7th. That
- 3 is as far as we have scheduled. In your
- 4 bullets, I framed approximately the right time
- 5 frame is November 1st through the 19th for the
- 6 next face to face, but of course, we will move
- 7 in whatever direction we need to, to
- 8 accommodate schedules.
- 9 CHAIRMAN MELIUS: I thought, these
- 10 future meetings, we had an 18-day meeting.
- 11 MR. KATZ: I don't think anybody
- 12 would survive 18 days together.
- 13 MEMBER MUNN: Was that in
- 14 November?
- 15 MR. KATZ: That would be November.
- MEMBER MUNN: Or December?
- 17 MR. KATZ: Well, November 1st
- 18 through 19th is the right time frame.
- 19 CHAIRMAN MELIUS: Ted, what is the
- 20 December date, 9th through 20th -- September
- 21 20th through October 1st?
- MR. KATZ: That is -- ignore that.

1	That	was,	before	I	realized	we	already	had
---	------	------	--------	---	----------	----	---------	-----

- 2 the teleconference set up for October 7th. So
- 3 you can ignore that. Ignore that little
- 4 parenthetical in your agenda. No matter.
- 5 CHAIRMAN MELIUS: I guess November
- 6 -- we all know, once we get past Thanksgiving,
- 7 scheduling is always difficult.
- 8 MEMBER MUNN: We did pretty well
- 9 this last year.
- 10 MR. KATZ: So we are looking from
- 11 November 1st through the 19th for three days
- 12 that work.
- 13 MEMBER MUNN: Well, some folks
- 14 wouldn't like to meet on Tuesday, the 2nd,
- 15 election day, and do the Feds have Veterans
- 16 Day off on the 11th, or not?
- 17 MEMBER ANDERSON: How about the
- week of the 15th, the 15th through the 19th,
- 19 somewhere in there?
- 20 CHAIRMAN MELIUS: How does that
- 21 week work?
- MEMBER MUNN: That would do.

1	MR.	KATZ:	Ιt	is	perfect.
---	-----	-------	----	----	----------

- 2 MEMBER MUNN: Sixteenth, 17, 18?
- 3 MR. KATZ: Sixteenth through 18th?
- 4 Is that good for everybody? How about for
- 5 you, David and Mike?
- 6 MEMBER GIBSON: Yes, that should
- 7 be okay, Ted.
- 8 MR. KATZ: How about David?
- 9 MEMBER RICHARDSON: Yes, I think
- 10 that is okay.
- 11 CHAIRMAN MELIUS: Okay.
- MR. KATZ: November 16th to the
- 13 18th. Okay, that is dates then.
- 14 CHAIRMAN MELIUS: Well, we have a
- 15 letter, a request from petitioners at Los
- 16 Alamos. I believe it is a security quard
- 17 petition group requesting that we meet in --
- 18 MEMBER LEMEN: Is that going to be
- 19 a problem with snow?
- 20 MR. KATZ: November 15th, it will
- 21 be.
- 22 CHAIRMAN MELIUS: -- in Los

1	Alamos.	We	have	met	times	in	Santa 1	Fe,	times
---	---------	----	------	-----	-------	----	---------	-----	-------

- 2 in Albuquerque.
- 3 MEMBER LEMEN: Whatever you want
- 4 to do.
- 5 MEMBER MUNN: Albuquerque is no
- 6 problem.
- 7 MEMBER LEMEN: I will just bring
- 8 my snowshoes.
- 9 MR. KATZ; Is everybody in favor
- 10 of that?
- 11 MEMBER POSTON: CDC has been
- 12 having meetings at the Buffalo Thunder Resort,
- which is about halfway between Los Alamos and
- 14 Santa Fe.
- 15 CHAIRMAN MELIUS: Do we think we
- 16 will have something to talk about? Obviously,
- 17 we have a full Board agenda, but in terms of
- 18 the sites out there.
- 19 MEMBER GRIFFON: Well, I think the
- 20 LANL Work Group would have met at least. Joe,
- 21 that is fair to say, right? LANL Work Group
- 22 would have met prior to November. I think it

1 is fair to say that we will have made	some
---	------

- 2 progress and something to report.
- 3 MEMBER SCHOFIELD: Can I throw in
- 4 my two cents on location? At that time of
- 5 year, it might be safer to pick Albuquerque.
- 6 It is not a very long drive from Los Alamos to
- 7 Albuquerque.
- 8 MR. KATZ: So you think that would
- 9 be okay for people from LANL to be able to
- 10 attend? Okay.
- 11 Phil, how far is it for the LANL
- 12 folks?
- 13 MEMBER SCHOFIELD: It is about an
- 14 hour and a half.
- 15 CHAIRMAN MELIUS: We might have
- 16 gotten out of Idaho Falls by then. Just come
- 17 directly.
- 18 MEMBER PRESLEY: Santa Fe at that
- 19 time of year will be all right.
- 20 MEMBER MUNN: Yes, it is.
- 21 CHAIRMAN MELIUS: Before we end
- 22 the public meeting, are there any other

1	issues?	I s	said t	he	public	part	of	the
2	meeting.	We wo	on't fo	rge	t ethic	s.		
3		One	thing	I	don't	think	we	have

had time to do, and I will put on the -- I 4 think we should put on the agenda for the next 5 meeting is Lew did ask for some response and 6

comments on the NIOSH review plan. 7 I think,

if individual Board Members want to comment

directly to Lew in the meantime, since they 9

10 are going to be doing some planning on this

and so forth, it would be appropriate. 11

can also talk about it at the meeting 12

13 coming up in March. Dr. Ziemer?

14 MEMBER ZIEMER: It just occurs to

15 me -- I am thinking back a moment here to the

16 ANWAG letter -- one of the items that was

17 raised in that letter was the issue of

automatic tasking of SC&A. We didn't actually 18

19 deal with that.

20 practice has been to wait Our

until the Board actually has a chance to see 21

the Evaluation Report, and at least from my 22

Τ	point of view, i recommend that we continue
2	that, but I think we owe at least the
3	opportunity for Board Members who may not
4	agree with that to voice that so that we can
5	at least indicate what the consensus is.
6	CHAIRMAN MELIUS: And as I said, I
7	noticed that also, but in, I think, the
8	response we would say that some of these
9	issues are under consideration and will be
10	considered by the Board. We will respond to
11	them, once we have done that.
12	Well, I will adjourn the public
13	part of the meeting, and everybody can leave
14	except us and Emily.
15	MEMBER CLAWSON: Can we take a
16	break?
17	CHAIRMAN MELIUS: No. She said
18	yes. Why don't we take a ten minute break.
19	(Whereupon, the above-entitled
20	matter went off the record at 4:43 p.m.)
21	

22

1

2

3

4